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Abstract 
Breast cancer is one of the most prevalent cancers among women worldwide and is the 
most commonly diagnosed cancer among Queensland women. Studies suggest that there 
is a relationship between sun exposure and breast cancer risk and mortality. Previous 
research has shown that women living in locations with higher ultra-violet (UV) 
radiation, or areas closer to the equator, have a lower risk
1-3
 and reduced mortality from 
breast cancer.
4,5
 Furthermore, spending more time outdoors was associated with a lower 
risk of breast cancer.
6-8
 Although some research has indicated increased sun exposure 
may reduce the risk of breast cancer, several studies have found no such association.
9-12
 
A plausible mechanism by which sun exposure protects against breast cancer risk and 
mortality is UV-induced vitamin D production. In vitro studies have shown that the active 
form of vitamin D, 1,25(OH)2D3, can influence breast cancer through inducing 
differentiation and apoptosis and inhibiting cellular proliferation of breast cancer 
cells.
6,9,13-18
 Moreover, in vivo studies have found lower levels of vitamin D (25-
hydroxyvitamin D3) are associated with a reduced risk of breast cancer incidence and 
mortality.
1,19-23
  While previous research has focused on breast cancer risk and mortality, 
no studies have investigated the association between lifetime sun exposure and breast 
cancer stage. However, some studies have found no relationship between vitamin D and 
breast cancer.
24
 
This study aimed to identify and explore the relationship between lifetime sun exposure 
and breast cancer stage, as a measure of prognosis, in women newly diagnosed with 
breast cancer. Study participants consisted of a random subset of women participating in 
Cancer Council Queensland’s (CCQ) Breast Cancer Outcomes Study (BCOS). 
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Participants were women aged 20-79 years, residing in Queensland with a histologically 
confirmed diagnosis of invasive breast cancer between January 1, 2011 and December 31, 
2012 and registered with the Queensland Cancer Registry. Sociodemographics, diagnostic 
information and tumour characteristics were obtained through the Queensland Cancer 
Registry and a telephone interview, and lifetime sun exposure information was obtained 
through a self-administered questionnaire.  Logistic regression modelling was used to 
obtain odds ratios for associations between lifetime sun exposure and breast cancer stage, 
while controlling for potential confounders.  
In the multivariate analysis adjusted for mammography, solarium use, physical activity, 
age at diagnosis, clinical breast exam history and rurality, no significant relationship 
between lifetime sun exposure and breast cancer stage was observed. The association 
remained insignificant in the additional analyses (controlling for tumour characteristics 
and using histological grade as an alternative prognostic indicator). Additionally, no 
significant association was observed between sun exposure during the years of breast 
development and breast cancer stage.  
This study was the first to investigate the association between lifetime sun exposure and 
breast cancer stage. This study did not support the hypothesis that higher lifetime sun 
exposure is associated with a decreased risk of advanced breast cancer. However, this 
study had several limitations, which could have affected the results. Inconsistencies exist 
in results of previous research examining the association between sun exposure and/or 
vitamin D and breast cancer risk and mortality. The inconsistencies in previous research, 
along with the limitations of this study, justify the need for further investigation.  
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Chapter 1: Introduction 
This chapter outlines the background (Section 1.1) and context (Section 1.2) of the 
research, while Section 1.3 discusses the significance of the research. Section 1.4 
describes the aim and scope of the research and Section 1.5 includes an outline of the 
remaining chapters of the thesis. 
1.1 BACKGROUND 
Breast cancer is a disease in which genetically abnormal breast cells replicate 
uncontrollably to form tumours. The disease primarily affects post-menopausal females 
but can also affect males.
25
 About 95% of breast cancers originate in the components of 
the mammary gland, ducts and lobules, with ductal cancers being the most common.
26
 
Although the cause of breast cancer is unknown, several factors have been associated 
with an increased risk of breast cancer, including increased age, earlier age of menarche, 
later age of menopause, nulliparity, later age at first pregnancy, family history of breast 
cancer, history of benign breast disease, obesity, alcohol use, and lower physical activity 
levels.
27
  
Breast cancer stage is one of the strongest indicators of prognosis and is determined by 
tumour size (T), lymph node status (N) and metastases (M).
28
 The TNM classification of 
breast cancer stage include in situ (non-invasive), stage I, stage II, stage III and stage IV, 
where the higher the stage, the  poorer the prognosis. Alternatively, breast cancer is 
staged using summary staging, which describes how far the cancer has spread outside of 
the site of origin in the breast.
29
 Summary staging places breast cancer into four 
categories: in situ, localised, regional and distant.
29
 In situ breast cancer describes 
malignant tumours still contained within the ducts or lobules of the breast,
29
 whereas 
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invasive or infiltrating breast cancer, describes malignant tumours that have invaded 
outside of the ducts or lobules into the breast stroma. Breast cancers that have not spread 
outside of the primary site in the breast tissue are defined as localised, while regional 
breast cancers are those that have spread past the primary site to nearby lymph nodes.
29
 
Breast cancers that have metastasised, or spread to distant lymph nodes or tissues and 
organs are classified as distant.
29
  
Breast cancer is the most commonly diagnosed cancer among Australian women and is 
the second highest cause of cancer-related death.
30
 In 2011, breast cancer accounted for 
14,465 cancer diagnoses and 15.6% of cancer-related deaths among Australian women. 
Nearly 3,000 women living in Queensland are diagnosed with breast cancer each year, 
and Queensland women have a one in eight risk of being diagnosed with breast cancer 
before the age of 85 years.
31
 
1.2 CONTEXT 
Previous research has indicated that there may be a relationship between sun exposure 
and breast cancer risk and mortality. Studies have shown that women living in areas with 
higher ultraviolet (UV) radiation or areas closer to the equator have a reduced risk
1-3
 and 
reduced mortality from breast cancer.
4,5
 Additionally, spending more time outdoors has 
been reported to be inversely associated with breast cancer risk.
6-8
 Studies using skin 
pigmentation or skin damage to retrospectively assess sun exposure also found a reduced 
risk of breast cancer in women whose skin suggested an increased amount of sun 
exposure.
1,18
 Although some research has indicated increased sun exposure may reduce 
the risk of breast cancer, several studies have found no such association.
9-12
 
While the reason as to why sun exposure may reduce breast cancer risk and mortality is 
still unknown, vitamin D synthesis is a possible mechanism for this relationship. Sunlight 
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induced vitamin D accounts for 80-95% of circulating vitamin D in humans.
32
 Once UV 
radiation is absorbed by skin, vitamin D is hydroxylated in the liver to form 25-
hydroxyvitamin D3 (25(OH)D), which is then hydroxylated in the kidneys to produce 1-
α,25-dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active form of vitamin D that 
circulates in the blood.
33,34
 The conversion of 25(OH)D to 1,25(OH)2D3 is tightly 
regulated in the kidneys, but 1,25(OH)2D3 can also be synthesised locally in breast 
tissues, which is not as tightly regulated.
33,34
 Therefore, an increase in sun exposure could 
result in an increase in local (breast tissue origin) production of 1,25(OH)2D3.
33,34
  
In vitro studies have shown that the active form of vitamin D, 1,25(OH)2D3, can influence 
breast cancer through inducing differentiation and apoptosis and inhibiting cellular 
proliferation of breast cancer cells.
6,9,13-18
 Additionally, in vivo studies have found lower 
levels of vitamin D, (25-hydroxyvitamin D3) are associated with a reduced risk of breast 
cancer incidence and mortality.
1,19-23
  However, some studies have found no relationship 
between vitamin D and breast cancer.
24
 
Although the optimal level of vitamin D is a continuing debate, recent guidelines state 
that serum 25(OH)D concentrations <50 nmol/L are insufficient.
35
 Australia has a high 
UV index year round, but about one-third of Australians are vitamin D insufficient (<50 
nmol/L) and women are more than twice as likely as men to have low levels of vitamin 
D.
35
 Vitamin D levels are lower in winter and spring months, with 40.5% of women 
living in Southeast Queensland  (average latitude of  27°S) women,  37.4% of women 
living in Geelong (latitude of 38°S) and 67.3% of women living in Tasmania (latitude of 
42°S) having insufficient levels of vitamin D (<50 nmol/L).
36
 Although a number of 
factors could contribute to vitamin D insufficiency, it is likely to be related to an increase 
in sun-consciousness, as sun protection behaviours have increased due to the ‘SunSmart’ 
campaign in Australia.
35
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In addition to vitamin D deficiency, other factors may contribute to the high rates of 
breast cancer in Australia despite having a high UV index year-round. Australia has a 
well-established population-based breast cancer screening program, BreastScreen, which 
targets women aged 50-74 years.
37
 Increased breast cancer rates may be an artefact of the 
screening program, as an increase in breast screening participation will likely result in an 
increased number of breast cancers detected.
38
 Lifestyle and environmental factors may 
also explain Australia’s high breast cancer rates. Being overweight or obese, particularly 
for post-menopausal women is associated with an increased risk of breast cancer, as well 
as low levels of physical activity.
27
 There is some evidence of a moderate association 
between alcohol intake and breast cancer risk.
27
 Additionally, exposure to high doses of 
ionizing radiation and polycyclic aromatic hydrocarbons (PAHs), such as cigarette smoke 
and air pollution may also lead to an increased risk of breast cancer.
39
  
1.3 SIGNIFICANCE OF RESEARCH 
The evidence relating to associations between breast cancer risk or mortality and sun 
exposure and vitamin D have been limited and inconsistent. Some studies have found an 
inverse relationship between sun exposure and/or vitamin D and breast cancer, while 
others have found no association. Previous research has focused on breast cancer risk or 
mortality, but none have focused on breast cancer stage at diagnosis as an outcome. This 
represents an important gap, as stage at diagnosis is one of the most important prognostic 
indicators. Because vitamin D has been shown to induce apoptosis and inhibit cellular 
proliferation, it seems plausible that it could have an association with the progression of 
breast cancer, thus affecting the prognosis. To date, no studies investigating sun exposure 
and breast cancer have been conducted in Australia or in a country with similar UV 
levels.  Additionally, if there is an association between sun exposure and breast cancer 
stage, are there particular age periods where sun exposure may matter most? A limiting 
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factor in furthering our understanding of whether a relationship exists, and if so the 
strength of that relationship, is the variety of sun exposure measures used in previous 
studies. Latitude, region of residence, UV radiation measures of current residence, skin 
damage, and reported time spent outdoors are all methods which have been used to 
measure sun exposure. Additionally, some studies only take into account current sun 
exposure or sun exposure within certain age groups, as opposed to lifetime sun exposure.  
This will be the first study to investigate the relationship between lifetime sun exposure 
and breast cancer stage in Australia. The study will examine previous research to inform 
the development of a questionnaire to measure lifetime sun exposure. Additionally, the 
study will examine various age periods to identify whether there are specific periods 
when sun exposure may matter most in terms of associations with breast cancer stage. 
This research will enhance the understanding of the effects of sun exposure, possibly 
mediated by vitamin D, on breast cancer stage, and possibly provide insight into ways in 
which the prognosis of breast cancer can be improved.  
1.4 AIM AND SCOPE 
The aim of this research was to “identify and explore the relationship between lifetime 
sun exposure and breast cancer stage, as a measure of prognosis, in women newly 
diagnosed with breast cancer”. The objectives were to: 
1. Define the role that location of residence has on breast cancer stage at 
diagnosis;  
2. Measure lifetime sun exposure in women newly diagnosed with breast cancer;  
3. Develop a model to define the role that lifetime sun exposure has on breast 
cancer stage at diagnosis, controlling for known breast cancer risk factors; 
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4. Determine at what stage of life sun exposure matters most in breast cancer 
stage at diagnosis  
A random subset of women from Cancer Council Queensland’s (CCQ) Breast Cancer 
Outcomes Study (BCOS) were used as participants for this study. Participants were 
women aged 20-79 years, residing in Queensland with a histologically confirmed 
diagnosis of invasive breast cancer between January 1, 2011 and December 31, 2012 and 
notified to the Queensland Cancer Registry. Sociodemographics, diagnostic information 
and tumour characteristics were obtained through the Queensland Cancer Registry and a 
telephone interview, and lifetime sun exposure information was obtained through a self-
administered questionnaire. These variables were used to determine the association 
between lifetime sun exposure and breast cancer stage while controlling for confounders.  
1.5 THESIS OUTLINE 
The first chapter of this thesis provides an introduction to breast cancer and an overview 
of the known relationship between breast cancer risk and mortality and sun exposure and 
the possible mechanisms behind the relationship. The purpose and specific aims of the 
study are discussed, followed by the study’s significance and contribution to public 
health. 
The second chapter is a review of the literature. This chapter contains an overview of 
breast cancer, including the biology, classification and staging of breast cancer, as well as 
breast cancer risk factors and the epidemiology of breast cancer in Australia and 
Queensland.  Previous studies examining breast cancer risk and mortality and sun 
exposure are discussed, along with the possible mechanisms by which sun exposure 
affects breast cancer. Because vitamin D is the most accepted mechanism, a background 
on vitamin D is included in the literature review, as well as a discussion of previous 
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research relating to vitamin D and breast cancer risk and mortality. The literature review 
chapter ends with a summary of the literature and the rationale for our research.  
Chapter three details a study that was developed and conducted as a ‘proof of concept’ for 
this PhD research. The purpose and aim of the study are discussed, followed by the data 
sources, variables used and analyses. The results of the study are reported, and the chapter 
ends with the discussion of the study results and conclusion.  
The fourth chapter contains the research design and analytical approach of the study. The 
PhD study was a retrospective cohort study nested in a larger cohort study (the Breast 
Cancer Outcomes Study) conducted by Cancer Council Queensland. The details of the 
Breast Cancer Outcomes study are first described, including study design, recruitment, 
eligibility criteria, data collection, data entry, and data management. Next, the PhD aims, 
objectives and research questions are outlined, along with the study design, methods, data 
collection, data analysis, and variable information. Lastly, the ethical approvals for both 
studies are described.  
The major study results are presented in the fifth and sixth chapters. The fifth chapter 
discusses the preliminary results, including the participant characteristics, descriptive data 
for sun exposure variables and breast cancer-related variables and the bivariate analyses. 
The results of the statistical model are presented in Chapter six. First, the results of the 
bivariate analyses of the outcome variable (stage at diagnosis) and the exposure variable 
(lifetime UV) with each covariate are presented in tables. Next, the method for choosing 
confounders and the outcome of the final model are explained, followed by a discussion 
of the results of additional analyses.  
The final chapter, Chapter 7, is the discussion of the thesis. This chapter includes a review 
of the aims and methods of the study, as well as a review of the study presented in 
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Chapter three. A comparison between the study results and results of previous studies is 
described, followed by possible explanations for the findings. Next, the strengths and 
limitations of the study are listed, along with the interpretations of findings. The chapter 
concludes with a discussion of future directions and a conclusion to the research. 
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Chapter 2:  Background and Literature Review 
2.1 WHAT IS BREAST CANCER? 
2.1.1 Biology of female breasts  
The female breast consists of both stromal and epithelial components.
40
 Adipose, 
connective tissue, blood and lymphatic vessels make up the stromal component of the 
breast, while the epithelial components of the breast consist of the functional units of the 
mammary glands (Figure 2.1).
40
 The mammary glands consist of lobules (milk producing 
glands) and ducts (small tubes that carry milk from the lobule to the nipple).
25
 Over 95% 
of breast cancers begin in the epithelial components of the mammary glands with the 
majority originating in the ducts (ductal cancers).
25,40,41
  
 
Figure 2.1. Simple illustration demonstrating the anatomy of the female breast.
42
 
 
2.1.2 Cell biology of breast cancer 
All cancers, including breast cancers, begin as a change in a cell’s DNA.43 This change 
may be inherited and is described as a germline mutation or may develop spontaneously 
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and is called a de novo mutation. DNA mutations that can lead to cancer commonly occur 
in cell cycle control genes. For example, mutations in the BRCA1 or BRCA2 genes 
increase one’s risk of developing breast and ovarian cancer and account for 5-10% of 
breast cancers.
25
 This is because BCRA1 and BRCA2 are DNA repair genes. When a cell’s 
DNA becomes damaged during the cell cycle, normally, the cell recognises the 
abnormality and will either successfully repair the damage or undergo apoptosis, or cell 
death.
43
 In cancerous cells with mutations in DNA repair genes, the DNA is not repaired 
and the cells do not die as they should, resulting in replication of abnormal cells, 
accumulation of further mutations and subsequently the formation of malignant tumours 
(Figure 2.2).
43
  
 
Figure 2.2. Molecular basis of cancer
44
 
 
The remaining 90-95% of breast cancers are due to sporadic or de novo mutations in other 
genes such as TTP53 and yet to be identified genes.
25
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Failure of cell cycle checkpoint mechanisms 
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2.1.3 Classifying breast cancer 
Breast cancer is classified in several ways including: origin and malignancy; tumour 
receptor status; and molecular subtyping.   
2.1.3.1 Origin and malignancy 
The malignancy of breast cancer is defined as either in situ (non-invasive) or invasive 
(infiltrating) cancer.
40
 An in situ carcinoma is contained within the lobules (lobule 
carcinoma in situ, LCIS) or ducts (ductal carcinoma in situ, DCIS), and has not invaded 
the surrounding stroma, and typically has a better prognosis.
27,40
 However, if left 
untreated, a non-invasive cancer could potentially develop into an invasive cancer.
27
 
Invasive cancers can originate in the ducts (invasive ductal carcinoma, IDC) or the 
lobules (invasive lobule carcinoma, ILC), and they can metastasise to other parts of the 
body. Invasive breast cancers require more aggressive treatment and have a poorer 
prognosis.
25,27,41
 The most common types of invasive breast cancers are ductal 
carcinomas, accounting for 75-80% of invasive breast cancers, and lobular carcinomas, 
accounting for 5-10% of invasive breast cancers.
40
 Less common types of breast cancer 
and diseases of the breast include inflammatory breast cancer, Paget’s disease of the 
nipple, phyllodes tumour, angiosarcoma, medullary, tubular, mucinous, and adenoid 
cystic.
25,40
  
2.1.3.2 Hormone receptor status  
Breast cancer is also classified and treated by determining hormone receptor status. A 
large majority of breast cancer tumours express both oestrogen and progesterone 
receptors.
40
 When oestrogen and progesterone receptors are expressed in breast tumours 
at levels higher than a specific cut-off, the tumours are considered oestrogen receptor 
(ER) positive and/or progesterone receptor (PR) positive.
40
 About 75% of all breast 
cancers are ER
+
, and about 65% of those are also PR
+
.
40
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2.1.3.3 Molecular subtypes  
Breast cancers are also categorised by gene expression profiles into five main molecular 
subtypes: Luminal A, Luminal B, HER2/neu (Human epidermal growth factor receptor 
2/protooncogene 2)-positive, basal-like, and Claudin-low.
45
 An additional subtype is 
normal breast, but its clinical significance is yet to be determined.
45
 Subtyping breast 
cancers in this way is based on the following: tumour receptor status, HER2/neu status, 
proliferation markers (ki67), TTP53 mutations, and histologic grade.
45
 Human epidermal 
growth factor receptor two/protooncogene neu (HER2/neu) is a protein that can be found 
on the cell surface of some breast cancers.
40
 Breast cancer with cells that over-express 
this protein are classified as HER2/neu positive and account for 10-15% of all breast 
cancers.
46
 HER2/neu positive breast cancers tend to be more aggressive and have a poorer 
prognosis,
46
 however HER2/neu positive cancers can now be treated with the drug 
Trastuzumab which has improved survival outcomes.
47
 Ki67 is a cellular proliferation 
marker protein in breast cancer.
48
 Levels of ki67 can be measured by the percentage of 
cells staining positive for ki67, where a low percentage of ki67 is associated with low 
numbers of actively dividing cancer cells, and high ki67 correlates with high numbers.
46
 
TP53 is a tumour suppressor protein that is involved in the progression of both sporadic 
and hereditary breast tumours.
49
 If undamaged, TP53 regulates cell cycle and suppresses 
tumours, but if its gene is mutated, it can act as an oncogene, which is a gene with the 
potential to cause cancer.
49
 Histologic grade refers to what extent cancer cells resemble 
normal cells; the lower the histologic grade, the more resemblance to a normal cell.
43
 
Table 2.1 summarises the features of the breast cancer molecular subtypes. 
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Table 2.1 
 Features of molecular subtypes of breast cancer
45
 
Molecular 
Subtype 
Frequency ER, PR, 
HER2 
1
CK5/6 
EGFR 
Genes of 
proliferation 
Histologic 
grade 
TP53 
mutations 
Prognosis 
Basal-like 10-20% ER
-
, PR
-
,  
HER2
-
 
+ High High High Poor 
HER2+ 10-15% ER
-
, PR
-
, 
HER2
+
 
+/- High High High Poor 
Normal 
breast 
5-10% ER
-/+
, 
HER2
-
 
+ Low Low Low Intermediate 
Luminal A 50-60% ER
+
, PR
+
, 
HER2
-
 
- Low Low Low Excellent 
Luminal B 10-20% ER
+/-
, PR
+/-
, 
HER2
+/-
 
- High Intermediate/
High 
Intermediate Intermediate/ 
Poor 
Claudin-
low 
12-14% ER
-
, PR
- 
, 
HER2
-
 
+/- High High High Poor 
1 
Cytokeratin 5/6; Epidermal Growth Factor Receptor  
2.2 STAGING AND OTHER PROGNOSTIC INDICATORS 
Several factors are used to determine the prognosis of breast cancer.
50
 The three strongest 
prognostic indicators in breast cancer are tumour size and lymph node status (determined 
by stage) and tumour histologic grade.
28
 Other factors that help determine prognosis 
include: hormone receptor status, tumour markers, and rate of cell division (mitotic 
index).
50
 
2.2.1 Stage 
Stage of breast cancer refers to the extent to which a tumour has progressed at the time of 
diagnosis and is one of the most important factors in determining prognosis and treatment 
options.
51
  Stage can be classified as either clinical stage or pathologic stage. Clinical 
stage can be determined by a physical examination and biopsy, as well as other imaging 
tests such as chest x-rays, mammograms, bone scans, computed tomography (CT) scans, 
magnetic resonance imaging (MRI), and/or positron emission tomography (PET).
51
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Clinical stage is used for determining treatment options, as well as a baseline comparison 
for the cancer’s response to treatment.51,52 Pathologic stage is determined by the 
pathologist’s examination of the lymph nodes and tumour tissue removed during 
surgery.
51,52
  Pathologic staging tends to be more accurate than clinical staging, as it 
provides a more precise impression of the extent of the cancer which can be used in 
predicting treatment response and prognosis.
51,52
    
Breast cancer stage (pathologic) is classified using  the American Joint Committee on 
Cancer (AJCC) TNM system (Appendix A).
51
  With this system, breast cancer stage is 
determined by tumour size, nodal involvement, (i.e., whether the cancer has invaded the 
surrounding lymph nodes), whether or not the cancer is locally invasive or not, and 
metastatic status. 
27,53
 Tumour size is a strong predictor of breast cancer prognosis, as 
larger tumours usually pose a higher risk of mortality and have been associated with more 
positive lymph nodes when compared to smaller tumours.
50,54
 Additionally, patients with 
breast cancers that have spread to lymph nodes (node-positive) have a 4-8 times higher 
risk of mortality and a lower 5-year survival rate than those with node-negative breast 
cancer, as well as an increased risk  of recurrence.
50,55,56
 Once the cancer has 
metastasised, the 5-year survival rate significantly decreases.
50
  
Stage I breast cancers are defined as tumours of no more than 20mm in diameter with no 
evidence of lymph node involvement or distant metastases.
27
 Stage II and III are breast 
cancers larger than 20mm in diameter and/or evidence of spread to lymph nodes and no 
distant metastases.
27
 Stage IV breast cancers are any size tumours with lymph node 
involvement and distant metastases.
27
  
Another way to stage breast cancer is summary staging, which describes how far the 
cancer has spread and groups cancer into 4 main categories: In situ, localised, regional, 
and distant.
29
 In situ cancers are defined as the presence of abnormal cells only within the 
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cell group from which they originated.
29
 Localised cancers are those in which the cancer 
has not spread past the organ of origin.
29
 Regional stage is the broadest category, and 
because the boundary between regional and distant is not always clear, it is difficult to 
properly identify.
57
 It is defined as cancer that has spread beyond the primary site to 
nearby lymph nodes.
29
 Distant cancers are those which have metastasised, or spread to 
distant lymph nodes or distant tissues or organs.
29
 Table 2.2 provides a more detailed 
summary of the breast cancer stages.    
Table 2.2 
Summary of breast cancer stages
53,58
 
TNM classification of staging  Summary 
Stage 
Stage T Class N Class M Class  
Stage 0 No evidence of 
primary tumour 
Carcinoma in situ  
No regional lymph 
nodes metastasis  
No distant metastasis  In situ 
Stage I 
 
< 2 cm in greatest 
dimension  
No regional lymph 
nodes metastasis 
No distant metastasis Localised  
Stage II     
 IIA No evidence of 
primary tumour 
Metastasis to movable 
ipsilateral axillary 
lymph node(s) 
No distant metastasis Regional  
< 2 cm in greatest 
dimension 
Metastasis to movable 
ipsilateral axillary 
lymph nodes(s) 
No distant metastasis Regional 
2-5 cm in greatest 
dimension 
No regional lymph 
nodes metastasis 
No distant metastasis Localised 
 IIB 2-5 cm in greatest 
dimension 
Metastasis to movable 
ipsilateral axillary 
lymph node(s) 
No distant metastasis Regional 
>5 cm in greatest 
dimension  
No regional lymph 
nodes metastasis 
No distant metastasis Localised  
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TNM classification of staging  Summary 
Stage 
Stage T Class N Class M Class  
Stage 
III 
    
 IIIA No evidence of 
primary tumour 
Metastasis to ipsilateral 
axillary lymph node(s) 
fixed to one another or 
to other structures  
No distant metastasis Regional  
< 2 cm in greatest 
dimension 
Metastasis to ipsilateral 
axillary lymph node(s) 
fixed to one another or 
to other structures  
No distant metastasis Regional 
2-5 cm in greatest 
dimension 
Metastasis to ipsilateral 
axillary lymph node(s) 
fixed to one another or 
to other structures  
No distant metastasis Regional 
>5 cm in greatest 
dimension 
Metastasis to ipsilateral 
axillary lymph node(s)  
OR 
Metastasis to ipsilateral 
axillary lymph node(s) 
fixed to one another or 
to other structures 
No distant metastasis Regional 
 IIIB Any size with direct 
extension to chest 
wall or skin  
Any node category No distant metastasis Regional 
Any primary tumour 
category 
Metastasis to ipsilateral 
internal mammary 
lymph node(s) 
No distant metastasis Regional  
Stage IV Any tumour 
category  
Any node category  Distant metastases 
(includes metastasis 
to supraclavicular 
lymph nodes) 
Distant  
2.2.2 Histologic grade 
Histologic grade, or differentiation, is a measure of the degree to which  cancer cells 
resemble normal cells of the same tissue type and is indicative of the potential 
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aggressiveness of the tumour.
59,60
 Each type of cancer uses a different grading system, 
and for breast cancer, grades are on a scale from 1 to 3: Grade 1 (well differentiated), 
Grade 2 (moderately differentiated), and Grade 3 (poorly differentiated).
61,62
 A lower 
grade indicates a slower-growing, less aggressive cancer and generally a better prognosis. 
Table 2.3 summarises breast cancer grades.  
Table 2.3 
Summary of breast cancer histologic grade
61
 
Histologic Grade Differentiation Significance 
Grade 1 (low grade) Well differentiated Cancer cells still resemble 
normal breast cells; cancer 
grows slowly in well-
organised patterns; not many 
actively dividing cells; 
generally less aggressive 
Grade 2 (moderate grade) Moderately differentiated Cancer cells look different 
from normal breast cells; 
cancer is growing/dividing 
faster than normal  
Grade 3 (high grade) Poorly differentiated Cancer cells look very 
different from normal breast 
cells; cells grow quickly in 
irregular patterns; many 
actively dividing cancer cells; 
generally more aggressive 
2.2.3 Hormone receptor status 
As previously stated, breast cancer cells that contain receptors, or binding sites, for 
oestrogen and progesterone are known as hormone receptor-positive cells (ER
+
 and/or 
PR+).
40
  Women tend to have a better prognosis if their tumours are hormone receptor-
positive because these cancer cells usually grow more slowly than receptor-negative 
cells.
40,50
 Hormone receptor-positive breast cancers generally respond to hormone 
therapy, such as Tamoxifen or aromatase inhibitors, and are referred to as “hormone 
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sensitive.”50 Therefore, women with receptor-positive breast cancer have more treatment 
options, as receptor-negative breast cancers can only be treated with chemotherapy as a 
drug modality.
50
 Also, women with receptor-positive breast cancer have lower mortality 
rates and a slightly lower chance of recurrence in the first five years after diagnosis than 
receptor-negative breast cancers.
46,50
  
2.2.4 Tumour markers 
Tumour markers can be substances (usually proteins) found in the blood or urine when 
cancer is present, and are useful in helping to detect and predict the aggressiveness of 
some cancers.
50
 Other tumour markers are measured using immunohistochemistry on the 
tissue itself. HER2/neu is a growth-promoting proto-oncogene and is overexpressed in 
about 20% of breast cancers.
40
 HER2-positive cancers are faster-growing, more 
aggressive, and are associated with a poorer prognosis.
40,50
 Studies suggest that the 
overexpression of HER2/neu plays a direct role in the pathogenesis and aggressiveness of 
tumours, and the presence of HER2/neu overexpression may be associated with 
metastatic disease.
63
 Slamon et al., showed that the over-expression of HER2/neu was 
strongly correlated with disease-free survival and overall survival.
64
  HER2/neu also can 
be used to predict response to  therapy as  women with HER2/neu overexpression tend to 
have a poor response to chemotherapy, resulting in a reduced disease free survival.
40,63
 
Trastuzumab is a new therapy targeted for treatment of HER2-positive breast cancers, and 
in combination with chemotherapy has shown to improve (30% improvement) the rate of 
overall 5-year survival in patients with advanced disease.
65
 Additionally in early stage 
HER2-potivie breast cancers, therapies using trastuzumab have improved overall survival 
(HR=0.66, P<0.001) and disease-free survival (HR=0.60, P<0.001) compared to 
treatments using chemotherapy alone.
66
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2.2.5 Rate of cell division 
The higher the rate of cell division, the faster a tumour grows and the more dangerous it 
is.
50
 The Mitotic Index (MI) is a measure of the rate of cell proliferation.
56
 High mitotic 
rates are associated with a more aggressive cancer and a poorer prognosis.
50,56
  
2.3 BREAST CANCER SCREENING  
2.3.1 Screening recommendations  
As previously stated, breast cancer stage refers to the degree to which a tumour has 
progressed at the time of diagnosis. Thus, early diagnosis is an important factor in 
improving prognosis. Breast cancer screening is recommended for women as a tool for 
early detection, and includes mammograms, clinical breast examinations (CBE) and 
breast self-examinations. Mammography is the most recommended tool for breast cancer 
screening for women over 50 years of age.
67
 BreastScreen Australia, a national 
mammographic breast cancer screening program, offers free mammograms every two 
years to women aged 40 years and older. However, the program is largely targeted at 
women aged 50-74, who receive invitation letters every two years.
37
 CBEs and breast 
self-exams do not have official recommendations in Australia, as there is no evidence that 
using these screening tools reduces the mortality of breast cancer.
67
 However, the 
American Cancer Society (ACS) recommends women in their twenties and thirties should 
have a CBE every three years and every year for women in their forties. Additionally the 
ACS recommends that women should begin breast self-exams in their twenties.  
2.3.2 Participation in the national breast screening program in Australia  
In 2011-2012, 1,779,524 women participated in BreastScreen Australia. Of these women, 
1,407,065 were in the target age group for this period (50-69 years), representing 54.6% 
of the Australian population aged 50-69 years.
68
 Queensland had a slightly higher 
participation rate (57.4%) than the national rate (54.6%).
68
 Participation marginally 
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increased with increasing socioeconomic status (SES) ranging from 52.7% in the lowest 
SES to 54.3% in the highest SES.
68
 Additionally, participation among the target age 
group was significantly higher in non-Indigenous women (54.4%) compared to 
Aboriginal and Torres Strait Islander women (37.8%).
68
 Highest screening rates were 
observed for women aged 60-64 years, although all five-year age groups within the target 
age group had a screening rate of 48.9% or higher (Figure 2.3).
68
 Of the women who 
participated in BreastScreen Queensland between 2011 and 2012, 12.7% were 40-49 
years, 79.1% were 50-69 years, and 8.2% were 70 years and older.
68
 Mammography rates 
varied according to remoteness area, with the lowest rate (46.0%) observed in very 
remote areas.
68
   
When surveyed about reasons for not participating in BreastScreen, women’s main reason 
(23%) for not participating was that they were ‘too lazy’ or ‘had not got around to it.’69 
Other reasons for not participating were that they did ‘not have a family history’ (19%) 
and ‘not having any symptoms’ (13%).69 
 
Figure 2.3. Distribution of BreastScreen participation by five-year age groups 
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2.4 RISK FACTORS FOR BREAST CANCER 
There are various factors known to increase the risk of breast cancer. Risk factors can be 
grouped into: 
 Age; 
 Reproductive and hormonal factors; 
 Family history and genetic susceptibility; 
 History of benign breast disease; and  
 Obesity and health-related lifestyle behaviours.  
2.4.1 Age 
Breast cancer incidence increases with age, with the majority of breast cancers (about 
75%) occurring after the age of 50 years.
27
 As age increases, the risk of being diagnosed 
with breast cancer increases greatly, with incidence rates peaking among women aged 65-
69 years (Figure 2.4).
27
 The risk for breast cancer increases with age due to the decrease 
in DNA repair capabilities as we age.
70
 As previously stated, when a cell’s DNA becomes 
damaged, the cell recognises the abnormality and will either repair the damage or undergo 
apoptosis.
43
 If DNA repair mechanisms are compromised, the DNA is not repaired and 
the cells do not die as they should, resulting in replication of abnormal cells, 
accumulation of further mutations and subsequently the formation of malignant 
tumours.
43
 
 40 Chapter 2: Background and Literature Review 
 
Figure 2.4. Age-specific incidence rates of breast cancer among Australian women in 
2011 
2.4.2 Reproductive and hormonal factors 
There is some research evidence that the more oestrogen a woman is exposed to over her 
lifetime, the greater the risk of breast cancer.
46
 Lifetime levels of oestrogen are linked 
with the age at menopause, as well as age of menarche. The later a woman goes through 
menopause or the earlier the age of menarche, the longer the breast tissue is exposed to 
oestrogens released during the menstrual cycle, which may be associated with an 
increased risk of breast cancer.
40,46
 Studies show that women who go through menopause 
over the age of 55 years or who began menstruation before the age of 12 years have an 
increased risk of breast cancer.
46
 Additionally, both the number of children a woman has, 
as well as the age at her first birth, affects the risk of breast cancer.
40,71
 Hormonal 
exposure during pregnancy stimulates the breast tissue to undergo final maturation, which 
is a protective factor against breast cancer.
72
 Nulliparous women have a greater risk of 
breast cancer than parous women, but only for breast cancers occurring after 40-45 years 
of age.
72
 Women who have their first full-term pregnancy at a younger age and women 
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with a higher number of births have a reduced lifetime risk of breast cancer. Although 
pregnancy reduces lifetime risk of breast cancer, the protection is not immediate, and can 
take up to 15 years to manifest. Furthermore, women have an increased risk of breast 
cancer for up to 10 years following first pregnancy.
72
  
2.4.3 Family history and genetic susceptibility  
A family history of breast cancer has been shown to strongly increase the risk of 
developing breast cancer.
27
 The level of risk depends on the number of relatives 
affected.
27
 Additionally, a number of genetic mutations have been linked to a family 
history of breast cancer. Gene mutations such as BRCA1 and BRCA2 are known to 
increase risk of breast cancer and occur in about 5-10% of breast cancer cases.
27
  
2.4.4 Benign breast diseases 
The risk of developing breast cancer can also increase with a history of benign breast 
conditions, including a greater risk for women with a higher density of breast tissue.
27
 
Additionally, pre-invasive breast diseases such as DCIS, LCIS and fibrocystic breast 
disease confer an increased risk of breast cancer.
27
 
2.4.5 Obesity and other health-related lifestyle behaviours 
Excess weight, particularly for post-menopausal women has been associated with an 
increased risk of breast cancer.
27
 Additionally, there is some evidence of a moderate 
association between alcohol intake and breast cancer risk. Low levels of physical activity 
have also been shown to increase risk.
27
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2.5  EPIDEMIOLOGY OF BREAST CANCER 
2.5.1 Incidence 
Breast cancer is the most commonly diagnosed cancer in Australian women.
30
 In 2011, 
14,465 women in Australia were diagnosed with breast cancer.
30
 In Queensland, breast 
cancer is the most common cancer diagnosed in women (with the exception of 
keratinocyte cancers), with approximately 2900 women diagnosed every year (Figure 
2.5). Women residing in Queensland have a 1 in 8 (or 12%) risk of being diagnosed with 
breast cancer before the age of 85 years.
27
 In 2008-2012, the incidence of breast cancer in 
Queensland was 124.0 (per 100,000 women), representing 28% of all cancer diagnoses in 
women.
73
 From 1982 until 1999, breast cancer incidence rates in Queensland had a 2.1% 
annual percentage increase.
73
 Since 1999, breast cancer incidence rates have remained 
stable, although the actual number of women diagnosed with breast cancer is increasing 
(Figure 2.6 and Figure 2.7).
73
 This is most likely due to our increasing and aging 
population. 
 
Figure 2.5. Average count per year for the most common cancers diagnosed among 
females in Queensland
73
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Figure 2.6. Incidence rate trends for breast cancer, Queensland, 1982-2012
73
 
 
 
Figure 2.7. Number of breast cancer diagnoses, Queensland, 1982-2012
73
 
Between the years 2002 to 2006, almost half (47%) of the breast cancer cases diagnosed 
were stage I, while 45% were more advanced breast cancers.
27
  The proportion of stage I 
breast cancers was greatest among women aged 50-79 years, which is consistent with 
mammogram screening occurring at this age.
27
 Women aged 0-39 years had the highest 
 44 Chapter 2: Background and Literature Review 
proportion of stages II/III/IV breast cancers (61%), which is indicative of younger women 
being diagnosed with more aggressive tumours (Figure 2.8).
27
 
 
Figure 2.8. Average number of diagnoses per year by stage of breast cancer and age 
group among females, Queensland, 2002-2006
27
 
2.5.2 Mortality  
Breast cancer mortality rates have been decreasing over time. In 2011, there were 2,914 
breast cancer-related deaths among women in Australia, which is a 30% decline in breast 
cancer deaths since 1994.
74
 Among Queensland women in 2012, the mortality rate was 
20.2 per 100,000 compared to 26.1 per 100,000 in 1982 (Figure 2.9).
73
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Figure 2.9. Mortality rate trends for breast cancer, Queensland, 1982-2011
73
 
 
2.5.3 Survival 
In recent years, survival rates of breast cancer have increased. Between the years 2006-
2010, the five-year survival rate for Australian women was 89.4%, an increase from 72% 
in 1982-1987.
75
 Stage at diagnosis has a significant influence on breast cancer survival.
27
 
Between the years 2001-2006, the 5-year survival for stage I breast cancer was 98%, 
while more advanced breast cancer stages have a 5-year survival rate of 83%. There was a 
similar pattern in survival by stage of breast cancer for women in the BreastScreen target 
age group (ages 50-69) (Figure 2.10).
27
 Breast cancer is a major public health burden, and 
in 2010, it accounted for 61,100 disability-adjusted life years (DALYs).
27
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Figure 2.10. Relative survival from female breast cancer by stage of cancer, Queensland, 
2001-2006
27
 
 
2.6 SUN EXPOSURE AND BREAST CANCER RISK AND MORTALITY  
Several studies have examined the relationship between sun exposure and breast cancer 
risk and mortality; however, results have been inconsistent. While some studies suggest 
higher levels of sun exposure protect against breast cancer risk and/or mortality, others 
have found no such relationship. Sections 2.6.1 and 2.6.2 discuss the studies which have 
investigated the association between sun exposure and breast cancer with further details 
of studies provided in Table 2.4 
2.6.1 Sun exposure and breast cancer risk 
A number of studies have reported that high levels of UV radiation are associated with a 
reduction in breast cancer incidence.
1-3,76
 For example, John et al. (1999) found a 27% 
reduction in breast cancer incidence for women living or born in areas of higher UV 
radiation (>366 cal/cm
2
/day) when compared to women living or born in areas of low 
ultra-violet radiation (<305 cal/cm
2
/day), and a greater risk reduction (31%) was seen in 
women living in an area of high UV radiation for more than half their lifetime.
1
 Other 
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studies have had similar findings, although weaker associations were observed. High 
solar radiation (2.7-4.2 kJ/m
2
/day) was associated with a 10-15% breast cancer risk 
reduction when compared to those living in areas of low solar radiation (<2.4 
kJ/m
2
/day).
2,3
 
Women living closer to the equator have a lower incidence of breast cancer.
1,2,32
 Breast 
cancer incidence rates have been shown to be positively correlated with latitude in both 
premenopausal (r=0.36) and postmenopausal (r=0.46) women in 107 countries around the 
world.
32
 Ecological studies have found that women living in more southern latitudes  have 
a lower risk of breast cancer than those living in more northern latitudes, with almost a 
30% reduction seen in women living in the south of the U.S. (<37°N) and a 10% 
reduction in women living in the south of France (<46°N).
1,2
 Similarly, a decreased risk 
of PR- and ER
+
 PR- breast cancers and breast tumours with no lymph node involvement 
was observed in women living in the south of the U.S. (37°N), although these results 
were not significant.
9
 
Breast cancer incidence has been shown to decrease with increasing time spent 
outdoors.
9,10,77
 A 26-50% reduction in  breast cancer incidence was observed  in women 
who spent >21 hours per week (vs. <6 hours/week) outdoors during all life periods 
(teenage years, 20-39 years, 40-59 years, and 60-74 years), with the strongest association 
for most time outdoors between the ages 60-74 years.
10
 Similarly, women aged 40-44 
years who spent the greatest amount of time (>2.19 hr/day) outside (used as a proxy 
measure for sun exposure)  had almost 60% less odds of breast cancer incidence than 
those who spent the least amount of time outside (<1.32 hr/day), after controlling for 
breast cancer risk factors including factors that may be associated with the amount of time 
spent outdoors, such as body mass index, waist-to-hip ratio, physical activity and sun 
protection use.
77
 A higher reduction in odds (63%) was observed when women spent the 
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majority of their time outside between the ages of 6-12 years, which is inconsistent with 
the previous study which observed a stronger effect in time spent outdoors in older 
ages.
10,77
 Millen et al. (2009) found that women who reported spending an average of less 
than 30 minutes outside per day in daylight hours, in summer, in other seasons, or year 
round, had an 18%, 23%, and 20% increased risk of breast cancer, respectively, when 
compared to women who reported spending greater than 2 hours outside per day.
9
 
Corresponding with time spent outdoors, outdoor activities have also been found to be 
inversely associated with breast cancer risk.
6,7
 Women who had the highest number of 
outdoor activities between the ages 10-19 years and 20-29 years had a 35% reduction in 
breast cancer incidence.
7
 An inverse association with increasing frequency of outdoor 
activities and breast cancer among 10-19 year olds was also reported in another study, but 
results were limited to ER
+
 /PR
+
 and ER
+
/PR
-
 tumours.
6
   
A study by John et al. (2007) measured sun exposure by taking skin pigmentation 
measures in areas usually exposed to sun (facultative) and in areas not usually exposed to 
sun (constitutive), and the difference between the two was used as an index for sun 
exposure.
18
 Results showed that increasing facultative pigmentation was associated with a 
trend for decreasing risk of advanced breast cancer in light pigmented women. Women 
with the highest sun exposure index had a 47% reduced risk of advanced breast cancer 
(p=0.02).  Another study estimated sun exposure by a dermatological assessment of skin 
damage, as well as sun-induced skin damage. Women with considerable sunlight 
exposure, as assessed by a dermatologist, and moderate to severe sun damage, had a 30% 
and 20% reduction in breast cancer risk, respectively.
1
  
However, some studies have found little or no association between sun exposure and 
breast cancer incidence. Several studies have found no differences in breast cancer 
incidence with respect to region of residence or latitude
9-12
 Also, sun protection practices 
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and erythemal UV radiation of residence were also not associated with breast cancer 
incidence in one study.
10,11
 Additionally, one study had opposite results and found that 
women living in areas of low UV radiation had a 15% decreased risk of breast cancer 
compared to women living in areas of high UV radiation, although this was not 
significant.
9
  
2.6.2 Sun exposure and breast cancer mortality  
Some studies have suggested that low levels of sun exposure may increase breast cancer 
mortality. Grant et al. (2002) found an inverse relationship  between local UV doses and 
premature mortality rates for 13 cancers, one being breast cancer.
78
 Results suggest that 
insufficient UV radiation results in 4000 premature deaths from breast cancer in white 
women, and 60 in black women.
78
 A significantly strong inverse association between sun 
exposure (measured by UV radiation and region of residence) and breast cancer mortality 
rates were observed among white women in the U.S., particularly among urban areas.
4
 
The highest mortality rates were in women living in northern states (>37N), which have 
lower UV levels, and the lowest breast cancer mortality rates were seen in areas of the 
U.S. with high daily UV radiation that exceeded 445 cal/cm
2
.
4
 Consistent with these 
findings, Freedman et al., found that residential exposure was negatively and significantly 
associated with breast cancer mortality in the U.S.
5
 Residential exposure, assessed by 
state of residence and place of birth, was assigned one of three levels of UV radiation, and 
results showed that women living in regions with the highest (OR=0.74; 95% CI:0.72, 
0.76) and medium sunlight (OR=0.84, 95% CI: 0.82, 0.86) had lower odds of breast 
cancer mortality.
5
 When looking at regions of the U.S., breast cancer mortality rates 
among women greater than 50 years old were found to be higher in the West, Midwest, 
and Northwest (MR=1.13, 1.08, and 1.13, respectively) when compared to the South, 
although the same trend was not seen in younger (< 50 years) women.
8
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Table 2.4 
Details of sun exposure and breast cancer studies 
Source and 
Year 
Year Study type Population and 
location 
UV measure used Outcome  Results 
Kuper H et al.   2009 Cohort Women aged 30-50; 
Sweden 
Self-report: sun sensitivity, 
history of sunburn, sun-
seeking holidays, solarium 
use 
Incidence  Sun sensitivity and solar exposure variables not associated 
with breast cancer risk  
Blackmore et 
al. 
2008 Case-
control 
Women <70 years 
old with invasive 
breast cancer; 
Ontario, Canada 
Self-report: time spent 
outdoors, outdoor 
activities, occupational 
exposure, sun protection, 
skin sensitivity, sun-seeking 
holidays, solarium use 
Incidence  Between ages 10-19, inverse association with increasing 
frequency of outdoor activities (presented in quartiles) for 
ER
+
/PR
+
 (OR=0.88, 0.76, and 0.65 for quartiles 2, 3, and 4, 
respectively; p=0.007) and ER
+
/PR
-
 tumours (OR=0.88, 
0.45, 0.64 for quartiles 2, 3, and 4, respectively; p=0.04) 
John EM et 
al.  
2007 Case-
control 
Hispanic, African 
American, and non-
Hispanic white 
women aged 35-79 
with invasive breast 
cancer; San 
Francisco, California, 
USA 
Self-report: outdoor 
activities, skin 
pigmentation (facultative 
and constitutive) 
Incidence Lifetime outdoor activity not associated with advanced or 
localised breast cancer in any pigment group. For light 
pigmented women, increasing facultative pigmentation 
associated with a trend for decreased risk of advanced 
breast cancer (OR=0.73, 0.56, 0.54 or quartiles 2, 3, and 4, 
respectively; p=0.02) and reduced breast cancer risk for 
those with the highest sun exposure index compared to 
lowest  (OR=0.53; p=0.02) 
Millen et al.  2009 Cohort Postmenopausal 
women (ages 50-79 
years); USA 
Region of residence: 4 
regions: 1) South (<37° N), 
2) North (>40°N), 3) Middle 
(between N and S), and 4) 
outside US; solar 
irradiance; self-report: skin 
response to sun 
Incidence No association with region of residence at birth or with 
other measures of solar irradiance. Women spending <30 
min/day outside in daylight hours, when compared 
to >2hrs/day, in summer, in other seasons, and year round 
had an 18% (HR=1.18), 23% (HR=1.23), and 20% (HR=1.20) 
increased risk of breast cancer, respectively (p=0.001 for 
trend).  
John EM et 
al.  
1999 Cohort White women, aged 
25-74; USA 
Self-report: time spent 
outdoors, recreational and 
occupational exposure; 
dermatological exam, 
residential exposure  
Incidence Risk reductions for women with considerable sun exposure 
assessed by physician report (RR=0.70), moderate to 
severe sun damage (RR=0.80), and frequent recreational 
and occupational sun exposure (RR=0.67). Reduced risk for 
women living in the South (RR=0.73) and those born in a 
state of high solar radiation (RR=0.69)   
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Source and 
Year 
Year Study type Population and 
location 
UV measure used Outcome  Results 
Gorham et al. 1990 Ecological USSR  Total average annual 
ambient UV per day  
Incidence Republics with least sunlight had higher rates of breast 
cancer (23.5 and 22.8) compared to areas with 
intermediate sunlight (16.9, 12.3, and 11.2) and highest 
sunlight (9.0, 7.8, 8.5). Correlation between breast cancer 
incidence and sunlight levels (R=-0.75, p=0.001)  
Engel et al. 2011 Cohort France  Residential exposure, 
average daily UV dose solar 
irradiance estimates 
Incidence Living in regions with the highest UV dose (>2.7kJ/m2/day) 
associated with decrease breast cancer risk compared to 
women living in regions with the lowest UV dose (HR=0.91, 
p=0.06), especially for postmenopausal women (HR=0.92, 
p=0.05. Decreased risk of breast cancer for women living 
in the North (>49°N) compared to women living in the 
South (<46°N) (HR=0.90, p=0.02) 
Boscoe et al.  2006 Ecological White and black 
women within the 
SEER registries; USA 
UV data from NASA’s TOMS Incidence, 
Mortality  
Weak association between UV and breast cancer. 
Higher incidence (RR=1.15) and mortality (RR=1.11) 
in the north than south for blacks. Same association 
for whites but weaker with a RR=1.06 for incidence 
and RR=1.15 for mortality 
Mohr et al. 2008 Ecological 107 countries  Latitude, adjusted UVB 
irradiance (TOMS) 
Incidence Age-adjusted incidence rates were higher at latitudes 
distant from the equator (R
2
=0.43, p=0.00). Latitude was 
positively related to breast cancer incidence rates for both 
premenopausal (r=0.36) and postmenopausal (r=0.46) 
women 
Grant et al. 2002 Ecological White and black 
women; USA 
(excluding AK, AZ, CA, 
FL, and NE) 
DNA-weighted UVB 
radiation (TOMS), UVB data 
from USDA monitoring 
stations  
Mortality Approximately 15,000 white and 700 black 
Americans annually died prematurely from cancer 
between 1970-1994 due to insufficient UVB 
radiation. For breast cancer, insufficient UV was 
associated with  4000 premature deaths per year  in 
whites (r=-0.67)and 60 deaths per year in blacks (r=-
0.30)(per year)  
Garland et al. 1990 Ecological 87 locations Average annual sunlight Mortality Highest mortality rates seen in Northern and 
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Source and 
Year 
Year Study type Population and 
location 
UV measure used Outcome  Results 
throughout the USA 
(1950-1969) 
measures based on NOAA Northeastern states, which receive less sunlight than 
rest of country. Strong inverse association between 
sunlight and mortality rates among white women in 
urban areas (r=-0.80, p<0.00). Lowest rates in 
Honolulu, Phoenix and Tampa, Fort worth, Las 
Vegas, and Albuquerque, which  had an average UV 
of  >445 cal/cm
2
 
Freedman et 
al. 
2002 Case-
control 
USA Residential exposure, solar 
radiation from US weather 
bureau, occupational 
exposure from death 
certificate 
Mortality Residential exposure was negatively associated with 
mortality from breast cancer, among those in the 
highest (OR=0.74) and medium (OR=0.84) sunlight 
region. Outdoor non-farming jobs significantly 
associated with decreased odds of breast cancer 
(OR=0.82).  
Sturgeon et 
al. 
1995 Ecological White women aged 
20-79; USA 
Place of residence  Mortality Breast cancer mortality among older women (>50 
years) was higher in the West (MR=1.13), Midwest 
(MR= 1.08), and the Northwest (MR= 1.13) when 
compared to the South 
Fuhrman et 
al.  
2013 Case-
control 
Women with invasive 
breast cancer; USA 
Self-report: time spent 
outdoors; annual UVB 
measures 
Incidence No significant differences with respect to geographic 
region of residence at study baseline or for average annual 
sunlight for the state of residence at baseline. Marginally 
significant trend across quartiles of ambient UV for state 
of birth (OR=0.86, 0.85, and 0.69 for quartiles 2, 3, and 4, 
respectively). No trend for time spent outdoors and breast 
cancer risk 
Anderson et 
al.  
2011 Case-
control 
Mostly white (90%) 
women aged 25-74 
years; Ontario, 
Canada 
Self-report: time outdoors, 
sun protection, residential 
history, skin colour; UVB 
radiation (TOMS) 
Incidence High solar vitamin D score (calculated from UV hours per 
week, skin colour, and sun protection) was associated with 
a reduced risk of breast cancer across all age periods 
(OR=0.79, 0.76, 0.75, 0.64, 0.59 for  teenage years, 20s-
30s, 40s-50s, 60s-74, respectively). Time spent outdoors 
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Source and 
Year 
Year Study type Population and 
location 
UV measure used Outcome  Results 
was associated with a reduced risk of breast cancer during 
4 periods of life (>21 vs. <6 hours/week) (OR=0.71, 0.64, 
0.74, & 0.50 for teenage years, 20s-30s, 40s-50s, 60s-74, 
respectively). Sun protection practices, latitude, and 
erythemal UV of residence were not associated with 
breast cancer. 
Laden et al. 1997 Ecological USA Place of residence  Incidence No association between region of residence and breast 
cancer risk  
Robsaham et 
al.  
2004 Cohort Norway Self-report: occupational 
exposure; average annual 
UV radiation  
Mortality No association between residential UV radiation and case 
fatality for breast cancer. Breast cancer cases diagnosed in 
autumn had a lower case fatality than those diagnosed in 
winter (RR=0.85, 0.70 for two groups). No trend seen for 
UV and occupational exposure  
Wu et al.  2013 Cohort  Premenopausal 
women aged 35-45 
years; Hong Kong 
Self-report: skin reaction to 
sun, time spent outdoors, 
sun protection, outdoor 
activities, occupational 
exposure, solarium use; 
residence  
Incidence Inverse association between time spent in sun and breast 
cancer risk - Women aged 40-44 who were at highest 
tertile of lifetime hrs spent outdoors (>2.19 hr/day) had a 
lower risk of breast cancer (OR=0.41) compared to those 
in the lowest tertile (<1.32 hr/day). Women aged 40-44 in 
highest tertile of time in sun between the ages of 6 and 12 
had lower breast cancer risk (OR=0.37), but no association 
across age groups 13-19, 20-34, and over 35 years.  
Engel et al.  2014 Cohort North Carolina and 
Iowa, USA 
Self-report: time spent in 
sun, occupational 
exposure, sun protection  
Incidence Small decreased risk in women with sun exposure >1 
hr/day compared to <1 hr/day 10 years before enrolment 
(HR=0.80; 95%CI: 0.6,1.0), association slightly stronger in 
ER
+ 
tumours (HR=0.70; 95%CI: 0.5,0.9) than ER
-
 tumours 
(HR=1.10, 95%CI: 0.6,2.1)  
Knight et al.  2007 Case-
control 
Women <70 years 
with invasive breast 
cancer; Ontario, 
Canada 
Self-report: sun exposure 
history, time spent 
outdoors, outdoor 
activities, occupational 
exposure, sun protection, 
skin reaction to sun, sun-
seeking holidays, solarium 
use 
Incidence  Women aged 10-19: reduced risk for outdoor activity 
episodes for 3rd quartile (OR: 0.74; 0.57, 0.96) and 4th 
quartile (OR: 0.65; 0.50, 0.85) compared to lowest quartile 
of outdoor activity. Reduced risk with outdoor job for 1 
year (OR: 0.69; 0.50, 0.96) and >1 year (OR: 0.61; 0.46, 
0.80) with compared to never having an outdoor job. 
Women aged 20-29: Reduced risk of breast cancer for 
those spending 7 days per week outside (OR: 0.72; 0.56, 
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Source and 
Year 
Year Study type Population and 
location 
UV measure used Outcome  Results 
0.93) when compared to <3 days. Reduced risk of breast 
cancer with increasing outdoor activity episodes (2nd 
quartile: OR=0.65; 3rd quartile: OR=0.72; 4th quartile: 
OR=0.65). No significant associations for ages 45-54. 
Yang et al.  2011 Cohort Women aged 30-49 
years; Sweden 
Self-report: history of 
sunburn, sun-seeking 
holidays, solarium use 
Incidence Reduced breast cancer risk among women who spend one 
week or more per year on sunbathing vacations between 
ages 10-29 years (HR: 0.56; 95%CI: 0.36,0.89). Decreased 
risk of breast cancer for women whose skin colour was 
brown after chronic sun exposure, compared to those 
whose skin was light or never brown (HR=0.85; 95%CI: 
0.73,0.99). Reduced risk of breast cancer among women 
who used the solarium between 10-39 years (HR: 0.63; 
95%CI: 0.41, 0.96). No association between breast cancer 
risk and annual number of sun burns. 
Edvardsen et 
al.  
2011 Cohort Norway  Self-report: sun-seeking 
holidays, solarium use, 
frequency of sunburn; solar 
radiation for place of 
residence 
Incidence No association between solar radiation, sun-seeking 
holidays, solarium use, or frequency of sunburn and breast 
cancer risk.  
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2.6.3 Summary 
Although several studies have examined the relationship between lifetime sun exposure 
and breast cancer risk or mortality, results have been inconsistent.  This is most likely due 
to study heterogeneity and inconsistencies in how lifetime sun exposure was measured. 
Latitude, region of residence, ambient UV measures, and self-reported data (time spent 
outdoors, outdoor activity, occupational exposure, sun-seeking holidays, solarium use, 
sun sensitivity, and other sun behaviours) have been used among studies to measure sun 
exposure. The absence of a gold standard to measure sun exposure in individuals is a 
limitation. However, regardless of the differences in sun exposure measures, there is 
some evidence to suggest there may be  a relationship between sun exposure and breast 
cancer, although the mechanism by which sun exposure affects breast cancer is still 
unknown.  
 
2.7 POSSIBLE MECHANISMS BY WHICH SUN EXPOSURE MAY 
PROTECT AGAINST BREAST CANCER  
Possible mechanisms by which UV exposure may protect against breast cancer include: 
melatonin production, folate degradation, and UV-induced vitamin D production.
79,80
 
2.7.1 The role of melatonin 
Studies have found that melatonin levels are associated with reduced breast cancer risk.
79
 
Melatonin exerts anti-cancer effects via inhibition of cellular proliferation and stimulation 
of apoptosis and differentiation of breast cancer cells.
81,82
  It is also a hormone that 
induces sleep and plays an important role in synchronising circadian rhythms.
79
  Its 
production by the pineal gland is inhibited by bright blue light, so levels are highest 
during the night.
79
  Breast cancer incidence is not randomly distributed throughout the 
year, but varies with the amount of sunlight and seasonally.
83
  More breast cancer is 
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diagnosed in the spring and autumn than in winter and summer, in both the Northern and 
Southern Hemispheres, and regardless of menopausal status; however, seasonality is more 
prominent as population distance from the equator increases.
83
  Melatonin production is 
higher during the winter than the summer, as there are fewer daylight hours in the 
winter.
79
 Thus melatonin may reduce the risk of breast cancer in the winter, which may 
explain the lower number of diagnoses during this season.
79,83
  Lack of sunlight and being 
exposed to artificial light at night can disrupt circadian rhythms and suppress melatonin,
84
 
and possibly prevent melatonin-induced tumour suppression.
85
 Some studies have shown 
that circadian rhythm disruption may also play an important role in the progression of 
cancer.
86
 One study found that individuals who work evening/overnight shifts are exposed 
to light at night and may have an increased risk of breast cancer.
84
  Consistent with these 
findings, Knutsson (2013) found that individuals who worked night shifts had an 
increased risk of breast cancer (HR=2.02, 95% CI: 1.03, 2.07) compared to those who 
didn’t work night shifts.87 However, a study conducted in Western Australia found no 
consistent association between shift work and breast cancer, although the authors 
acknowledged some shift work-related factors may be associated with breast cancer.
88
   
2.7.2 Folate degradation  
Another possible mechanism by which UV exposure protects against breast cancer is by 
UV-induced folate degradation.
80
 Prognosis varies with the season of diagnosis, with 
higher breast cancer survival rates in women diagnosed in the summer or autumn.
83
 It has 
been hypothesised that this could be due to sun-induced folate degradation.
80
 Folate is an 
essential metabolite for DNA replication and cell division.
80
 In cancerous tissues, where 
cells are dividing very rapidly, low levels of folate would be expected to alter DNA 
synthesis and induce the inhibition of tumour growth.
80
 Some animal experiments have 
shown that low folate levels or administration of a folate antagonist promote 
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tumourigenesis.
80,89
 However, results of these studies have been very inconsistent, and 
more research is required.  
2.7.3 Vitamin D synthesis  
Exposure to UV activates the body to produce vitamin D.
79
 Through various mechanisms, 
the biologically active form of vitamin D, 1-α,25-dihydroxyvitamin D3 (1,25(OH)2D3), 
can impact breast carcinogenesis by inhibiting cellular proliferation and inducing 
differentiation and apoptosis in breast cancer cells.
6,9,13-18
 Lower levels of vitamin D, as 
measured by 25-hydroxyvitamin D (25(OH)D), are associated with a reduced risk of 
breast cancer incidence and mortality.
1,19-23
  The sun-activated synthesis of vitamin D is 
the most likely mechanism for UV protection against breast cancer, and will be discussed 
in further detail.  
2.8 VITAMIN D AND ITS ROLE IN HUMAN HEALTH  
2.8.1 Introduction 
Vitamin D, commonly referred to  as the sunshine vitamin, is very important to the 
development, growth, and maintenance of the human body.
90
 Vitamin D is a fat-soluble 
molecule that is an essential precursor to the steroid hormone, calcitriol.
34
 Two types of 
vitamin D exist: Vitamin D3 and Vitamin D2. Vitamin D3 (cholecalciferol) occurs 
naturally in food sources or is derived from sunlight from the precursor 7-
dehydrocholesterol (7-DHC).  Vitamin D2 (ergocalciferol) is formed by a conversion of 
the plant steroid ergosterol by UV radiation.
13,34
 Vitamin D can be obtained through 
certain foods, supplements, and exposure to sunlight. Vitamin D occurs naturally in fatty 
fish, eggs, and some meats, but most adults are unlikely to obtain more than 5-10% of 
their vitamin D requirement through dietary sources.
91
 
,92
 The average daily intake of 
vitamin D has been measured to be very low in the Australian population, varying from 
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80-120 IU per day, while the daily recommendations range from 600-800 IU/day.
91,93
 
Supplements and fortified foods such as milk, juice, yogurt and cheese, are other potential 
sources of vitamin D, although vitamin D fortification of food is not widespread in 
Australia.
91,92
 Exposure of the skin to sunlight is the main source of vitamin D and 
accounts for 80-95% of circulating vitamin D in humans.
32
 
2.8.2 Metabolism and functions 
Vitamin D is synthesised in the skin by UV radiation.
94
 Once UVB radiation (290-320 
nm) is absorbed by the skin, it converts to the natural precursor 7-dehydrocholesterol to 
vitamin D3 (cholecalciferol).
95
 Vitamin D3 is then hydroxylated in the liver by the enzyme 
25-hydroxylase (CYP27A1) to form the circulating metabolite 25-hydroxy vitamin D3 
(25(OH)D).
94
 Catalysed by 1-α-hydroxylase (CYP27B1), 25(OH)D is then hydroxylated 
in the kidney to produce 1-α,25-dihydroxyvitamin D3 (1,25(OH)2D3), or calcitriol (see 
Figure 2.11).
95
 Calcitriol is the biologically active metabolite of vitamin D that circulates 
in the blood in an endocrine fashion and applies its actions by binding to nuclear vitamin 
D receptors (VDR) in the intestine, bone, breast, and other tissues.
14,96
 VDR belongs to a 
nuclear hormone receptor superfamily that regulates gene transcription.
21,97
 The endocrine 
functions of 1,25(OH)2D3 include the homeostasis regulation and metabolism of calcium 
and phosphorus, regulation of other hormones, and regulation of the immune system.
95
 
However, recent research suggests that calcitriol produced locally may inhibit the growth 
of cancerous cells by triggering apoptosis.
34
 
The endocrine conversion of 25(OH)D to 1,25(OH)2D3 is tightly regulated by parathyroid 
hormone (PTH), calcium, phosphorous, and fibroblast growth factor 23 in the kidneys.
33
 
Therefore, an increase in exposure to sunlight will result in an increase in 25(OH)D 
levels, but not in circulating 1,25(OH)2D3 levels.
33
 Through autocrine mechanisms, 
1,25(OH)2D3 can be synthesised locally in breast and other tissues.
33
 Many tissues in the 
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body, including the breast, express 1-α-hydroxylase that is not as tightly regulated as it is 
in the kidneys.
33,34
 Raising the concentration of circulating 25(OH)D, which acts as a 
substrate, determines the rate of local production of 1,25(OH)2D3 (shown in Figure 
2.11by the dotted line).
33,34
 This local production of 1,25(OH)2D3 is believed to be 
important in regulating cell growth.
33
 More than 50% of the world’s population and 
nearly one-third of Australians have some form of vitamin D insufficiency and about 5-
6% are deficient .
91,98
                                                                                                               
                                                                                              
 
Figure 2.11. Vitamin D metabolism
34
 
2.8.3 Factors affecting vitamin D production  
Several factors can influence the cutaneous (skin) production of vitamin D. Because the 
majority of vitamin D is produced by sunlight, variables affecting UV radiation can 
influence vitamin D levels, such as pollution, cloud coverage, altitude, latitude, season, 
and time of day. Additionally, vitamin D production can be affected by the use of sun 
protection (e.g., sunscreen, protective clothing, duration of exposure, age, skin colour, 
and body fat).  
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2.8.3.1 Variables affecting UV radiation 
Several variables can affect the amount of UV radiation in a particular geographical area, 
thus limiting the ability for cutaneous production of vitamin D. This includes individuals 
who live in areas with high air pollution and high cloud coverage.
99,100
 Stratospheric 
ozone and air pollution containing ozone absorb UVB photons, thus reducing the 
cutaneous production of vitamin D.
101
 UV is also dependent  on geographic location 
(altitude, and latitude) and season.
101
 For every 1 km increase in altitude, solar UV 
radiation increases by about 7%, assuming clear sky conditions.
102
 Vitamin D levels are 
inversely associated with latitude, especially in areas 37 degrees or more from the 
equator, thus individuals living at high latitudes are at an increased risk of vitamin D 
deficiency.
22
 Because UV radiation is greater in the summer months, seasonal changes 
from summer to winter will affect the amount of cutaneous vitamin D production. A 
study conducted  in Boston, illustrated that cutaneous production of vitamin D was at a 
maximum in June and July and gradually declined as the autumn and winter months 
approached.
101
 Vitamin D production from sunlight is also dependent on the time of 
day.
101,103
 Generally, the best times of day for adequate vitamin D production are 
10:00am to 2:00pm, however this will vary depending on latitude
103
   
2.8.3.2 Factors decreasing ability for vitamin D production    
Factors that can potentially decrease individual sun exposure, and thus decrease the 
ability for vitamin D production, are use of sunscreen and sun protection.
100
 Additionally, 
age, skin colour, and body fat may also play a role in an individual’s ability to produce 
vitamin D.
100
 The proper use of sunscreen with a sun protection factor (SPF) of 15 
reduces cutaneous production of vitamin D by more than 99%.
104
 Also, the amount of 
skin exposed to the sun, which is dependent on sun protective clothing, affects vitamin D 
production. One study found that a minimum of 40% of skin surface should be exposed to 
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the sun for optimal vitamin D production.
105
 Older individuals, particularly those over the 
age of 50 years, have an increased risk for low vitamin D levels. As individuals age, the 
amount of 7-dehydrocholesterol in the skin decreases, for example a 70 year old has a 
25% reduced capacity to produce vitamin D compared to  a young adult.
106
 Holick (1995) 
reported that when the elderly and young adults were exposed to 15 minutes of solar 
radiation, younger subjects had a larger increase in vitamin D concentration than older 
subjects.
101
 Furthermore, as people age, the kidney produces less calcitriol, as vitamin D 
is not synthesized efficiently by the skin.
107
 Darker skin pigmentation is another risk 
factor for low vitamin D levels as greater amounts of melanin diminish the efficiency for 
the production of vitamin D from sunlight.
100,101
 Vitamin D production occurs up to six 
times faster in light skinned individuals (Skin type I-III) than in dark skinned individuals 
(Type IV & V).
108,109
 Furthermore, Clemens et al. have illustrated that dark-skinned 
populations may require 10-50 times more exposure to UVB radiation to produce the 
same amount of vitamin D as lighter skinned populations.
110
 Individuals who have high 
percentages of body fat are also at an increased risk for vitamin deficiency.
99
 Because so 
many variables can affect vitamin D production, it is very difficult to determine the 
necessary length of sun exposure time for an individual to produce optimal amounts of 
vitamin D.
111
 
2.9 THE ROLE OF VITAMIN D IN BREAST CANCER RISK AND 
SURVIVAL  
Various studies have examined the association between 25(OH)D serum levels (the best 
estimates of vitamin D status) and breast cancer risk. Most found that serum 25(OH)D 
levels in the highest category (>42-52 ng/mL) were associated with up to a 50% reduction 
in breast cancer risk.
15,20,21,99
 Although these studies found an inverse association between 
high serum 25(OH)D  levels and breast cancer risk, there are still discrepancies on how 
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much vitamin D is needed. Additionally, studies have examined the relationship between 
25(OH)D levels and tumour size, and found that high levels of 25(OH)D are associated 
with a smaller tumour size.
112
 One study found specifically that a decrease of 0.40 +/- 
0.15 ng/mL in serum 25(OH)D levels led to a 1cm increase in tumour size.
112
 These 
findings suggest that vitamin D may apply  a growth-inhibitory effect in the early phase 
of tumour initiation and growth.
112
  
In vitro studies have proposed several mechanisms by which vitamin D protects against 
breast cancer, including the inhibition of cellular proliferation and induction of cell 
differentiation and apoptosis of breast cancer cells.
94
 Although in vitro studies find that 
vitamin D protects against breast cancer risk, in vivo studies have produced more 
inconsistent results. Individual breast cancer-related variables, such as menopausal status, 
tumour receptor status, vitamin D receptor status, and calcium levels, may affect the 
association and/or the magnitude of the association between vitamin D and breast cancer.   
2.9.1 Possible mechanisms of action  
1,25(OH)2D3 can impact breast carcinogenesis by inhibiting cellular proliferation and 
inducing differentiation and apoptosis in breast cancer cells.
6,9,13-18
 1,25(OH)2D3 induces 
apoptosis by suppressing the expression of anti-apoptotic genes, such as Bcl-2, and can 
diminish ER expression and inhibit oestrogen stimulation of cellular proliferation in ER
+
 
breast cancer cells.
15,21
 Angiogenesis, the process by which new blood vessels form from 
pre-existing vessels, is necessary for tumours to continue to grow and spread.
113
 
1,25(OH)2D3 has been demonstrated to exhibit anti-angiogenic activity, which contributes 
to a reduced likelihood of metastasis.
93,114
 In carcinogen-exposed rats, 1,25(OH)2D3 
decreases breast cancer tumour size, delays mammary tumour development, and reduces 
overall breast cancer incidence.
6
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Further, 1,25(OH)2D3 reduces the expression of Cyclooxygenase (Cox-2) in both ER
-
 and 
ER
+
 cells, and there is a clear inverse relationship between Cox-2 protein levels and 
disease-free breast cancer survival.
15
 Cox-2, is an early response gene and its expression 
is activated by cytokines, tumour promoters, and growth factors, and it is over expressed 
in about 40% of breast carcinomas.
15
 This over-expression is highly correlated with large 
tumour size, higher histology grade, increased proliferation, and an overall poorer 
prognosis.
15,34
 
1,25(OH)2D3 is also associated with ki67, as previously discussed, a protein that 
stimulates cell proliferation.
21
 High ki67 levels result in a higher number of actively 
dividing breast cancer cells and is associated with poorer prognosis.
115,116
  
P53 is a tumour suppressor protein that can be mutated in some breast cancers.
115
 When 
the  TP53 gene is mutated, tumour suppression is reduced.
46
 Breast cancers with TP53 
mutations demonstrate high rates of proliferation due to high levels of ki67.
115
 One study 
showed that 25(OH)D serum levels in patients with TP53 mutations were significantly 
lower than in patients without TP53 mutations.
117
 This may provide some explanation for 
the role that vitamin D plays in influencing breast cancer outcomes.
117
  
The epithelial-mesenchymal transition (EMT), a process that is characterised by a loss of 
cell adhesion, is crucial to the development of cancer. When contact between cells is lost, 
cancer cells can begin to move from their site of origin and can eventually metastasise to 
other parts of the body.
44
 E-cadherin is an adhesion molecule expressed in most normal 
epithelial tissues, and is considered a tumour suppressor gene since cell adhesion inhibits 
cell division.
44,118
 Loss of the E-cadherin gene is common in cancer cells and is associated 
with a poor prognosis.
44
 1,25(OH)2D3 increases the expression of E-cadherin, helping to 
inhibit EMT and prevent invasion and metastasis.
44,93
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2.9.2 Factors affecting 25(OH)D and breast cancer risk  
Several breast cancer-related factors may affect the association between vitamin D and 
breast cancer. These include menopausal status, tumour receptor status, vitamin D 
receptor (VDR) status and calcium levels.  
2.9.2.1 Menopausal status  
Studies examining the association between menopausal status and breast cancer risk have 
shown inconsistent results. One study found that plasma 25(OH)D levels were inversely 
associated with breast cancer risk, but the risk reduction was more evident in post-
menopausal women versus pre-menopausal women.
20
 A similar study also found a 
significant inverse association between 25(OH)D serum concentration and risk of breast 
cancer, but the association was more pronounced in pre-menopausal women compared to 
post-menopausal women.
119
 When examining vitamin D and breast cancer in either pre-
menopausal or post-menopausal women only, an inverse association exists for both.
120,121
  
2.9.2.2 Receptor status  
The association between breast cancer risk and vitamin D levels appears to vary 
depending on tumour receptor status. Studies have shown a stronger inverse association 
between vitamin D and breast cancer risk in receptor-positive tumours than in receptor-
negative tumours (OR=5.0 for receptor-positive breast cancers with low vitamin D versus 
OR=1.1 for receptor-negative breast cancers with low vitamin D).
122
 Some studies show 
that vitamin D reduces the risk of ER
+
 breast cancers, but not of ER
-
 breast 
cancers.
6,17,122,123
 One possible mechanism of action could be that ER
+
  breast cancer cells 
appear to be more sensitive to the growth inhibitory effects of calcitriol than ER
-
 cells, 
and calcitriol may directly regulate the transcription of the ER gene.
34,123
 In a study 
involving post-menopausal women, results indicated that there was no difference in the 
effect of vitamin D on breast cancer by receptor status.
121
 These findings were 
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inconsistent with  data from the Nurse’s Health Study (NHS), which reported an inverse 
association for ER
-
/PR
-
, but not for ER
+
 /PR
+
 and ER
+
/PR
-
 tumours.
121
 A further study 
examining the association between vitamin D and breast cancer risk in pre-menopausal 
women found a strong inverse relationship in ER
-
 and PR
-
 tumours only.
120
 One study 
examined the association between 25(OH)D concentrations at diagnosis and the tumour 
receptor status.
124
 Results showed that higher concentrations of 25(OH)D  were 
significantly associated with a reduced risk for both pre-menopausal and post-menopausal 
breast cancer, but only in ER
-
/PR
-
 tumours.
124
 This study also showed that patients with 
ER
-
 tumours tended to have lower 25(OH)D concentration levels, and that VDR 
expression was lower in patients with ER
-
 tumours versus ER
+
 tumours.
124
 A possible 
explanation for this is that vitamin D interferes with the oestrogen signalling pathway, 
and this could prevent the occurrence of ER
-
 breast cancers.
124
  
2.9.2.3 Vitamin D receptors (VDR) 
1,25(OH)2D3 inhibits growth and promotes differentiation of breast tumour cells and 
VDR is required for these actions to take place.
1,125
 After 1,25(OH)2D3 binds to the 
receptors, the VDRs then bind to DNA sequences, which regulate gene transcription.
18
 In 
a study that examined the expression of the enzymes CYP27A1 and CYP24B1 in breast 
tissues, which are responsible for the synthesis of 25(OH)D and 1,25(OH)2D3, 
respectively, results indicated that VDR is more frequently expressed in benign lesions 
and the levels of expression decrease with tumour stage.
97
 It has been suggested that 
during tumour development, vitamin D signalling is disrupted, resulting in the 
proliferation of cancer cells.
97
 Another study using knockout mice demonstrated 
increased proliferation and reduced apoptosis in mice lacking the VDR.
125
 One reason 
that breast cancer tumours are more prevalent in individuals with loss of VDR expression 
may be due to the relationship between VDR and TP53. TP53 is a good indicator of 
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cellular stress, and if damaged, tumour suppression is reduced, resulting in increased 
proliferation.
46,125
 Recent studies show that P53 up-regulates VDR, suggesting that 
regulation of VDR pathways may aid in the suppressive effects of P53, specifically those 
that function in cellular response.
125
 There has also been increasing interest in discovering 
how polymorphisms of the VDR gene may affect the risk of breast cancer.
96
 Although 
several polymorphisms have been identified, it is not known how these differences affect 
the receptor protein. 
96
 One study found a significant association between breast cancer 
and the Bsm-1 polymorphism. Results showed that the homozygous recessive genotype 
(bb) was associated with an increased risk of breast cancer four times that of the 
homozygous dominant genotype (BB).
96
 Most research on VDR polymorphisms, 
however, has yielded inconsistent results.  
2.9.2.4 Calcium  
Calcium is required for a number of physiological and biochemical functions in the 
body.
126
 In order for these functions to be carried out, calcium must be absorbed 
efficiently, and vitamin D assists in the absorption of calcium and regulation of calcium 
levels.
126
 Because vitamin D and calcium are highly correlated, several studies have 
examined how calcium may act as a protective factor in breast cancer risk. Some case-
control studies have reported an inverse association between calcium and breast cancer 
risk,
127-129
 while others have found no significant association.
130
 A randomized control 
trial comparing calcium alone, calcium plus vitamin D, and a placebo in lowering the risk 
of breast cancer found both calcium alone (RR=0.532) and calcium plus vitamin D (RR 
=0.402) provided a greater protective effect than the placebo.
131
 The authors suggested 
that calcitriol concentrations are reduced by the high intake of calcium.
131
 High breast 
density is associated with an increased risk of breast cancer, and lower breast density has 
been associated with higher vitamin D and calcium levels.
13
 In a study evaluating the 
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association between vitamin D and calcium and breast density, results showed that breast 
density was inversely associated with dietary calcium and vitamin D intake among post-
menopausal women.
132
 Because vitamin D and calcium are interrelated, it is difficult to 
determine their independent associations with breast cancer.
13
 
2.9.3 Summary 
As the population increases and ages, the number of women diagnosed with breast cancer 
is expected to increase, presenting a significant public health burden.
133
 Research has 
shown that sun exposure and vitamin D may have an association with breast cancer. 
While research has indicated that vitamin D may be a protective factor, it is still unknown 
how much vitamin D is required in order to act as a protective factor for breast cancer. 
Exposure of the skin to the sun accounts for approximately 80-95% of vitamin D 
production. Because the amount and intensity of UV radiation varies by latitude, location 
of residence might have a significant impact on breast cancer. Ecological studies have 
examined geographic residence and breast cancer incidence, but results have been 
inconsistent. Although some research has examined the relationship between vitamin D 
and prognostic factors, little to no research has been conducted examining whether there 
is an association between sun exposure and breast cancer stage, which is the most 
important prognostic factor.  
2.10 CONCLUSION AND RATIONALE FOR RESEARCH  
While some research has shown that sun exposure and vitamin D have an inverse 
association with breast cancer risk and mortality, results have been inconclusive and gaps 
in knowledge remain. Also, major inconsistencies exist when examining vitamin D levels 
and breast cancer by menopausal status and hormone receptor status. There is also a lack 
of epidemiological research conducted on UV exposure and/or vitamin D and breast 
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cancer stage.  Currently, there are no studies that have examined whether association 
between lifetime sun exposure and breast cancer stage exist. Because vitamin D has been 
shown to induce apoptosis and inhibit cellular proliferation, it seems plausible that an 
association exists with the progression of breast cancer. There is also a lack of knowledge 
pertaining to the question of: at which age  does sun exposure matter most, in terms of 
protection against breast cancer progression? This project will aim to answer this 
question. This research has the potential to improve the understanding of the effects of 
vitamin D, through sun exposure, on breast cancer stage at diagnosis.   
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Chapter 3: A SEER Population Based Analysis of 
Breast Cancer Stage and Location of 
Residence in the United States 
The first part of my PhD was a study developed to examine the relationship between 
location of residence (in the U.S.) and breast cancer stage. Data were obtained from the 
Surveillance, Epidemiology and End Result (SEER) program, a publically available 
database representative of the demographics of the U.S. population.  
These data was used due to its large population size, comprehensive collection of 
variables (demographic and tumour-related) and broad latitude bands of locations. This 
allowed the investigation of the research question: “Does location of residence impact on 
breast cancer stage at diagnosis?”  
3.1 INTRODUCTION  
In the U.S., breast cancer remains the most common cancer diagnosed amongst women 
(excluding keratinocyte cancers) and the second most common cause of cancer 
mortality,
134
 with 220,097 breast cancer diagnoses and 40,931 breast cancer associated 
deaths in 2011.
134
 Location of residence may be associated with breast cancer stage as 
several reports indicate that living in locations closer to the equator may reduce both 
incidence and mortality from breast cancer.
1,2,8,32
 A recent, large, French population 
cohort study revealed that women who resided at southern latitudes (<46° N) had a 10% 
decreased risk of breast cancer compared to women living at northern latitudes (>49°N).
2
 
Similarly, another study revealed a dose-response relationship between breast cancer 
incidence rates and latitude in 175 countries, with breast cancer incidence increasing as 
the distance from the equator increased (R
2
=0.43, P<0.001).
32
 Sturgeon et al. found that 
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older women (>50 years) living in the northeast (Maine, Vermont, New Hampshire, 
Massachusetts, Connecticut, Rhode Island, New York, New Jersey, Pennsylvania) of the 
U.S. had a 13% greater risk of breast cancer mortality compared to women in the south 
(Delaware, Maryland, D.C., West Virginia, Virginia, Kentucky, Tennessee, North 
Carolina, South Carolina, Georgia, Florida, Alabama, Mississippi, Louisiana, Oklahoma, 
Arkansas, and Texas).
8
  
While studies have investigated the relationship between location of residence and breast 
cancer incidence and mortality, no research has been conducted on location of residence 
and breast cancer stage at diagnosis. The aim of this study is to investigate the association 
between location of residence and breast cancer stage at diagnosis. It is hypothesised that 
women living in northern latitudes of the U.S. (>37°N), would be more likely to be 
diagnosed with advanced breast cancer rather than localised breast cancer as compared to 
women living in southern latitudes (<37° N).   
3.2 MATERIALS AND METHODS  
3.2.1 Data source and variables  
Data for this project were obtained from the National Cancer Institute’s Surveillance, 
Epidemiology and End Results (SEER) program, a publically available population-based 
database containing 18 cancer registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, 
New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San Jose-
Monterey, Rural Georgia, Greater Georgia, Greater California, Kentucky, Louisiana, New 
Jersey and the Alaska Native Tumour Registry), representing approximately 28% of the 
U.S. population.
135
 Variables used included patient demographics, primary tumour 
characteristics, and stage at diagnosis. The study population was restricted to women aged 
20 years and over (at diagnosis) diagnosed with an invasive breast cancer (International 
Classification of Diseases, 3
rd
 edition, site code C500-C506, C508-C509) from January 1, 
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2000 to December 31, 2010 identified in the SEER 18 registry. Women with records of 
missing or unknown values were excluded.   
SEER Summary Stage 2000 (1998+) was used for stage, which is a combination of 
clinical and pathological documentation of the extent of disease.
135
 Stage was 
dichotomised into “localised” and “advanced,” where localised stage refers to cancers that 
have not spread past the site of origin (breast) and advanced stage is defined as cancer 
spread beyond the local site (includes regional and distant breast cancer metastases). For 
the purposes of this study, I was only interested in invasive breast cancer. In situ breast 
cancer (ductal or lobular carcinoma in situ) is considered a pre-cancer and may never 
progress to invasive cancer 
136
, thus women with in situ breast cancer were excluded 
(19.4%). Women with unknown breast cancer stages were also excluded (5.7%). Location 
of residence at the time of diagnosis was defined by latitude. The average latitude of each 
registry was dichotomized into “North” and “South” with residential locations <37° N 
defined as “South” and residential locations >37° N defined as “North” (see Figure 3.1).  
The cut-off of 37° N was chosen based on previous research that suggests in U.S. states 
north of 37° N, UV levels are insufficient for vitamin D production (a potential 
mechanism for protection against breast cancer risk), except in summer months (April to 
September).
22
  North SEER registries included San Francisco-Oakland, Connecticut, 
Detroit, Iowa, Seattle (Puget-Sound), Utah, Kentucky, New Jersey, and northern counties 
of Greater California; and South registries included New Mexico, Atlanta, Los Angeles, 
Rural Georgia, Louisiana, Greater Georgia, San Jose-Monterey, and the southern counties 
of Greater California. The analysis was limited to the continental U.S., thus Alaska and 
Hawaii registries were excluded.  
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Figure 3.1. Map of the SEER registries illustrating the 37th parallel separating of North and South.135 
County-level variables were used for population demographics and in the analyses as 
potential confounders. County-level variables are not individually-based; rather, 
classification is assigned to individuals, based on the probability that the subjects from a 
specific county would have such characteristics. County attribute variables were 
calculated using 2000 Census data, and include educational attainment, percent of 
families below poverty, percent of persons unemployed, percent of foreign born, and 
percent median household income, which has been adjusted for the cost-of-living. The 
cost-of-living index was developed based on the Economic Policy Institute’s Basic 
Family Budget analysis, which estimates the cost of basic family expenditure (food, 
housing, transportation, health care, child care, additional necessities, and taxes) for 
metropolitan and non-metropolitan areas in each state.
137
  Additional county-level 
variables include mammography and rurality. Estimates of mammography were 
calculated for women aged 40 years and older and obtained through Small Area Estimates 
of the National Cancer Institute.
135
  Small Area Estimates are developed using the 
Behavioural Risk Factor Surveillance System and the National Health Interview 
Survey.
135
  Mammography was defined as women aged > 40 years who reported having 
had a mammogram within the 2 years prior to the interview and was presented as 
proportions per county.
135
  Rurality was categorized within counties and defined as 
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“metropolitan” and “nonmetropolitan” by the Rural-Urban Continuum Code definition, 
which distinguishes metropolitan counties by the population size of their metropolitan 
area and nonmetropolitan counties by degree of urbanization and adjacency to a 
metropolitan area or areas.
135
 Counties were defined as metropolitan if they contained at 
least one urbanised area of at least 50,000 people, regardless of total population size.  
Nonmetropolitan counties were defined as either an area with an urban cluster population 
of less than 50,000 people or a non-urban (rural) area.
138
   
3.2.2 Analyses  
Analyses were conducted using Stata (Stata/SE, version 13.0, StataCorp LP). Bivariate 
analyses were tested using chi-squared tests and one-way ANOVA (analysis of variance) 
tests. Logistic regression was used to examine the association between location of 
residence and stage at diagnosis while adjusting for potential confounders, which 
included age at diagnosis, ER and PR status, marital status, rurality, race, mammography, 
education, family income, poverty level, unemployment, being foreign born, and 
smoking. Results of this analysis are presented as odds ratios with their corresponding 
95% confidence intervals and P-values. For all analyses, statistical significance was 
assessed at α<0.05, as determined by a two-tailed test.  
3.3 RESULTS 
From 2000 to 2010, a total of 756,170 cases of breast cancer were reported to the 18 
SEER registries. After exclusions based on the population criteria (females aged 20 years 
and older living in the continental U.S. diagnosed with invasive breast cancer from 2000 
to 2010), 490,463 women were included in this study, 220,317(44.9%) in the South 
(<37°N) and 270,146 (55.1%) in the North (>37°N). The majority of the study population 
was white (84.0%), 9.9% were black and 6.1% other races. Localised breast cancer 
accounted for 63.0% of diagnoses while 37.0% were diagnosed as advanced. Most 
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diagnoses occurred in women 50-69 years of age (47.6%), with a mean age of diagnosis 
of 61 years (Table 3.1).  
The associations between demographic variables and location of residence are presented 
in Table 3.1and Table 3.2. Age at diagnosis was similar for both regions, with most 
diagnoses occurring at ages 50-69 years, followed by 70 years and older. Most women 
lived in a metropolitan area in both the North (87.9%) and the South (91.8%). While the 
majority of women were white in both regions, the South had a larger proportion of black 
women (12.8% vs 7.6%) and women of other races (7.3% vs 5.2%) compared to the 
North. Compared to Northern women, women in the South lived in areas with lower 
education levels (P<0.001), lower family income (P<0.001), more families below the 
poverty line (P<0.001), lower proportions of smoking (current or ever) (P<0.001) and 
lower proportions of mammography (P<0.001).  The distribution of breast cancer stage 
(localised vs advanced) was similar in both regions, with localised accounting for 61.8% 
in the South and 63.8% in the North.  
 
Table 3.1 
Summary descriptive statistics of individual-level variables and associations with location of 
residence in a U.S. population 
Variable  
South (<37° N)  
(n=220,317) 
North (>37° N)  
(n=270,146) 
 
Total  
(n=490,463) 
 n % n % P-value % 
Age at diagnosis       <0.001  
 <30 years 1,228 0.60 1,186 0.40  0.50 
 30-49 years 51,818 23.5 59,103 21.9  22.6 
 50-69 years 106,194 48.2 127,323 47.1  47.6 
 70+ years  61,077 21.7 82,534 30.6  29.3 
Marital Status      <0.001  
 Single 95,073 43.2 113,734 42.1  42.6 
 Married/living as 
married   
125,244 56.8 156,412 57.9  57.4 
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Variable  
South (<37° N)  
(n=220,317) 
North (>37° N)  
(n=270,146) 
 
Total  
(n=490,463) 
Rurality      <0.001  
 Metropolitan  202,244 91.8 537,364 87.9  89.63 
 Nonmetropolitan  18,073 8.2 32,782 12.1  10.37 
Race     <0.001  
 White 176,259 80.0 235,642 87.2  84.0 
 Black 28,084 12.8 20,650 7.6  9.9 
 Other 15,974 7.3 13,854 5.2  6.1 
Stage at diagnosis      <0.001  
 Localised 136,136 61.8 172,323 63.8  62.9 
 Advanced  84,181 38.2 97,823 36.2  37.1 
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Table 3.2 
Summary descriptive statistics of county-level variables and associations with location of 
residence in a U.S. population 
Variable South (<37° N) 
(n=220,317) 
North (>37° N) 
(n=270,146) 
 Total 
(n=490,463) 
 Mean SD Mean SD P-value Mean SD Range  
% Mammography
a
  68.9 5.0 71.4 5.2 <0.001 61.0 14.0 20.0-114.0 
Education         
 % <9
th
 grade  10.9 4.5 6.3 3.8 <0.001 8.36 4.7 0.60-33.8 
 % <High school 23.8 6.8 16.7 6.4 <0.001 19.9 7.5 3.7-50.8 
 % At least a 
bachelor’s 
degree 
24.8 8.4 27.5 9.7 <0.001 26.3 9.2 4.9-60.5 
% Family income
b
  49.3 7.7 56.0 8.5 <0.001 53.0 8.8 23.6-91.7 
% Families below 
poverty level  
11.5 4.6 7.2 3.8 <0.001 9.1 4.7 1.6-41.7 
% Unemployed 6.9 2.2 5.6 2.0 <0.001 6.2 2.2 1.8-17.2 
% Foreign born 19.8 12.7 12.4 9.0 <0.001 15.7 11.5 0.00-38.5 
Smoking          
 % Current 
smoker 
18.2 4.5 20.9 4.3 <0.001 19.6 5.1 9.1-41.5 
 % Ever smoker 38.8 4.8 45.6 6.2 <0.001 42.5 6.5 20.7-65.8 
Abbreviations: SE, standard deviation 
a
 Refers to % of women 40 years of age and older who reported having a mammogram within the last 2 years at the time of the 
interview  
b
 Income is presented in tens, representing tens of thousands of dollars  
 
Table 3.3 shows the association between risk of being diagnosed with advanced breast 
cancer and sociodemographic and tumour characteristics. Age was significantly 
associated with stage at diagnosis. The younger the age at diagnosis, the higher the odds 
of being diagnosed with advanced stage breast cancers, with women under 30 years 
having the highest risk (OR=2.49; 95% CI:  2.29, 2.70). Women who were oestrogen 
receptor (ER) -negative or progesterone receptor (PR) -negative had a 12% (OR=1.12; 
95% CI:  1.10, 1.14) and 19% (OR=1.19; 95% CI:  1.17, 1.21) increased risk of being 
diagnosed with advanced breast cancer, respectively, for all races combined. Women who 
 Chapter 3: A SEER Population Based Analysis of Breast Cancer Stage and Location of Residence in the United States
 77 
were married or living as married were 13%  less likely to be diagnosed with advanced 
stage breast cancer compared to those who were single or not living with a significant 
other (OR=0.87; 95% CI: 0.86, 0.89). Education levels were inversely associated with 
risk of advanced breast cancer. A 10% increase in the proportion of individuals with less 
than a high school education was attributed to a 5% increase in advanced breast cancer 
(OR=1.05; 95% CI:  1.01, 1.09). Furthermore, a 3% risk reduction was also observed 
with an increase in the proportion of individuals with at least a bachelor’s degree 
(OR=0.97; 95% CI:  0.96, 0.99). 
An increase in the proportion of mammography was associated with a 3% decreased risk 
of advanced breast cancer (OR=0.97; 95% CI:  0.96, 0.99). No significant associations 
were observed between risk of advanced breast cancer and family income, poverty level, 
unemployment, foreign born, or smoking status (Table 3.3).  
In relation to place of residence, results of the unadjusted analysis indicated that women 
living in the North were 8% less likely (OR=0.92; 95% CI: 0.91, 0.93) to be diagnosed 
with an advanced breast cancer. However, after adjusting for potential confounders (age 
at diagnosis, ER status, PR status, marital status, rurality, race, mammography, education, 
family income, poverty level, unemployment, being foreign born, and smoking) no 
significant association between advanced breast cancer and location of residence 
(OR=1.00, 95% CI:  0.99, 1.02) was found. However, compared to white women, black 
women had a 32% increased risk of advanced breast cancer (OR=1.32; 95% CI:  1.30, 
1.35). I then tested the interaction between latitude and race and found that the magnitude 
of risk of advanced breast cancer was significantly different for different races (test for 
interaction: χ2=11.26, df=2, P=0.003). To explore the differences between the races, I 
then conducted a stratified analysis (Table 3.4).  
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When restricting the analysis to white women, I found no association between location of 
residence and risk of advanced breast cancer (OR=1.01; 95% CI: 0.99, 1.03); similarly for 
women of races other than white or black (OR=0.98; 95%CI: 0.90, 1.06). However, when 
restricting the analysis to black women, I found a 7% reduction in risk of being diagnosed 
with advanced breast cancer for women living in the North (OR=0.93; 95% CI: 0.88, 
0.98) compared to women living in the South.  
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Table 3.3 
Association between advanced breast cancer stage at diagnosis and sociodemographic and tumour characteristics in a U.S. population 
Covariate  Advanced breast cancer  Advanced breast cancer 
 Crude ORa 95% CI P-value Adjusted ORb 95% CI P-value 
Latitude       
 South (<37° N) 1.00 --- --- 1.00 --- --- 
 North (>37° N) 0.92 0.91, 0.93 <0.001 1.00 0.99, 1.02 0.74 
Age at diagnosis        
 <30 yrs 2.73 2.52, 2.96 <0.001 2.49 2.29, 2.70 <0.001 
 30-49 yrs 1.85 1.82, 1.88 <0.001 1.85 1.82, 1.89 <0.001 
 50-69 yrs 1.29 1.27, 1.30 <0.001 1.30 1.28, 1.32 <0.001 
 70+ yrs  1.00 --- --- 1.00 --- --- 
ER status         
 ER+ or borderline 1.00 --- --- 1.00 --- --- 
 ER-  1.39 1.37, 1.41 <0.001 1.12 1.10, 1.14 <0.001 
PR status       
 PR+ or borderline 1.00 --- --- 1.00 --- --- 
 PR-  1.32 1.30, 1.33 <0.001 1.19 1.17, 1.21 <0.001 
Marital status       
 Single 1.00 --- --- 1.00 --- --- 
 Married/living as married   0.93 0.92, 0.94 <0.001 0.87 0.86, 0.89 <0.001 
Rurality        
 Metropolitan  1.00 --- --- 1.00 --- --- 
 Nonmetropolitan 0.99 0.97, 1.01 0.29 0.98 0.96, 1.01 0.19 
Race       
 White 1.00 --- --- 1.00 --- --- 
 Black 1.52 1.50, 1.55 <0.001 1.32 1.30, 1.35 <0.001 
 Other  1.08 1.05, 1.10 <0.001 1.00 0.97, 1.02 0.81 
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Covariate  Advanced breast cancer  Advanced breast cancer 
% Mammographyc  0.95 0.94, 0.96 <0.001 0.97 0.96, 0.99 0.002 
% <9th grade education  1.10 1.08, 1.11 <0.001 0.92 0.88, 0.97 0.002 
% <High school education  1.08 1.07, 1.09 <0.001 1.05 1.01, 1.09 0.01 
% At least a bachelor’s degree 0.96 0.95, 0.96 <0.001 0.97 0.96, 0.99 <0.001 
% Family incomed  0.94 0.93, 0.94 <0.001 0.98 0.97, 0.99 <0.001 
% Families below poverty level 1.14 1.13, 1.16 <0.001 0.99 0.95, 1.04 0.80 
% Unemployed 1.26 1.23, 1.29 <0.001 0.99 0.94, 1.05 0.82 
% Foreign born 1.01 1.00, 1.01 <0.001 1.01 0.99, 1.02 0.31 
% Current smoker 1.04 1.03, 1.05 <0.001 1.03 1.00, 1.06 0.07 
% Ever smoker 0.97 0.97, 0.98 <0.001 0.95 0.93, 0.97 <0.001 
Abbreviations: OR, odds ratio; CI, confidence interval; ER, oestrogen receptor; PR, progesterone receptor 
a
 Bivariate analysis between stage at diagnosis and each individual covariate 
b 
Adjusted for individual-level variables (age at diagnosis, ER status, PR status, marital status, rurality, and race) and county-level variables (mammography, education, family income, poverty level, 
unemployment, being foreign born, and smoking) 
c
 Refers to % of women 40 years of age and older who reported having a mammogram within the last 2 years at the time of the interview 
d 
Income is presented in tens, representing tens of thousands of dollars
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Table 3.4 
Association between advanced breast cancer stage at diagnosis and sociodemographics and tumour characteristics by race in a U.S. population 
Covariate  Whites (n=411,901) Blacks (n=48,734)  Other (n=29,828) 
 Adjusted OR
a 
95% CI P-value Adjusted OR
a 
95% CI P-value Adjusted OR
a 
95% CI P-value 
Latitude          
 South (<37° N) 1.00 --- --- 1.00 --- --- 1.00 --- --- 
 North (>37° N) 1.01 0.99, 1.03 0.18 0.93 0.88, 0.98 0.01 0.98 0.90, 1.06 0.56 
Age at diagnosis           
 
 
<30 yrs 2.55 2.31, 2.80 <0.001 2.49 2.06, 3.07 <0.001 1.87 1.42, 2.46 <0.001 
 30-49 yrs 1.89 1.86, 1.93 <0.001 1.63 1.54, 1.71 <0.001 1.80 1.67, 1.94 <0.001 
 50-69 yrs 1.30 1.28, 1.32 <0.001 1.24 1.18, 1.30 <0.001 1.33 1.24, 1.42 <0.001 
 70+ yrs  1.00 --- --- 1.00 --- --- 1.00 --- --- 
ER status           
 ER
+
 or borderline 1.00 --- --- 1.00 --- --- 1.00 --- --- 
 ER
-
  1.13 1.10, 1.15 <0.001 1.04 0.99, 1.10 0.11 1.24 1.15, 1.34 <0.001 
PR status          
 PR
+
 or borderline 1.00 --- --- 1.00 --- --- 1.00 --- --- 
 PR
-
  1.19 1.17, 1.22 <0.001 1.17 1.12, 1.23 <0.001 1.10 1.02, 1.17 0.01 
Marital status          
 Single 1.00 --- --- 1.00 --- --- 1.00 --- --- 
 Married/living as married   0.88 0.86, 0.89 <0.001 0.86 0.83, 0.89 <0.001 0.88 0.84, 0.93 <0.001 
Rurality           
 Metropolitan  1.00 --- --- 1.00 --- --- 1.00 --- --- 
 Nonmetropolitan 0.97 0.94, 1.00 0.02 1.11 1.01, 1.21 0.03 1.14 0.94, 1.39 0.18 
% Mammography
b
  0.97 0.96, 0.99 0.01 0.99 0.93, 1.05 0.67 0.89 0.81, 0.98 0.02 
% <9
th
 grade education 0.95 0.90, 1.00 0.07 0.75 0.62, 0.90 <0.001 0.67 0.48, 0.95 0.02 
% <High school education  1.04 1.00, 1.08 0.07 1.11 0.97, 1.26 0.12 1.36 1.06, 1.75 0.02 
% At least a bachelor’s degree 0.97 0.95, 0.98 <0.001 0.95 0.91, 0.99 0.03 1.07 0.99, 1.16 0.08 
% Family income
c 
0.98 0.96, 0.99 <0.001 1.02 0.97, 1.07 0.44 0.97 0.91, 1.02 0.24 
% Families below poverty level  1.01 0.97, 1.06 0.65 0.98 0.88, 1.09 0.70 0.67 0.53, 0.87 0.002 
% Unemployed  0.95 0.89, 1.01 0.10 1.17 0.99, 1.38 0.07 1.54 1.04, 2.27 0.03 
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Covariate  Whites (n=411,901) Blacks (n=48,734)  Other (n=29,828) 
 Adjusted OR
a 
95% CI P-value Adjusted OR
a 
95% CI P-value Adjusted OR
a 
95% CI P-value 
% Foreign born  1.01 0.99, 1.04 0.29 1.06 1.01, 1.11 0.01 0.99 0.92, 1.06 0.73 
% Current smoker 1.01 0.98, 1.04 0.57 1.11 1.00, 1.24 0.06 1.19 0.99, 1.42 0.06 
% Ever smoker 0.96 0.94, 0.98 0.01 0.93 0.85, 1.01 0.08 0.91 0.81, 1.03 0.15 
Abbreviations: OR, odds ratio; CI, confidence interval; ER, oestrogen-receptor; PR, progesterone receptor 
a
 Adjusted for individual-level variables (age at diagnosis, ER status, PR status, marital status, rurality, and race) and county-level variables (mammography, education, family income, poverty level, 
unemployment, being foreign born, and smoking) 
b
 Refers to % of women 40 years of age and older who reported having a mammogram within the last 2 years at the time of the interview  
c
 Income is presented in tens, representing tens of thousands of dollars 
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In addition to location of residence, significant interactions were observed between race 
and age, rurality, ER status, and PR status (test for interaction: χ2=45.20, df=6, 
P<0.001for age; χ2=12.98, df=2, P=0.002 for rurality; χ2=24.87, df=2, P<0.001for ER 
status; and χ2=13.86, df=2, P=0.001 for PR status). Although the magnitude of the risk of 
being diagnosed with advanced breast cancer according to age was different among the 
racial groups, the trend was similar for all racial groups, with the risk being highest for 
women under 30 years of age (OR=2.55; 95% CI: 2.31, 2.80 for white women; OR=2.49; 
95% CI: 2.06, 3.07 for black women; OR=1.87; 95%CI: 1.42, 2.46 for other races). Black 
women living in nonmetropolitan areas had an 11% increased risk of breast cancer 
compared to those living in metropolitan areas. This increased risk was not observed for 
nonmetropolitan women of other races or for nonmetropolitan white women, who had a 
slight reduction in risk (OR=0.97; 95% CI: 0.94, 1.00; P=0.02). ER
-
 breast cancers were 
associated with a 13% and 24% increased risk of advanced breast cancer for whites 
(OR=1.13; 95%CI: 1.10, 1.15) and women of other races (OR=1.24; 95%CI: 1.15, 1.34), 
respectively, but not for black women. PR- breast cancers were significantly associated 
with a 19%, 17%, and 10% increased risk of advanced breast cancer in whites (OR=1.19; 
95%CI: 1.17, 1.22), blacks (OR=1.17; 95%CI: 1.12, 1.23), and women of other races 
(OR=1.10; 95%CI: 1.02, 1.17), respectively.  
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3.4 DISCUSSION  
In this study, the aim was to define the relationship between location of residence and 
breast cancer stage at diagnosis. Women aged 20 years and older with invasive breast 
cancer were identified through the SEER database. This is the first study of this scale to 
examine the relationship between location of residence and breast cancer stage at 
diagnosis.  Previous studies have investigated location of residence and breast cancer risk; 
however the results of such studies have been inconsistent.
1,2,9,10,12,32
 Some indicated no 
association between location of residence and risk of breast cancer.
9,10,12
 Others found 
that individuals living in areas closer to the equator have a reduced risk of breast cancer, 
with one study finding a risk reduction of almost 30% for women living in the South of 
the U.S. (<37° N) compared to women living in the North (>37° N).
1,2,32
   
In the adjusted analysis, I found that black women living in the North were 7% less likely 
to be diagnosed with advanced breast cancer compared to black women living in the 
South. However there was no evidence of a corresponding decrease in adjusted risk for 
white women and for all races combined, even though it was observed in the crude 
analyses. The decreased risk of advanced breast cancer in black women living in the 
North may suggest that additional factors exist between black women in the North and 
South, which could explain this relationship.   
Sociodemographic differences between black women in the North and black women in 
the South may explain why black women living in the North had a reduced risk of 
advanced breast cancer when compared to black women living in the South. Black 
women in the South resided in areas that had significantly lower education levels, lower 
family income, more families living below the poverty line, and higher proportions of 
unemployment than black women in the North (data not shown). Additionally, black 
women living in the South were less likely to live in metropolitan areas and had higher 
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proportions of women diagnosed at younger ages (<30 years and 30-49 years) than black 
women living in the North (data not shown). Although I controlled for these factors in the 
analyses, residual confounding may have occurred, as the sociodemographic variables 
were not at an individual-level, but rather a county-level measure.  
Although this study cannot infer causality, a plausible mechanism for how location of 
residence may affect breast cancer stage is through UV exposure; possibly mediated by 
vitamin D production. Latitude is correlated with UV levels, where the closer a region is 
to the equator, the higher the UV levels, hence increasing vitamin D production. UV 
exposure contributes to higher vitamin D levels in the population and research suggests 
that high levels of vitamin D reduce the risk and mortality of breast cancer by inhibiting 
cellular proliferation and inducing differentiation and apoptosis of breast cancer 
cells.
34,119,130
 One previous study has investigated UV exposure and breast cancer stage 
and found that increasing UV exposure was associated with a trend for decreasing risk of 
advanced breast cancer in lightly pigmented women, with a reduction of 47% in the 
highest UV exposure category (OR=0.53, 95% CI: 0.31, 0.91).
18
 Similarly, Palmieri et al. 
found women with early-stage breast cancer had significantly higher vitamin D levels 
than those with advanced breast cancer;
139
 however, neither study investigated location of 
residence and breast cancer stage.  
While the findings on the association between the latitude of location of residence and 
breast cancer stage are inconsistent with the literature, I additionally found a number of 
factors that were associated with advanced breast cancer including age at diagnosis, 
tumour receptor status, marital status, and mammography. For all races combined, for 
white women and black women: the younger the age at diagnosis, the higher the risk of 
advanced breast cancer.  This is consistent with the literature, which confirms that in the 
U.S., advanced breast cancer cases are increasing among women aged 25-39 years. 
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Possible explanations for this are that younger women tend to be diagnosed with more 
aggressive breast cancers and breast cancer screenings are not recommended for women 
under the age of 40 years.
140
 Tumour receptor status was significantly associated with 
breast cancer stage, with an increased risk of advanced breast cancer for women who 
were ER
-
 and/or PR
-
. Breast cancers that are either ER+ and/or PR+ tend to be less 
aggressive with slower proliferating cells, possibly explaining why these cancers are 
diagnosed at earlier stages.
26,141
 Women of all races, white women, and black women 
within this study who were married or living as married, had a 13%, 12%, and 14% 
reduced risk of advanced breast cancer, respectively, compared to women who were 
single. These findings are consistent with previous research showing that unmarried 
women are more likely to be diagnosed with more advanced breast cancers, as spouses 
can promote positive health behaviour (i.e., screening, regular doctor visits).
142
 It is well 
known that mammography is associated with less advanced breast cancer diagnoses,
143
 
which was confirmed by the results which showed that an increase in the proportion of 
mammography was associated with a decreased risk of advanced breast cancer in all races 
combined and white women.  
The results should be interpreted with consideration of several limitations. The SEER 
registries only represent 28% of the US population, which limits the ability to assume the 
results are representative of the population as a whole. Women who had records with 
missing or unknown values were excluded, which could potentially add bias to the 
analyses, especially in cases of unknown stage. Incomplete staging is common in the 
elderly and women with a frailty (due to age or other reasons) or an advanced co-
morbidity, as a thorough investigation of the cancer is not always considered necessary in 
these circumstances.
144,145
 Some variables used in the analysis were county-level rather 
than individual-level variables. Using county-level variables assumes that the variable 
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measure for each participant is the same as the average measure for the county in which 
she resides, which could be misrepresentative. Other risk factors for breast cancer, 
including family history of breast cancer, reproductive and hormonal factors (oestrogen 
exposure), and obesity and health-related lifestyle behaviours (e.g. diet, physical activity 
level, alcohol consumption) are not collected by the SEER registries and, therefore, could 
not be considered in the analyses. Potential confounders of location of residence, such as 
community attitudes and behaviours, and genetic and environmental factors were also not 
accounted for in this study. This was an ecological study, and while it allows for 
inferences about the possible relationships between breast cancer stage at diagnosis and 
location of residence, it cannot determine causality.   
Importantly, a strength of this study was the use of the SEER dataset, which is a large-
scale population-based cancer database within the U.S. and provides accurate data. Whilst 
SEER collects data from 20 U.S. geographic areas, the areas it covers are representative 
of the demographics of the entire U.S. population.
135
 The SEER dataset provided a large 
sample size, allowing the examination of specific subgroups of women in regard to race, 
cancer stage, and geographic location.  
To my knowledge, this study is the first to investigate the relationship between location of 
residence and breast cancer stage, and future studies would benefit from the inclusion of 
individual-level data, such as sociodemographics, health-related lifestyle behaviours, and 
breast cancer risk factors. Understanding the effect of location of residence on breast 
cancer stage may provide insight into the factors that may impact early diagnosis, 
therefore possibly improving prognosis.  
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Chapter 4: Research Design and Analytic 
Approach 
4.1 INTRODUCTION 
Previous studies investigating lifetime sun exposure (and/or vitamin D) and breast cancer 
risk and mortality have produced inconsistent results. Specifically, there are currently 
gaps in the literature in relation to potential relationships between sun exposure and breast 
cancer stage. Using previous studies as a guide, this project was developed to investigate 
the relationship between lifetime sun exposure and breast cancer stage, using methods to 
help address some of the limitations of previous research. This chapter will overview and 
describe the project aims, objectives, and design, as well as methodology for data 
collection and analyses. This project was a nested retrospective cohort study, using a sub-
sample of participants and data derived from the Breast Cancer Outcomes Study (BCOS). 
Details of the BCOS will be discussed first, followed by details of the PhD project.  
4.2 BREAST CANCER OUTCOME STUDY (CCQ) 
4.2.1 Study design  
Conducted by Cancer Council Queensland (CCQ), and led by A/Prof Philippa Youl, the 
BCOS is a population-based five-year longitudinal study of women aged 20 to 79 years 
newly diagnosed with invasive breast cancer. The study aims to investigate the 
inequalities in diagnostic and treatment processes, psychosocial care services utilisation, 
and survival for women newly diagnosed with breast cancer in Queensland.
133
 
Quantitative and qualitative data were collected by computer-assisted telephone 
interviews (CATI), as well as self-administered questionnaires (SAQ) at two time points: 
4-6 months post-diagnosis (Time 1) and 18 months post-diagnosis (Time 2) (Appendix 
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B).  Clinical data were collected and included information on the diagnostic process and 
disease progression, tumour site, histology, stage, lymph node status, and other prognostic 
indicators.
133
 Treatment data were collected some 24 months following diagnosis.
133
  
Other information such as mammographic screening, surgical and other therapeutic 
procedures was collected from participants and supplemented with data from 
BreastScreen, Medicare, and Queensland Hospital Admitted Patient Data Collection 
(QHAPD).
133
 Queensland and interstate Cancer Registries, as well as the National Death 
Index were used to collect information on recurrence and survival.
133
 Area-level data 
were obtained from the Australian Bureau of Statistics.
133
  
4.2.2 Recruitment  
All recruitment for the BCOS was performed by Cancer Council Queensland. Patient 
names and the names of their treating doctors were obtained through the Queensland 
Cancer Registry (QCR) using a rapid ascertainment procedure.
133
 With this procedure, 
research staff accessed and recorded breast cancer notifications being entered into the 
QCR system, thus reducing the lag period from diagnosis to ascertainment to a minimum. 
As required with QCR procedures, letters were sent to the treating physician requesting 
patient contact. A study information sheet, consent form, and reply-paid envelope were 
then sent to all patients for whom doctors’ consent had been acquired.133 Non-responding 
doctors and patients were sent a mailed reminder followed by a telephone call.  
Participants were asked for permission to access their medical records within the QCR as 
well as permission to match their name to other data sources.
133
 Separate consent was 
obtained to access Medicare and BreastScreen data. Additional consent was obtained for 
the collection of a blood samples for genetic and molecular analyses.
133
 Over 3,000 
women have been recruited for the BCOS.   
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4.2.3 Eligibility criteria  
Eligibility criteria for the BCOS included women aged 20-79 years, who were residents 
of Queensland with a histologically confirmed diagnosis of invasive breast cancer (ICD0-
3 C50) between January 1, 2011 and December 31, 2012 and notified to the Queensland 
Cancer Registry.
133
 The Queensland Cancer Registry is a population-based register with 
virtually universal coverage of individuals diagnosed with cancer in Queensland. It 
maintains a record of all cases of cancer diagnosed in Queensland since 1982, and the 
details of all cancers diagnosed in Queensland are legally required to be included in the 
QCR under the Public Health Act 2005. Women who were unable to speak or understand 
English or had cognitive impairment were excluded from the study.
133
  
4.2.4 Data Collection  
4.2.4.1 Telephone interview 
Following consent, participants took part in a structured 30 to 40 minute telephone 
interview  (CATI) at approximately 4 to 6 months post-diagnosis (Time 1) and in a 
second shorter telephone interview (approximately 20 minutes) at 18 months post 
diagnosis (Time 2).
133
 Only information from the CATI at Time 1 was used for this study. 
The self-reported information collected during the telephone interview at Time 1 
included:  
Sociodemographics: education, marital status, occupation, private health insurance, gross 
household income, Indigenous status, family history of breast cancer, birth weight, age at 
menarche, menopausal status, parity, history of breastfeeding, use of oral contraceptives 
and hormone replacement therapy (HRT), current and pre-diagnostic weight, pre-existing 
medical conditions, current and pre-diagnostic smoking and alcohol consumption and 
levels of physical activity.
133
 
 92 Chapter 4: Research Design and Analytic Approach 
Pathways to diagnosis: how breast cancer was detected (self, screening, doctor or other 
lay person); self-reported history of mammography (through both BreastScreen and 
private facilities); symptoms and date of first recognition of abnormality (for symptom 
detected), date of mammography (for screen detected); date and outcomes of first 
appointment with doctor; date and outcomes of any subsequent appointments and 
procedures up to the date of diagnosis; and satisfaction with the process of diagnosis 
(including perceived delays, reasons for delays).
133
  
4.2.4.2 Demographics and tumour characteristics  
Clinical and demographic information was extracted from the QCR database including: 
date of birth; date of diagnosis; residence of diagnosis; tumour site; size of tumour;  
morphology; histological grade; stage; degree of lymph node involvement; and ER , PR 
and HER2 status. Physicians provided information on indicators of illness status and 
disease progression including stage, tumour site, maximum tumour diameter, lymph node 
status, presence of distant metastases and other prognostic indicators.
133
 For public 
hospital patients, the above information was collected from the hospital medical 
records.
133
 BreastScreen Queensland Register and Queensland Oncology Repository were 
also used to supplement any additional clinical and treatment information.
133
  
4.2.4.3 Area-level information  
Remoteness: remoteness of residence when diagnosed with breast cancer was categorised 
using the ARIA+ (Accessibility/Remoteness Index of Australia) classification. Because 
the ARIA+ does not account for access to specialised cancer treatment services, 
categories were developed based on distance to and from major treatment facilities.  
4.2.5 Data entry  
All telephone interviews were conducted by trained CCQ health interviewers and data 
were entered into the computer at the time of the interview. As per protocol, 20% of the 
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self-administered questionnaires were entered twice to check for accuracy and 
consistency. Clinical data from the QCR is extracted from pathology forms by trained 
clinical coders and entered into a purpose built database within the Cancer Registry. Once 
participant consent has been received, the relevant information is removed from the 
Registry and copied into the main research database in the research centre at Cancer 
Council Queensland. Additional clinical and treatment information is obtained from 
medical practitioners and through extraction of relevant information from the 
participants’ medical records by trained clinical coders. These data are then entered into 
the customised database located on the Cancer Council Queensland server.  
4.2.6 Data management, storage and security  
To ensure confidentiality, participants’ names and contact information were kept separate 
from other data and were only linked through the patient identification number. Trained 
CCQ health interviewers conducted all telephone interviews and data were entered into 
the computer at the time of the interview.  Clinical data and additional treatment and 
clinical information is stored on the main database which sits on the Cancer Council 
Queensland secured server.  
4.3 PHD PROJECT 
4.3.1 Aims, objectives, and research question  
The aim of this research was to identify and explore the relationship between lifetime sun 
exposure and breast cancer stage, as a measure of prognosis, for women newly diagnosed 
with breast cancer.  
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The objectives of this research were to: 
1. Define the role that location of residence has on breast cancer stage at 
diagnosis;  
2. Measure lifetime sun exposure in women newly diagnosed with breast cancer;  
3. Develop a model to define the role that lifetime sun exposure has on breast 
cancer stage at diagnosis, controlling for known breast cancer risk factors; 
4. Determine at what stage of life sun exposure matters most in breast cancer 
stage at diagnosis  
4.3.2 Research question  
The study research questions are: 
1. Do women diagnosed with localised breast cancers have a higher lifetime sun 
exposure than women diagnosed with advanced breast cancers? 
2. Are women with high levels of lifetime sun exposure at a lower risk of being 
diagnosed with advanced stage breast cancer compared to women with medium 
and low levels of sun exposure?  
3. Does lifetime sun exposure or sun exposure during the years of breast 
development matter more in influencing breast cancer stage at diagnosis?  
 
4.3.3 Study design  
A subset of participants from the BCOS was used to conduct a nested retrospective cohort 
study to investigate the influence of sun exposure on breast cancer stage. The use of the 
BCOS participants and data for this nested study design allowed for a larger-scale study 
within the confines of time and funding for a PhD project.  All information collected from 
participants was de-identified. The data collected through the BCOS, which were used in 
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this PhD project, included clinical data, mammographic screening, area-level data, and 
information collected from the Time 1 CATI (Appendix B). Information on lifetime sun 
exposure was collected by a questionnaire developed for the purposes of this study using 
existing literature on sun exposure measurements. While we considered using the blood 
samples collected for the BCOS to determine serum 25(OH)D levels (to compare against 
lifetime sun exposure levels), due to the timing of the blood collection, the 25(OH)D 
levels would not have been an accurate representation of the participant’s lifetime vitamin 
D. Participants’ blood was collected anywhere from 4 to 6 month post-diagnosis. Because 
25(OH)D has a half-life of around 2 weeks, serum 25(OH)D levels are only 
representative of the two week prior to blood draw. Serum levels could have been 
affected by cancer treatments or changes in sun behaviour due to cancer diagnosis. 
Additionally, women diagnosed with breast cancer are often put on vitamin D 
supplements, which would have also affected the 25(OH)D serum levels.  
4.3.4 Data collection  
Sun exposure questionnaire  
Sun exposure data were collected using a self-administered lifetime sun exposure 
questionnaire developed by the research candidate (Appendix C). The questionnaire was 
developed based on the existing literature measuring sun exposure.
6,9,10,18,19,22,100,101,146-152
 
Residential history is commonly used in measuring sun exposure, as results indicate the 
reproducibly of this measure is excellent.153  In an attempt to limit recall bias in 
participants, specific questions such as those relating to sunscreen use and protective 
clothing worn, were omitted from the questionnaire. Once developed, the questionnaire 
was tested among a random sample of women and adjustments were made following 
feedback.  
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The questionnaire collected a detailed residential history from birth to current location of 
residence. The residential history included two sections: the first covered the years before 
starting school (birth to age 5 years) and collected information on location and duration of 
residence(s);  and the second, from school age and onwards,  included location and 
duration of residence(s), occupational and recreational sun exposure. Additionally, the 
questionnaire collected data on participants’ phenotypic characteristics (hair colour, eye 
colour, and skin colour), reaction of the skin to the sun, and solarium use. Because sun 
exposure is highly correlated with vitamin D levels, participants were also asked about 
vitamin supplementation 12 months prior to breast cancer diagnosis, as vitamin D and/or 
calcium supplementation could act as a confounder. Questionnaires were mailed to a 
random cohort of women participating in the BCOS during the period of August 2013 and 
October 2014.  
4.3.5 Data entry  
Raw data from the participants’ questionnaires were entered into an Excel spreadsheet 
(Microsoft Excel 2010). Setup of the Excel spreadsheet, variable names, and coding of 
the categorical variables was completed prior to the beginning of data collection. Missing 
data were coded as -999. In instances where a section of the questionnaire was not 
applicable to a participant (e.g., supplementation use) and the section was unanswered, 
the cell in the Excel spreadsheet for the corresponding variable was left blank. For times 
when participants lived outside of Australia, the postcode variable cell was left blank. As 
data entry progressed, it was necessary to create rules for items frequently left 
unanswered or incorrectly completed in order to maximise the number of usable 
questionnaires. These rules are listed in Table 4.1. Random visual checking was 
performed on the data throughout data entry to ensure accuracy. Once all questionnaires 
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were entered into Excel, the spreadsheet was then exported to Stata Data Analysis and 
Statistical Software (Stata/SE, version 13.0, StataCorp LP). 
Table 4.1 
Data entry rules 
Rule Notes (if applicable)  
If left blank, “both” was entered for 
occupational exposure when occupation was 
“student”  
 
“0.5” was entered when duration of residence 
was < 6 months, and “1” was entered when 
duration of residence was > 6 months  
 
When a work postcode and a home postcode 
were given for the same occupation, the work 
postcode was used.   
Exception: instances where the work 
location was far in distance from the 
home location (e.g., mining jobs), in 
which case the duration was split in 
half and both postcodes were used.  
If a participant held the same occupation in 
multiple locations and listed all postcodes for 1 
duration of residence, the duration was split 
evenly between the locations.  
This rule only applied in cases when 
the locations were within the same UV 
band 
For occupations at the same location with the 
same occupational and recreational exposure, 
the 2 entries were collapsed to 1. 
 
If two postcodes were given for one duration 
and the latitude for the postcodes were within 
the same UV band, one postcode was used for 
the entire duration. 
 
If two postcodes were given for one duration 
and the latitudes for the postcodes were not 
within the same UV band, the duration was split 
in half and both postcodes were used.  
Exception: Durations that were longer 
than 5 years. Locations that were more 
than 1 UV band difference, in which 
case the entry was deemed 
“incomplete”  
If solarium use was left blank, it was assumed 
that the participant had never used a solarium 
Due to the fact that 90% of the 
participants had never used a solarium  
 
4.3.6 Data management, storage and security   
Sun exposure questionnaires were securely stored at CCQ. Data obtained from the 
questionnaires were entered on a CCQ computer and data entry files stored within the 
computer were only accessible by project staff. Additionally, the paper copies of the 
questionnaires, as well as the data entry files, are only identifiable by the participants’ 
unique identification numbers. Double entry was done for 20% of the questionnaires to 
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ensure consistency and accuracy. Hard copies of the questionnaires will be stored for 7 
years for possible future follow-up studies.  
4.4 DATA ANALYSIS PREPARATION  
Before beginning data analysis, each participant’s sun exposure was calculated, with 
some variables requiring recoding and/or regrouping. Additionally, data were checked 
and cleaned. At this stage, some participants were excluded from the study due to 
incomplete responses in the residential history section of the sun exposure questionnaire 
or missing stage data.  
4.4.1 Estimate of participant’s sun exposure 
UV bands 
Firstly, UV bands were created based on averages of UV radiation around the world. 
Average UV data were obtained from the Tropospheric Emission Monitoring Internet 
Service (TEMIS) and National Aeronautics and Space Administration’s (NASA) space-
based measurements of ozone and air quality, which were publically available. TEMIS is 
part of the Data User Programme (DUP) of the European Space Agency (ESA) and uses 
Scanning Imaging Absorption Spectrometer for Atmospheric Chartography 
(SCIAMACHY) and Global Ozone Monitoring Experiment (GOME) to calculate global 
measures of UV irradiance.
154
  NASA provides global erythemal UV measures using 
Total Ozone Mapping Spectrometer (TOMS).
155
 
UV bands were divided by latitude into 6 categories, where the latitude range for each 
category is identical for the North and South (Figure 4.1). UV bands were assigned a 
number of 1 through 6, where a higher number indicates a band with higher UV radiation. 
Table 4.2 provides details of latitudes of each category.  
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Figure 4.1. Map illustrating UV bands with corresponding category  
Table 4.2 
Latitude ranges of UV bands 
UV band  Latitude range (°N/S) UV strength  
Yearly average UV 
Index 
1 60.0 – 90.0  Low 1 
2 50.0 – 59.9   3 
3 40.0 – 49.9  4 
4 30.0 – 39.9   6 
5 20.0 – 29.9   9 
6 0.0 – 19.9  High 12 
 
Lifetime sun exposure calculation  
Based on the data provided in the questionnaire, individual lifetime sun exposure was 
calculated and a lifetime UV score was assigned to each participant. In order to assign 
latitude to postcodes for each location of residence, the questionnaire database was 
imported into Stata and merged with a database containing latitudes for all Australian 
postcodes. From there, code was written in Stata to assign UV bands to latitude for each 
location. For participants who lived outside of Australia at any period of time, UV bands 
were manually entered. Once UV bands were assigned to all locations for each 
participant, the database was transferred back into Excel to perform the sun exposure 
calculation.  
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The product of the UV band of residence, duration of residence, occupational exposure 
score and recreational exposure score provides an individual UV score for that particular 
location and occupation. The total UV score for each participant is then calculated by 
adding the individual UV scores. Sun exposure calculations were completed for three 
time points: birth to age 5 years, age 5 years to present, and lifetime (birth to present), and 
are presented in Exposure Units (EU). Because a detailed residential history is required to 
calculate lifetime sun exposure, participants who had incompletions in this section of the 
questionnaire were excluded, as an accurate lifetime sun exposure value was unable to be 
calculated.  The calculations are as follows: 
Birth to age 5: 
[(UV band1) x (duration1)] +  
[(UV band2) x (duration2)] + 
[(UV band3) x (duration3)] +… = UV score (<5yr) 
Age 5 to present:  
[(UV band1) x (duration1) x (outdoor occupation1) x (outdoor activity1)] +  
[(UV band2) x (duration2) x (outdoor occupation2) x (outdoor activity2)] +  
[(UV band3) x (duration3) x (outdoor occupation3) x (outdoor activity3)] +… = UV score 
(>5 yr) 
 
Lifetime: 
[UV score (<5 yr)] +[UV score (>5 yr)] = Lifetime UV score  
Where,  
- UV band = number of 1-6, based on latitude  
- Duration = number of years lived at residence  
- Outdoor occupation = number of 1-2 
 1 – indoor occupation 
 1.5 – both indoor and outdoor occupation 
 2 – outdoor occupation  
- Outdoor activity = number of 1-2  
 1 – did not participate in outdoor activities 
 2 – participated in outdoor activities   
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Example: 
Location Latitude UV 
band 
Age 
from 
(yrs) 
Age 
to 
(yrs) 
Duration 
(yrs) 
Outdoor 
occupation 
Outdoor 
activity  
Birth to Age 5 
Brisbane 27.5°S 5 0 3 3 --- ---  
Melbourne  37.8°S 4 3 5 2 ---  ---  
Age 5 onwards  
Melbourne 37.8°S 4 5 17 12 both yes 
Townsville 19.3°S 6 17 23 6 outdoors yes 
London 51.5°N 2 23 25 2 indoors no 
Toowoomba 27.6°S 5 25 33 8 indoors yes 
Hobart 42.9°S 3 33 52 19 indoors yes 
Redcliffe  27.2°S 5 52 67 15 both yes 
 
Birth to age 5 years: 
[(5) x (3)] + [(4) x (2)]  =  
[15] + [8] = 23  
UV score for <5 yrs = 23 EU 
Age 5 years to present:  
[(4) x (12) x (1.5) x (2)] + [(6) x (6) x (2) x (2)] + [(2) x (2) x (1) x (1)] + [(5) x (8) x (1) x 
(2)] + [(3) x (19) x (1) x (2)] + [(5) x (15) x (1.5) x (2)] = 
[144] + [144] + [4] + [80] + [114] + [225] = 711  
 
UV score for > 5yrs = 711 EU 
 
Lifetime: 
[23] +[711] = 734 EU 
Lifetime UV score = 734 EU 
 
Additionally, separate sun exposure scores were calculated for breast development years 
(7-18 years) in order to investigate the relationship between breast cancer stage and sun 
exposure at various time periods (Objective 4). Because the questionnaire did not contain 
a separate residential section for breast development years, all entries for residential 
history were examined for each participant and new variables were created in Excel to 
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collapse and/or expand entries so that the age range was 7 to 18 years. Sun exposure 
calculations were then performed in the same manner as “age 5 years to present” (see 
example below). Once all sun exposure calculations were complete, the data were 
imported back into Stata.  
Example:  
 Location Latitude UV 
band 
Age 
from 
(yrs) 
Age to 
(yrs) 
Duration 
(yrs) 
Outdoor 
occupation 
Outdoor 
activity  
Age 5 onwards  
Melbourne 37.8°S 4 5 12 7 both yes 
Townsville 19.3°S 6 12 16 4 outdoors yes 
London 51.5°N 2 16 25 9 indoors no 
 
The entries above were collapsed to only include ages 7-18 years.  
Location Latitude UV 
band 
Age 
from 
(yrs) 
Age 
to 
(yrs) 
Duration 
(yrs) 
Outdoor 
occupation 
Outdoor 
activity  
Age 5 onwards  
Melbourne 37.8°S 4 7 12 5 both yes 
Townsville 19.3°S 6 12 16 4 outdoors yes 
London 51.5°N 2 16 18 2 indoors no 
 
Age 7 to 18 years:  
[(4) x (5) x (1.5) x (2)] + [(6) x (4) x (2) x (2)] + [(2) x (2) x (1) x (1)] = 
[60] + [96] + [4] = 160 EU 
UV score for breast development years = 160 EU 
4.4.2 Merging data and categorisation of variables  
Data for this study were obtained from the QCR, the CATI, and the sun exposure 
questionnaire. Relevant variables were extracted from QCR and the CATI database, 
imported into Stata, and then merged with data from the sun exposure questionnaire. 
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Some categorical variables were collapsed or new variables generated.  Additionally, 
some continuous variables were categorised to better describe the study population. See 
Appendix D for details on all variable categorisation.   
Demographic variables (from CATI) 
Age was used as a continuous variable and was also categorized as “<50 years”, “50-69 
years”, and “70+ years”, which correspond with ages “younger than”, “of”, and “older 
than” recommended breast screening ages at the time of the study, respectively. Marital 
status was collapsed to “Married, or living as married” and “Single, living as single”. 
Education, Aboriginal and Torres Straight Island status, and ethnicity categories were 
collapsed due to numbers, and annual income categories were collapsed based on 
Australian tax brackets. Occupation prior to diagnosis was collapsed into “Full time paid 
work”, “Casual/Part time paid work”, “Unpaid Work” (work without pay in a family or 
other business and home duties), “Retired”, and “Other” (Unemployed, permanently 
unable to work, student, paid leave/sick leave, unpaid leave, and full time carer). Body 
Mass Index (BMI) was calculated from participants’ height and weight and categorised as 
“<18.5 kg/m2 (underweight),” “18.5-24.9 kg/m2 (normal),” “25.0-29.9 kg/m2 
(overweight),” and “>30 kg/m2 (obese).”  
Physical activity and smoking variables were generated by combining multiple variables 
from the CATI. Physical activity was grouped as “None”, “Light activity”, “Moderate 
activity”, and “Vigorous activity”, where light activity was walking for at least 10 
minutes at least one day per week; vigorous activity was defined as that  which resulted in 
hard breathing, puffing or panting; and moderate activity was defined as other activities 
excluding household chores or gardening  (e.g., gentle swimming, golf, social tennis). 
Smoking was categorised as “Current smoker”, “Used to smoke but quit”, and “Lifelong 
non-smoker”. Participants were assigned the “Used to smoke but quit” category if they 
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gave an age as to when they first started to smoke at least once per week, but reported that 
they currently do not smoke.  
Exposure-related variables 
The lifetime UV scores generated from the questionnaire were categorised into tertiles of 
“Low”, “Medium”, and “High”.  Vitamin supplementation was categorised into three 
groups of “No supplementation”, and “Supplementation containing vitamin D and/or 
calcium” and “Other supplementation”.   Solarium use was categorised into two groups of 
those who never have used a solarium and those who have used a solarium, regardless of 
frequency. Categories for eye colour, skin colour and skin’s reaction to the sun were kept 
the same as in the questionnaire. Hair colour was collapsed into “Red/Fair/Blonde”, 
“Light brown/Mouse brown/Grey”, or “Dark brown/Black”. For the few participants who 
answered “don’t know” for either hair colour or eye colour, a value was assigned to them 
based on their other phenotypic characteristics.  
A phenotypic index variable was created from hair colour, eye colour, skin colour and 
propensity to burn. Values were assigned based on the Fitzpatrick Skin Type. For each 
participant, the values from each variable were summed, representing their phenotypic 
score. Participants with a phenotypic score of 0 to 7 were categorised as “Light features” 
and those with a score of greater than 7 were categorised as “Dark features”. 
For season of diagnosis, “Winter” was defined as June, July and August, “Spring” as 
September, October and November, “Summer” as December, January and February, and 
“Autumn” as March, April and May. 
Outcome variable – breast cancer stage  
Stage at diagnosis was dichotomised into “localised” and “advanced” breast cancers, 
where localised cancers are defined as those cancers which have not spread past the site 
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of origin (breast), and advanced cancers are defined as those that have spread beyond the 
local site (includes regional and distant breast cancer metastases).  
Breast cancer-related variables  
Tumour size was categorised as “T1” (<2 cm), “T2” (2-5 cm) and “T3” (>5 cm). For 
instances when multiple sizes were recorded (i.e., an irregularly shaped tumour), the 
largest size was used. For PR status, “Negative” and “Unspecified” were combined, and 
for HER2/neu, “Equivocal” and “Unknown” categories were combined. History of skin 
cancer and other cancers were each categorized as “Yes”, or “No”.  Participants who 
reported having either a first or second degree relative with a history of breast cancer 
were categorised as “Yes” for family history of breast cancer, and those who had no 
family members with a history of breast cancer or who were unsure, were categorised as 
“No”.  
Screening variables (mammography, breast self-exam, clinical breast exam, ultrasound 
and MRI) were created from the CATI variables that included “ever been screened” and 
“frequency of screening” prior to diagnosis (monthly, every 3 months, every 6-12 
months, every 2 years, irregularly, and never). Participants who chose “Other” for 
screening frequency were required to specify. Based on this response, “Other” values 
were reassigned to the appropriate categories and a new category of “irregular/infrequent” 
was created.  
4.4.3 Data cleaning  
All variables were checked for errors using Stata v13. Frequencies, as well as minimum 
and maximum values, were checked for categorical variables to ensure no value was 
outside the possible range. The variable codebook was consulted in instances of 
inconsistencies. Minimum and maximum values were also checked for continuous 
variables to identify any abnormal values. Additionally, the mean and standard deviation 
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of continuous variables was checked to detect any outliers. All abnormal values and 
outliers were checked with the original data, and if an error was identified, values were 
corrected accordingly.  
4.5 DATA ANALYSIS  
Data were analysed using Stata Data Analysis and Statistical Software (Stata/SE, Version 
13.0, StataCorp LP) to investigate the association between lifetime sun exposure and 
breast cancer stage at diagnosis. Two-sided tests were used and a probability value (P-
value) of <0.05 was considered significant.   
4.5.1 Descriptive statistics and preliminary analyses  
Frequency tables with counts and percentages were generated to describe all categorical 
variables. For continuous variables, the means and standard deviations were used to 
describe the distribution of the variables. Relationships between variables were tested 
using Chi-squared tests, Fisher’s exact test (if cells had a frequency of 5 or less), and one 
way ANOVA.  All summary statistics (mean, standard deviation, median, range) were 
reported to 1 decimal place. 95% Confidence Intervals (95% CI), coefficients and P-
values were reported to 2 decimal places, unless the p-value was less than 0.001, in which 
case it was reported as P<0.001. 
4.5.2 Model and variable selection  
An epidemiological modelling approach was used to examine the association between 
lifetime sun exposure and breast cancer stage, while adjusting for potential confounders. 
This model building strategy was selected, as it allows for inclusion of important 
variables that are known to be associated with breast cancer stage but may not be 
statistically significant.  
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First, logistic regression was used to analyse the bivariate association between the 
outcome variable (breast cancer stage) and all covariates under consideration, as well as 
the main exposure (lifetime sun exposure) and all covariates. The covariates were those 
that have been shown in previous research studies to be associated with breast cancer 
stage, such as screening, age, use of hormone replacement therapy (HRT), SES, and 
remoteness/access to care. A confounder is a risk factor for the outcome, statistically 
associated with the exposure of interest, and is not in the causal pathway between the 
exposure of interest and the outcome. The presence of a confounder can bias the measure 
of the association between the main exposure and the outcome. To control for 
confounding effects, potential confounders were identified if they were significant at 
α<0.2 in the bivariate analysis for both stage at diagnosis and lifetime sun exposure.  
Next, the effect of the potential confounding variables on the association between lifetime 
sun exposure and breast cancer stage was examined. If the inclusion of the covariates (in 
the model with lifetime sun exposure and breast cancer stage) changed the coefficient of 
the outcome by 5% or greater, it was included in the preliminary multivariate model, as 
this signifies a confounding effect.  Covariates that were not considered significant in the 
bivariate analyses but were considered important were re-examined by adding them into 
the preliminary multivariate model one at a time. Again, if the inclusion of the covariate 
changed the coefficient of lifetime sun exposure by 5% or greater, it was kept in the 
model.  Effect modification was examined by using a multiplicative term in the 
preliminary multivariable model to identify if the magnitude of the effect was different 
for different groups. Significance of interaction terms were checked using Wald tests at 
α<0.05.  
Coefficients, rather than odds ratios, for lifetime sun exposure were used to determine if 
there was a 5% change or greater, as odds ratios are measured on a non-linear scale and 
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could affect the percent change. However, adjusted odds ratios are presented in the final 
model.  
4.5.3 Sample size calculation  
The sample size was calculated for the primary research question, “Do women who are 
diagnosed with localised breast cancer have  higher lifetime sun exposure than women 
who are diagnosed with advanced breast cancer?” A hypothesis test for relative risk was 
used to calculate sample size.   
𝑛 = {𝑧1−𝛼 2⁄  √[2?̅?(1 − ?̅?)] +  𝑧1−𝛽 √[𝑃1(1 − 𝑃1) + 𝑃2(1 − 𝑃2)]}
2𝑃  
(𝑃1 − 𝑃2)
2  
 
 
𝑅𝑅0 = 𝑃1 𝑃2⁄  
Where,  
RR0 = test value of the relative risk under the null hypothesis  
P1 = anticipated probability of disease in people with exposed variable  
P2 = anticipated probability of disease in people not exposed to variable  
RRa = anticipated relative risk  
100α% = level of significance  
100(1-β)% = power of test  
RR0 ≠RRa = alternative hypothesis (for two-sided test)  
 
RR0 = 1 
P1 = ? 
P2 = 0.37 
RRa = 0.62  
100α% = 5% 
100(1-β)%  = 80% 
 
Anticipated values required for the calculation were based on the limited previous 
research investigating sun exposure and breast cancer stage and past breast cancer 
statistics.
18
  For this calculation, disease was defined as advanced breast cancer and the 
exposure variable was sunlight. A probability of 37% was used for the anticipated 
probability of disease in people not exposed to the variable, based on statistics showing 
that this is the proportion of women who are diagnosed with advanced breast cancer. The 
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anticipated relative risk of 0.62 was based on previous research. A standard alpha level of 
0.05 (5% probability of rejecting the null hypothesis when it is true) and power level of 
80% (20% probability of failing to reject the null hypothesis when it is false, were used 
for this analysis. From the calculation, it was estimated that 307 participants were needed 
for each arm, totalling 614 participants.  
4.6 ETHICS 
4.6.1 Breast Cancer Outcomes Study (CCQ) 
A National Ethics Application Form (NEAF) for the Breast Cancer Outcomes Study was 
submitted to the Griffith University HREC and received approval on November 5, 2009 
(Appendix E). Additionally, CCQ submitted an expedited ethical review (reference #: 
PSY/01/11/HREC) to obtain further approval to collect blood samples for the BCOS). All 
participants were required to read and sign a consent form prior to participating in the 
project (Appendix F).  
4.6.2 PhD project  
Ethics documents were submitted to both Griffith University and QUT. An expedited 
ethical review (reference #: PSY/01/11/HREC) was submitted to Griffith University as an 
amendment to the original NEAF of the BCOS (Appendix G). Approval was granted on 
the August 20, 2014. Additional ethical clearance was required by QUT, as it is the 
institution leading the project. An administrative review application was submitted to the 
University Human Research Ethics Committee (UHREC) on October 18, 2013 (reference 
#: 39320) and received approval on November 11, 2013 (approval #: 1300000682) 
(Appendix H). 
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Chapter 5: Preliminary Results 
5.1 INTRODUCTION 
Results for this study will be presented in two chapters. As detailed in the previous 
chapter, an epidemiological modelling method was used to answer the research question, 
“Are women with high levels of lifetime sun exposure at a lower risk of being diagnosed 
with advanced stage breast cancer compared to women with medium and low levels of 
sun exposure?” Before beginning the modelling process, it is important to gain a more 
comprehensive understanding of the study population and variables. Therefore, in this 
chapter, descriptive statistics of the study population, exposure-related variables, and 
variables associated with breast cancer risk and/or stage are presented. Although the 
outcome of interest was breast cancer stage, variables associated with breast cancer risk 
were included in the bivariate analyses. There is limited research addressing risk factors 
specifically for advanced breast cancer, thus inclusion of variables associated with risk of 
breast cancer allowed me to evaluate all possible confounders, ensuring all true 
confounders were controlled for in the model. Furthermore, associations between 
variables of interest are also included. 
The study population is described in Section 5.2 with details of the response rate and 
participant demographics. Section 5.3examines exposure-related variables and Section 
5.4 examines breast cancer-related variables. Additionally, Section 5.4 includes data on 
the association between breast cancer-related variables and age, as breast cancer stage can 
differ according to age. Associations between the outcome of interest (stage at diagnosis) 
and all covariates (demographic, exposure-related, and breast cancer-related variables) 
are presented in Section 5.5.    
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5.2 GENERAL DESCRIPTIVE STATISTICS  
5.2.1 Response rate  
Sun exposure questionnaires were mailed with the SAQ from the Breast Cancer 
Outcomes Study from August 2013 to October 2013 at the appropriate time point 
according to participant recruitment date. A total of 693 questionnaires were mailed and 
561 (81%) were returned by the cut-off date (31 Oct 2014). Of the returned 
questionnaires, 97 were incomplete and unusable (i.e., incomplete residential history), 
thus these participants were excluded from the study. In comparison to those participants 
with completed questionnaires, excluded participants were similar in age, stage at 
diagnosis, and other sociodemographic variables.  An additional 25 participants were 
excluded due to missing breast cancer stage information. Therefore, a total of 439 
participants were included in the study, 286 with localised breast cancer and 153 with 
advanced breast cancer (Figure 5.1). Some participants had missing information for some 
of the clinical or telephone-based variables, so therefore, participant numbers may vary 
by the specific variable. The sample size of the final model (n=429) represents the 
number of participants with complete data for all included covariates.  
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Figure 5.1. Flow chart of study population  
5.2.2 Participant characteristics  
The majority of women were diagnosed between the ages of 50-69 years (60.8%), with an 
average age 59.8 years and a median age of 60.0 years. White women were over-
represented (98.6%) compared to other races, including Aboriginal and Torres Strait 
Islander women (1.4%) and the majority of women were born in Australia (82.2%). Just 
over half the study sample were diagnosed whilst living in major cities (57.8%), with 
21.9% living in inner regional, 16.2% in outer regional and 4.1% in remote or very 
remote areas. Three-quarters (76.2%) were married, or living as married, and 60.8% had 
 
Questionnaires not returned 
by cut-off date (n=132) 
Total participants in study 
(n=439) 
Sun exposure questionnaires 
sent out (n=693) 
Incomplete questionnaires 
(n=97) 
Returned questionnaires 
(n=561) 
Participants used in model 
(n=429) 
Completed questionnaires 
(n=464) 
Unknown stage (n=25) 
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completed technical or tertiary education. Employment status prior to diagnosis varied 
across the study population with 31.1% having worked full-time and 29.9% having 
worked part-time or casually; 29.5% were retired, 5.3% had worked without pay, and 
4.2% had other employment status. Approximately 29% of women had an annual income 
of $41,600-$83,199 and 23.6% had an income of $83,200-$155,999. Two-thirds (66.7%) 
had full private health insurance.  
The average current BMI was 27.5 kg/m
2
, with 27.6% considered obese (>30 kg/m
2
), 
31.6% overweight (25.0-29.9 kg/m
2
), 39.4% normal weight (18.5-24.9 kg/m
2
), and 1.4% 
underweight (<18.5 kg/m
2
). The majority of women (86.5%) had participated in some 
level of physical activity (walking, moderate, and/or vigorous) prior to diagnosis. Of 
these women, the average time per week participating in walking, moderate activity, and 
vigorous activity was 2.3 hours, 0.8 hours, and 0.7 hours, respectively. Over half of the 
women (57.6%) were lifelong non-smokers, 35.6% were smokers who had quit, and 6.8% 
were current smokers. Of those who smoked, the average age of beginning to smoke at 
least once per week was 18.1 years.  Just under two-thirds (63.9%) indicated they had at 
least one drink per month, and of those, the average age they began to drink alcohol at 
least once a month was 25.6 years. See Table 5.1 and Table 5.2 for details on 
sociodemographic variables.  
Table 5.1 
Summary descriptive statistics of categorical sociodemographic variables 
Variable  All ages 
 N (%) 
Age  
 <50 years 79 (18.0) 
 50-69 years 267 (60.8) 
 70+ years 93 (21.2) 
Marital status   
 Married, living as married 330 (76.2) 
 Single, living as single  103 (23.8) 
Highest level of education   
 School education level   169 (39.2) 
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Variable  All ages 
 N (%) 
 Certificate/diploma  164 (38.1) 
 Bachelor degree, equivalent, or higher  98 (22.7) 
Ethnicity   
 Caucasian/white 421 (97.9) 
 Other  9 (2.1) 
Aboriginal or Torres Strait Islander   
 Yes 6 (1.4) 
 No 422 (98.6) 
Employment   
 Full time paid work  134 (31.1) 
 Part time/Casual paid work  129 (29.9) 
 Unpaid work 23 (5.3) 
 Retired 127 (29.5) 
 Other 18 (4.2) 
Annual income   
 $0-$20,799 40 (9.3) 
 $20,800-$41,599 76 (17.7) 
 $41,600-$83,199 124 (28.9) 
 $83,200-$155,999 101 (23.6) 
 >$156,000 39 (9.1) 
 Don’t know/don’t want to tell  49 (11.4) 
Private health insurance  
 Yes, full health insurance 289 (66.7) 
 Yes, some insurance 42 (9.7) 
 No  102 (23.6) 
Born outside Australia   
 No 356 (82.2) 
 Yes  77 (17.8) 
Rurality   
 Major cities 254 (57.8) 
 Inner regional 96 (21.9) 
 Outer regional/ Remote/Very remote 89 (20.3) 
BMI  
 <18.5 kg/m
2
 6 (1.4) 
 18.5-24.9 kg/m
2
 168 (39.4) 
 25.0-29.9 kg/m
2
 135 (31.6) 
 >30 kg/m
2
 118 (27.6) 
Alcohol   
 Lifelong non-drinker 51 (11.8) 
 Drink less than once a month 81 (18.8) 
 Drink at least once a month  276 (63.9) 
 Used to drink but have stopped 24 (5.5) 
Physical Activity   
 None 58 (13.45) 
 Walking  156 (36.1) 
 Moderate activity 90 (20.8) 
 Vigorous activity  128 (29.6) 
Smoking   
 Current smoker 30 (6.8) 
 Used to smoke but have quit 156 (35.6) 
 Lifelong non-smoker  253 (57.6) 
1
Statistics represent females living in Queensland and were obtained from the Australian Bureau of Statistics (ABS). Census data from 
2011 was used for data on age, marital status, education, indigenous status, employment, and country of birth. The Australian Health 
Survey (AHS) was used for data on BMI, alcohol, physical activity, and smoking.  
2 Combined percentage for <18.5 kg/m2 and 18.5-24.9 kg/m2 
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Table 5.2 
Summary descriptive statistics of continuous sociodemographic variables  
Variable (n) Mean SD Range 
Age when started drinking
1
 (years) 25.6 10.9 15-67 
Age when started smoking
2
 (years) 18.1 4.5 8-52 
Walking time per week
3
 (hours) 3.1 3.1 0.07-45.0 
Moderate activity time per week
3
 (hours) 2.6 2.24 0.3-12.0 
Vigorous activity time per week
3
 (hours) 2.5 1.9 0.03-10.5 
1 
Drinking alcohol at least once a month (prior to diagnosis) 
2 
Smoking at least once per week (prior to diagnosis) 
3
 Representative of physical activity levels prior to diagnosis  
5.3 SUN EXPOSURE VARIABLES  
5.3.1 Descriptive data  
Summary statistics are provided in Table 5.3 and Table 5.4 for continuous and categorical 
exposure-related variables. Lifetime UV, calculated from the questionnaires, ranged from 
115 to 1182 Exposure Units (EU), with an average of 526.7 EU. The mean UV was 22.2 
EU (SD: 4.9) from birth to 5 years, 123.7 EU (SD: 40.3) during breast development years 
(7-18 years), and 504.4 EU (SD: 195.1) from 5 years to present (Table 5.3). Hair colour 
and eye colour varied among the population; however, most women had fair skin (68.3%) 
that sometimes burnt/usually tanned (55.1%) (Table 5.4). Eye colour, hair colour, skin 
colour, and skin reaction to the sun were combined to create a phenotypic index based on 
the Fitzpatrick Skin Type. Nearly two-thirds of women (62.9%) had “light” features 
compared to “dark” features (37.1%). Solarium use was not common among the study 
population with only 10.2% of women reporting having ever used a solarium. About half 
of the population took no vitamin supplements prior to diagnosis (51.7%), while 36.4% 
took vitamin D and/or calcium supplements and 11.9% took other vitamin supplements.  
One-fifth (20.1%) of women indicated they had a history of skin cancer (melanoma and 
non-melanoma). (Table 5.4).  
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Table 5.3 
Summary descriptive statistics for continuous exposure variables 
Exposure (n) Mean SD Range 
Lifetime UV (EU) 526.7 196.5 115-1182 
UV birth to 5 years (EU) 22.2 4.9 5-30 
UV breast development years (7-18 years) (EU) 123.7 40.3 22-220 
UV 5 years to present (EU) 504.4 195.1 105-1152 
 
Table 5.4 
Summary descriptive statistics for phenotypic and UV variables 
Characteristics All ages  
N (%) 
   
Lifetime UV  
 Low 146 (33.3) 
 Med 145 (33.0) 
 High 148 (33.7) 
UV (0-5years)  
 Low 59 (13.4) 
 Med 123 (28.0) 
 High 257 (58.6) 
   
UV (5 years-present)  
 Low 146 (33.3) 
 Med 146 (33.3) 
 High 147 (33.5) 
UV (7-18 years)  
 Low 133 (30.3) 
 Med 147 (33.5) 
 High 159 (36.2) 
Hair colour at age 21 yrs  
 Red/Fair/Blonde 106 (24.2) 
 Light/Mouse brown/Grey 177 (40.3) 
 Dark brown/Black 156 (35.5) 
Eye colour  
 Blue/Grey 173 (39.4) 
 Green/Hazel 172 (39.2) 
 Brown/Black 94 (21.4) 
Skin colour  
 Very Fair 47 (10.7) 
 Fair 300 (68.3) 
 Olive/Brown 92 (21.0) 
Skin reaction to the sun  
 Always burns, never tans 49 (11.2) 
 Usually burns, sometimes tans 121 (24.6) 
 Sometimes burns, usually tans 242 (55.1) 
 Never burns, always tans 24 (5.5) 
 Don’t Know 3 (0.6) 
Solarium use   
 Yes 45 (10.2) 
 No 394 (89.8) 
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Characteristics All ages  
N (%) 
Vitamin supplementation  
 Yes, vitamin D and/or calcium 160 (36.4) 
 Yes, other type of vitamin 52 (11.9) 
 No  227 (51.7) 
History of skin cancer   
 Yes 87 (20.1) 
 No/Unsure  345 (79.9) 
5.4 BREAST CANCER-RELATED DATA  
In this section, descriptive data are presented for breast cancer stage and related variables 
(Table 5.5, Table 5.6, and Table 5.8).  
5.4.1 Stage and tumour characteristics  
Approximately two-thirds of women (65.2%) were diagnosed with localised breast cancer 
and 34.8% diagnosed with advanced (regional and distant) breast cancer (Figure 5.2). 
About half of the tumours were moderately differentiated (grade 2) (50.7%), 32.2% 
poorly differentiated (grade 3) and 16.1% well differentiated (grade 1). In relation to 
mitotic rate, 60.2% of tumours had a rate of 0-9 mitoses/10hpf (high power fields), 24.8% 
a rate of 10-19 mitoses/10hpf, and 14.9% a rate of >20 mitosis/10hpf. The majority of 
women had ER
+
 (86.9%) and PR
+
 (77.4%) breast cancers, and of these, 76.3% were both 
ER
+
/PR
+
. Nearly three quarters (71.2%) of breast cancers were HER2/neu equivocal or 
unknown, with 15.2% HER2/neu negative and 13.6% HER2/neu positive (Table 5.5). 
 
Figure 5.2. Distribution of stage at diagnosis 
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Table 5.5 
Summary descriptive statistics for tumour-related categorical variables 
Characteristic N (%) 
Stage  
 Localised  286 (65.2) 
 Regional/distant  153 (34.8) 
Tumour size   
 T1 257 (58.9) 
 T2 160 (36.7) 
 T3 19 (4.3) 
Grade  
 Grade 1 70 (16.1) 
 Grade 2 221 (50.7) 
 Grade 3 145 (32.2) 
Mitotic activity   
 0-9 Mitoses/10hpf 206 (60.2) 
 10-19 Mitoses/10hpf 85 (24.8) 
 >20 Mitoses/10 hpf  51 (14.9) 
Oestrogen receptor status   
 ER+ 337 (86.9) 
 ER- 57 (13.1) 
Progesterone receptor status   
 PR+ 336 (77.4) 
 PR-/Not specified 98 (22.6) 
Tumour markers  
 HER2/neu+ 58 (13.6) 
 HER2/neu- 65 (15.2) 
 Equivocal/unk 304 (71.2) 
 
5.4.2 History of breast screening  
Prior to diagnosis, 16.7% of women had never had a mammogram with half of that group 
(50.7%) being younger than 50-69 years. Some 15.3% of participants had irregular or 
infrequent mammograms, with over half (56.7%) in the age range recommended for 
screening (50-69 years). About two-thirds of eligible women had a mammogram at least 
every 2 years (66.0%). Most women (88%) had conducted breast self-exams (BSE), and 
of these, 31.1% conducted a BSE monthly, 30.5% every 3 months, 21.1% every 6-12 
months, and 17.4% at irregular intervals.  The majority of women (81.4%) had had a 
clinical breast exam, and of those women, 33.1% had one at least once a year, 33.9% 
every 2 years, and 33.1% irregularly/infrequently. Under half (43.1%) had had an 
ultrasound to detect breast cancer; however only 1.4% had an MRI to detect breast 
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cancer. The average age of first mammogram, breast self-exam, and clinical breast exam 
was 43.2 years, 36.1 years, and 35.8 years, respectively (Table 5.6). 
Table 5.6 
Summary descriptive statistics for categorical breast cancer screening variables 
Characteristic N (%) 
Mammography  
 At least every 2 years 297 (68.0) 
 Irregularly  67 (15.3) 
 Never 73 (16.7) 
Breast self-exam   
 Monthly 118 (27.4) 
 Every 3 months 116 (26.9) 
 Every 6-12 months 80 (18.6) 
 Irregularly 66 (15.3) 
 Never  51 (11.8) 
Clinical breast exam   
 Every 6-12 months 116 (26.9) 
 Every 2 years 119 (27.6) 
 Irregularly 116 (26.9) 
 Never 80 (18.6) 
MRI  
 Yes 6 (1.4) 
 No 426 (98.6) 
Ultrasound  
 Every 6-12 months 41 (9.5) 
 Every 2 years 25 (5.8) 
 Irregularly 120 (27.8) 
 Never 246 (56.9) 
 
5.4.3 Additional factors known to be associated with breast cancer stage or risk  
The majority of the study population were postmenopausal (81.2%). Nearly 90% (88.7%) 
had used hormone contraceptives, but only 3.2% were currently taking hormonal 
contraceptives. Over a quarter of women reported having had a hysterectomy (26.6%), 
32.9% had used HRT, and 1.4%  reported having had radiotherapy to the chest prior to 
their breast cancer diagnosis. The vast majority of women reported having been pregnant 
(89.4%) with an average age of 25.4 years at birth of first child. The mean age of 
menarche was 12.9 years, with 37.9% beginning menstruation before the age of 12 years. 
Over one-third of women (39.1%) had a history of benign breast disease (BBD).  See 
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Table 5.7. A self-reported history of other cancers (excluding skin cancers) was recorded 
for 4.4% of the population, and nearly half (45.1%) of women reported that they had 
either a first degree or second degree relative with a history of breast cancer. See Table 
5.7 
Table 5.7 
Summary descriptive statistics for categorical variables known to be associated with breast 
cancer stage or risk   
Characteristic N (%) 
Menopause  
 Yes 350 (81.2) 
 No 55 (12.8) 
 Unsure  26 (6.0) 
Hormone contraceptives  
 Ever 383 (88.7) 
 Current  14 (3.2) 
 Never  35 (8.1) 
Hysterectomy   
 Yes 115 (26.6) 
 No 317 (73.4) 
HRT  
 Yes 142 (32.9) 
 No/Unsure  290 (67.1) 
Radiotherapy to chest  
 Yes 6 (1.4) 
 No 425 (98.6) 
Parity   
 Parous 386 (89.4) 
 Nulliparous  46 (10.6) 
History of BBD  
 Yes 169 (39.1) 
 No 263 (60.9) 
History of other cancers  
 Yes 19 (4.4) 
 No/Unsure  413 (95.6) 
Family history of breast cancer  
 Yes 187 (45.1) 
 No/Unsure 228 (54.9) 
5.4.4 Association between breast cancer-related variables and age 
Breast cancer risk factors can vary according to age. Thus,I investigated the association 
between breast cancer-related variables and age. Age was significantly associated with 
stage at diagnosis (χ2=11.22; df=2; p=0.004), mammography (χ2=89.26; df=4; p<0.001), 
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breast self-exams (χ2=19.92; df=8; p=0.01), clinical breast exams (χ2=21.04; df=6; 
p=0.002), HRT use (χ2=76.74; df=2; p<0.001; Fisher’s exact<0.001), hormone 
contraceptive use (χ2=26.45; df=4; p<0.001; Fisher’exact<0.001), hysterectomy 
(χ2=15.11; df=2; p=0.001), history of skin cancer (χ2=13.58; df=2; p=0.001), and history 
of BBD (χ2=7.96; df=2; p=0.02) (Table 5.8). For women younger than 50 years, the 
proportion of localised (49.4%) and advanced (50.6%) were similar. However as age, 
increased the proportion of women with localised breast cancer also increased. Over two-
thirds (67.4%) of women aged 50-69 years and 72.0% of women 70 years and older were 
diagnosed with localised breast cancer. Women aged 50-69 years and 70 years and older 
had significantly higher proportions of mammography every 2 years than women younger 
than 50 years. Proportions of clinical breast exams and self-breast exams varied among 
the age groups. Proportions of HRT use was lowest in women younger than 50 years 
(2.6%) and increased as age increased (30.5% for 50-69 years and 65.2% for 70+ years). 
Most women (88.7%) had used hormonal contraceptives at some point in their life; 
however, women younger than 50 years (3.8%) and 50-69 years (3.8%) had higher 
proportions of current use of hormonal contraceptives compared to women 70 years and 
older (1.1%). Additionally, women 70 years and older had the highest proportions of 
never having used hormonal contraceptives (20.6%) compared to the other age groups. 
Self-reported hysterectomy increased with age, with 14.1% in women less than 50 years, 
25.6% in 50-69 years, and 40.2% in 70 years and older.  
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Table 5.8 
Summary descriptive statistics for breast cancer-related categorical variables and associations 
with age 
  Age  
  <50 years 50-69 years 70+ years   
Characteristic N (%) N (%) N (%) P-value  
Stage    0.004 
 Localised  39 (49.4) 180 (67.4) 67 (72.0)  
 Advanced 40 (50.6) 87 (32.6) 26 (28.0)  
Tumour size     0.66 
 T1 41 (52.6) 161 (60.8) 55 (59.1)  
 T2 32 (41.0) 93 (35.1) 35 (37.6)  
 T3 5 (6.4) 11 (4.2) 3 (3.2)  
Grade    0.44 
 Grade 1 12 (15.4) 43 (16.2) 15 (16.1)  
 Grade 2 33 (42.3) 138 (52.1) 50 (53.8)  
 Grade 3 33 (42.3) 84 (31.7) 28 (30.1)  
Mitotic activity     0.25 
 0-9 Mitoses/10hpf 34 (50.8) 129 (61.4) 43 (66.2)  
 10-19 Mitoses/10hpf 18 (22.4) 54 (25.7) 13 (20.0)  
 >20 Mitoses/10 hpf  15 (22.4) 27 (12.9) 9 (13.8)  
Oestrogen receptor status     0.39 
 ER+ 65 (82.3) 232 (88.2) 80 (87.0)  
 ER- 14 (17.7) 31 (11.8) 12 (13.0)  
Progesterone receptor 
status  
   0.66 
 PR+ 65 (78.5) 206 (78.3) 68 (73.9)  
 PR-/Not specified 17 (21.5) 57 (21.7) 24 (26.1)  
Tumour markers    0.30 
 HER2/neu+ 15 (19.5) 42 (16.2) 8 (8.9)  
 HER2/neu- 9 (11.7) 38 (14.6) 11 (12.2)  
 Equivocal/unk 53 (68.8) 180 (69.2) 71 (78.9)  
Mammography    <0.001 
 A least every 2 years 21 (26.6) 196 (74.0) 80 (86.0)  
 Irregularly  21 (26.6) 38 (14.3) 8 (8.6)  
 Never 37 (46.8) 31 (11.7) 5 (5.4)  
Self-exam     0.01 
 Monthly 20 (25.6) 75 (28.7) 23 (25.0)  
 Every 3 months 28 (35.9) 69 (26.4) 19 (20.7)  
 Every 6-12 months 14 (18.0) 47 (18.0) 19 (20.7)  
 Irregularly 2 (2.6) 47 (18.0) 17 (18.5)  
 Never  14 (18.0) 23 (8.8) 14 (15.2)  
Clinical breast exam    0.002 
 Every 6-12 months 20 (25.6) 81 (31.0) 15 (16.3)  
 Every 2 years 24 (30.8) 76 (29.1) 19 (20.7)  
 Irregularly 18 (23.1) 69 (26.4) 29 (31.5)  
 Never 16 (20.5) 35 (13.4) 29 (31.5)  
Ultrasound    0.09 
 Every 6-12 months 8 (10.3) 29 (11.1) 4 (4.4)  
 Every 2 years 5 (6.4) 13 (5.0) 7 (7.6)  
 Irregularly 16 (20.5) 83 (31.7) 21 (22.8)  
 Never 49 (62.8) 137 (52.3) 60 (65.2)  
HRT    <0.001 
 Yes 2 (2.6) 80 (30.5) 60 (65.2)  
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  Age  
  <50 years 50-69 years 70+ years   
Characteristic N (%) N (%) N (%) P-value  
 No/Unsure  76 (97.4) 182 (69.5) 32 (34.8)  
Hormone contraceptives    <0.001 
 Ever 73 (93.6) 238 (90.4) 72 (78.3)  
 Current 3 (3.8) 10 (3.8) 1 (1.1)  
 Never  2 (2.6) 14 (5.3) 19 (20.6)  
Hysterectomy     0.001 
 Yes 11 (14.1) 67 (25.6) 37 (40.2)  
 No 67 (85.9) 195 (74.4) 55 (59.8)  
History of other cancers    0.24 
 Yes 3 (3.9) 9 (3.4) 7 (7.6)  
 No/Unsure  75 (96.2) 253 (96.6) 85 (92.4)  
Family history of breast 
cancer
1
 
   0.91 
 Yes 35 (46.1) 115 (45.5) 37 (43.0)  
 No/Unsure 41 (54.0) 138 (54.6) 49 (57.0)  
History of BBD    0.02 
 Yes 22 (28.1) 116 (44.3) 31 (33.7)  
 No 56 (71.8) 146 (55.7) 61 (66.3)  
Parity     0.06 
 Parous 64 (82.1) 237 (90.5) 85 (92.4)  
 Nulliparous  14 (18.0) 25 (9.5) 7 (7.6)  
Radiotherapy to chest    0.19 
 Yes 0 (0.0) 3 (1.2) 3 (3.3)  
 No 78 (100.0) 258 (98.9) 89 (96.7)  
1
Family history of breast cancer refers to first degree relatives (mother, sister, daughter, father, 
brother) 
5.5 BIVARIATE RELATIONSHIP BETWEEN COVARIATES AND 
BREAST CANCER STAGE 
Data on the association between breast cancer stage and all covariates are presented in 
this section.  
5.5.1 Sociodemographic variables and stage at diagnosis  
 
Age at diagnosis and marital status were significantly associated with stage at diagnosis 
(χ2=11.22; df=2; p=0.004, and (χ2=4.46; df=1; p=0.04, respectively) (Table 5.9). A higher 
proportion of advanced breast cancers (26.1%) were diagnosed in younger women (<50 
years) compared to localised breast cancer (13.7%). Nearly three-quarters (73.1%) of 
women diagnosed with localised breast cancer and 82.1% with advanced breast cancer 
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were married, or living as married. No other sociodemographic variable were associated 
with stage at diagnosis at the bivariate level.  
Table 5.9 
Relationship (χ2, or Fisher’s exact) between demographic variables and stage at diagnosis  
   Stage at diagnosis   
Variable  Localised 
N(%) 
Advanced  
N(%) 
P-value 
 
Age   0.004 
 <50 years 39(13.7) 40(26.1)  
 50-69 years 180(62.9) 87(56.9)  
 70+ years 67(23.4) 26(17.0)  
Marital status    0.04 
 Married, living as married 206(73.1) 124(82.1)  
 Single, living as single  76(26.9) 27(17.9)  
Highest level of education    0.73 
 School education level   111(39.6) 58(38.4)  
 Certificate/diploma  103(36.8) 61(40.4)  
 Bachelor degree, equivalent, or 
higher  
66(23.6) 32(21.2)  
Ethnicity    0.10 
 Caucasian/white 278(99.3) 143(95.3)  
 Other  2(0.7) 7(4.7)  
Aboriginal or Torres Strait Islander    0.67 
 No 274(98.2) 148(99.3)  
 Yes 5(1.8) 1(0.7)  
Employment    0.33 
 Full time paid work  89(31.7) 45(30.0)  
 Part time/Casual paid work  79(28.1) 50(33.3)  
 Unpaid work 12(4.3) 11(7.3)  
 Retired 90(32.0) 37(24.7)  
 Other 11(3.9) 7(4.7)  
Annual income    0.71 
 $0-$20,799 23(8.9) 15(10.1)  
 $20,800-$41,599 54(19.3) 22(14.8)  
 $41,600-$83,199 82(29.3) 42(28.2)  
 $83,200-$155,999 61(21.8) 40(26.9)  
 >$156,000 24(8.6) 15(10.1)  
 Don’t know/don’t want to tell  34(12.1) 15(10.1)  
Private health insurance   0.76 
 Yes, full health insurance 185(65.6) 104(68.9)  
 Yes, some insurance 29(10.3) 13(8.6)  
 No  68(24.1) 34(22.5)  
Born outside Australia    0.41 
 No 235(83.3) 121(80.1)  
 Yes  47(16.7) 30(19.9)  
Rurality    0.11 
 Major cities 164(57.3) 90(58.8)  
 Inner regional 70(24.5) 26(17.0)  
 Outer regional/ Remote/Very remote 52(18.8) 37(24.2)  
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   Stage at diagnosis   
Variable  Localised 
N(%) 
Advanced  
N(%) 
P-value 
 
BMI   0.81 
 <18.5 3(1.1) 3(2.0)  
 18.5-24.9 107(38.6) 61(40.7)  
 25.0-29.9 90(32.5) 45(30.0)  
 >30 77(27.8) 41(27.3)  
Alcohol    0.22 
 Lifelong non-drinker 37(13.2) 14(9.3)  
 Drink less than once a month 56(19.9) 25(16.5)  
 Drink at least once a month  176(62.6) 100(66.2)  
 Used to drink but have stopped 12(4.3) 12(8.0)  
Physical Activity    0.07 
 None 32(11.4) 26(17.2)  
 Walking  99(35.2) 57(37.7)  
 Moderate activity 68(24.2) 22(14.6)  
 Vigorous activity  82(29.2) 46(30.5)  
Smoking    0.46 
 Current smoker 17(5.9) 13(8.5)   
 Used to smoke but have quit 106(37.1) 50(32.7)  
 Lifelong non-smoker  163(57.0) 90(58.8)  
 
Tumour characteristics and breast-cancer related variables and stage at diagnosis Table 
5.10 presents the association between categorical variables and stage at diagnosis. 
Tumour size (χ2=61.13; df=2; p<0.001), histological grade (χ2=13.68; df=2; p=0.001), 
and mammography (χ2=19.24; df=2; p<0.001) were significantly associated with breast 
cancer stage at diagnosis. Significantly more women   with localised breast cancer were 
diagnosed with smaller tumours (T1: <2 cm) (71.8%) compared to those diagnosed with 
advanced breast cancer (34.9%) (P<0.001).  Additionally, women with advanced breast 
cancer had a higher proportion of grade 3 breast cancer (40.8%) compared to those with 
localised breast cancer (29.2%) (P<0.00). Three quarters (74.6%) of women with 
localised breast cancer compared to 55.6% of women with advanced breast cancer 
reported having a mammogram at least every two years (p <0.001). No significant 
associations were observed between stage at diagnosis and mitotic index, ER status, PR 
status, tumour markers, history of breast self-exams, clinical breast exams, ultrasounds, 
HRT, hormone contraceptive use, hysterectomy, menopausal status, history of other 
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cancers, family history of breast cancer, history of BBD, parity, radiotherapy to chest, age 
of menarche, age of first pregnancy, age of first mammography, age of first breast self-
exam, or age of first clinical breast exam (Table 5.10 and Table 5.11).  
Table 5.10 
Relationship (χ2, or Fisher’s exact) between categorical breast cancer-related variables and stage 
at diagnosis 
 Stage at diagnosis   
Variable  Localised 
N (%) 
Advanced  
N (%) 
P-value 
 
Tumour size    <0.001 
 T1 204 (71.8) 53 (34.9)  
 T2 76 (26.8) 84 (55.2)  
 T3 4 (1.4) 15 (9.9)  
Grade   0.001 
 Grade 1 58 (20.4) 12 (7.9)  
 Grade 2 143 (50.4) 78 (51.3)  
 Grade 3 83 (29.2) 62 (40.8)  
Mitotic activity    0.30 
 0-9 Mitoses/10hpf 145 (65.3) 61 (50.8)  
 10-19 Mitoses/10hpf 47 (21.2) 38 (31.7)  
 >20 Mitoses/10 hpf  30 (13.5) 21 (17.5)  
Oestrogen receptor status    0.80 
 ER+ 245 (86.6) 132 (87.4)  
 ER- 38 (13.4) 19 (12.6)  
Progesterone receptor status    0.61 
 PR+ 217 (76.7) 119 (78.8)  
 PR-/Not specified 66 (23.3) 32 (21.2)  
Tumour markers   0.81 
 HER2/neu+ 38 (13.7) 20 (13.4)  
 HER2/neu- 40 (14.4) 25 (16.8)  
 Equivocal/unk 200 (71.9) 104 (69.8)  
Mammography   <0.001 
 At least every 2 years 212 (74.6) 85 (55.6)  
 Irregularly  39 (13.7) 28 (18.3)  
 Never 33 (11.6) 40 (26.1)  
Breast self-exam    0.85 
 Monthly 75 (26.8) 43 (28.5)  
 Every 3 months 72 (25.7) 44 (29.1)  
 Every 6-12 months 53 (18.9) 27 (17.9)  
 Irregularly 44 (15.7) 22 (14.6)  
 Never  36 (12.9) 15 (9.9)  
Clinical breast exam   0.10 
 Every 6-12 months 74 (26.4) 42 (27.8)  
 Every 2 years 86 (30.7) 33 (21.9)  
 Irregularly 76 (21.2) 40 (26.5)  
 Never 44 (15.7) 36 (23.8)  
Ultrasound   0.19 
 Every 6-12 months 8 (5.3) 33 (11.7)  
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 Stage at diagnosis   
Variable  Localised 
N (%) 
Advanced  
N (%) 
P-value 
 
 Every 2 years 9 (6.0) 16 (5.7)  
 Irregularly 43 (28.5) 77 (27.4)  
 Never 91 (60.2) 155 (55.2)  
HRT   0.10 
 Yes 100 (35.6) 42 (27.8)  
 No/Unsure  181 (64.4) 109 (72.2)  
Hormone contraceptives   0.26 
 Current  248 (88.3) 135 (89.4)  
 Ever 7 (2.5) 7 (4.6)  
 Never  26 (9.3) 9 (6.0)  
Hysterectomy    0.62 
 Yes 77 (27.4) 38 (25.2)  
 No 204 (72.6) 113 (24.8)  
Menopause   0.93 
 Yes 228 (81.4) 122 (80.8)  
 No 36 (12.9) 19 (12.6)  
 Unsure  16 (5.7) 10 (6.6)  
History of other cancers   0.09 
 Yes 16 (5.7) 3 (2.0)  
 No/Unsure  265 (94.3) 148 (98.0)  
Family history of breast cancer   0.26 
 Yes 128 (47.1) 59 (41.3)  
 No/Unsure 144 (52.9) 84 (58.7)  
History of BBD   0.10 
 Yes 118 (42.0) 51 (33.8)  
 No 163 (58.0) 100 (66.2)  
Parity    0.76 
 Parous 252 (89.7) 134 (88.7)  
 Nulliparous  29 (10.3) 17 (11.3)  
Radiotherapy to chest   1.00 
 Yes 4 (1.4) 2 (1.3)  
 No 276 (98.6) 149 (98.7)  
 
Table 5.11 
Relationship (one way ANOVA) between continuous breast cancer-related variables and stage at 
diagnosis 
 Stage at diagnosis  
Exposure Localised Advanced P-value 
 Mean SD Mean SD  
Age
*
 of menarche  12.9 1.6 12.9 1.5 0.69 
Age
*
 of first pregnancy  25.2 5.2 25.6 5.2 0.50 
Age
*
 of first mammography  43.5 7.4 12.7 7.5 0.34 
Age
*
 of first self-exam 36.5 10.7 35.4 10.9 0.32 
Age
*
 of first clinical breast 
exam 
36.3 11.8 34.7 11.8 0.24 
*
Age is presented in years 
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5.5.2 UV exposure-related variables and stage at diagnosis  
In this section, the first research question, “Do women diagnosed with localised breast 
cancers have a higher lifetime sun exposure than women diagnosed with advanced breast 
cancers?” is examined. Lifetime sun exposure and sun exposure during breast 
development years (ages 7-18 years), as continuous variables, were plotted by stage of 
diagnosis (Figure 5.3 and Figure 5.4). There were no significant differences between 
mean lifetime UV for localised breast cancer (537.6 EU) and for advanced breast cancer 
506.3 EU (χ2=1.16; df=1; p=0.28). Similarly, no significant differences were observed in 
the mean UV for breast development years  for women with localised breast cancer 
(122.4 EU) compared to advanced breast cancer  (126.03 EU) (χ2=0.16; df=1; p=0.69). 
Similar results were observed when examining categorical UV, in which lifetime UV 
(χ2=1.42; df=2; p=0.49) and UV in breast development years (χ2=0.27; df=2; p=0.87) 
were not associated with breast cancer stage (Table 5.12).  
 
Figure 5.3. Lifetime sun exposure by breast cancer stage 
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Figure 5.4. Sun exposure during breast development years by breast cancer stage 
 
In terms of other categorical sun exposure variables, only solarium use was found to have 
a statistically significant association with stage at diagnosis at the bivariate level, with a 
higher proportion of women with advanced breast cancers indicating they had used a 
solarium in the past (15.7%) compared to women with localised breast cancers (7.3%) 
(χ2=7.54; df=1; p=0.01). (Table 5.12).  
Table 5.12 
Relationship (χ2, or Fisher’s exact) between categorical exposure-related variables and stage at 
diagnosis 
 Stage at diagnosis   
Variable  Localised 
N (%) 
Advanced  
N (%) 
P-value 
 
Lifetime UV   0.49 
 Low 90 (31.7) 56 (36.6)  
 Med 99 (34.6) 46 (30.1)  
 High 97 (33.9) 51 (33.3)  
UV (0-5yrs)   0.91 
 Low 37 (12.9) 22 (14.4)  
 Med 81 (28.3) 42 (27.5)  
 High 168 (58.7) 89 (58.2)  
UV (5yrs-present)   0.55 
 Low 90 (31.5) 56 (36.6)  
 Med 98 (34.3) 48 (31.4)  
 High 98 (34.3) 49 (32.0)  
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 Stage at diagnosis   
Variable  Localised 
N (%) 
Advanced  
N (%) 
P-value 
 
UV (7-18 yrs)   0.87 
 Low 89 (31.1) 44 (28.8)  
 Med 94 (32.9) 53 (34.6)  
 High 103 (36.0) 56 (36.6)  
Hair colour at age 21 yrs   0.99 
 Red/Fair/Blonde 69 (24.1) 37 (24.2)  
 Light/Mouse brown/Grey 115 (40.2) 62 (40.5)  
 Dark brown/Black 102 (35.7) 54 (35.3)  
Eye colour   0.29 
 Blue/Grey 113 (39.5) 60 (39.2)  
 Green/Hazel 106 (37.1) 66 (43.1)  
 Brown/Black 67 (23.4) 27 (17.7)  
Skin colour   0.50 
 Very Fair 32 (11.2) 15 (9.8)  
 Fair 190 (66.4) 110 (71.9)  
 Olive/Brown 64 (22.4) 28 (18.3)  
Skin reaction to the sun   0.64 
 Always burns, never tans 35 (12.2) 14 (9.2)  
 Usually burns, sometimes tans 81 (28.3) 40 (26.1)  
 Sometimes burns, usually tans 155 (54.2) 87 (56.9)  
 Never burns, always tans 13 (4.6) 11 (7.2)  
 Don’t Know 2 (0.7) 1 (0.6)  
Solarium use    0.01 
 Yes 21 (7.3) 24 (15.7)  
 No 265 (92.7) 129 (84.3)  
Vitamin supplementation   0.42 
 Yes, vit D and/or calcium 101 (35.3) 59 (38.6)  
 Yes, other 38 (13.3) 14 (9.1)  
 No  147 (51.4) 80 (52.3)  
History of skin cancer   0.27 
 Yes 61 (21.7) 26 (17.2)  
 No/Unsure 220 (78.3) 125 (82.8)  
 
 
5.6 BIVARIATE RELATIONSHIP BETWEEN COVARIATES AND 
LIFETIME UV  
The association between lifetime UV and covariates of interest (age, rurality, physical 
activity, solarium use, history of skin cancer, and breast screening variables) was 
examined. Variables significantly associated with lifetime UV include age (χ2=47.51; 
df=4; p<0.001), rurality (χ2=25.89; df=4; p<0.001), physical activity (χ2=12.80; df=6; 
p=0.05), solarium use (χ2=18.64; df=2; p<0.001), and mammography (χ2=25.17; df=4; 
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p<0.001) (Table 5.13). A higher proportion of women with high lifetime UV levels was 
diagnosed at 50-69 years (65.5%) and 70+ years (30.4%) compared to those with medium 
(22.8%) and low (10.3%) lifetime UV levels. Additionally, more women with low 
lifetime UV levels (32.2%) were diagnosed younger than 50 years of age compared to 
those with medium (17.9%) and high (4.1%) lifetime UV levels. Across all levels of UV, 
the highest proportion of women lived in major cities. However, a larger proportion of 
women with low UV levels lived in major cities (69.2%) compared to women of other 
UV levels. Additionally, a larger proportion of women with high UV levels lived in outer 
regional/remote/very remote areas (32.4%) compared to women of other UV levels.   
Women with low UV levels had the highest proportion of no physical activity (16.6%) 
compared to those with medium (14.2%) and high (9.6%) UV levels, with these 
differences being marginally significant (p=0.05). The majority of women reported never 
having used a solarium regardless of lifetime UV level; however, the proportion of 
women who reported using a solarium increased with increasing lifetime UV exposure 
(Low=18.5%; Medium=9.0%; High=3.4%). Mammography was also significantly 
associated with lifetime UV. Women with high UV levels were more likely to report 
having a mammogram at least every 2 years (81.8%) compared to those with medium 
(63.5%) and low (58.3%) lifetime UV levels.  
Table 5.13 
Relationship (χ2, or Fisher’s exact) between variables of interest and lifetime UV 
  Lifetime UV  
  Low Medium High  
Characteristic N (%) N (%) N (%) P-value  
Age    <0.001 
 <50 years 47 (32.2) 26 (17.9) 6 (4.1)  
 50-69 years 84 (57.5) 86 (59.3) 97 (65.5)  
 70+ years 15 (10.3) 33 (22.8) 45 (30.4)  
Rurality     <0.001 
 Major cities 101 (69.2) 81 (55.9) 72 (48.7)  
 Inner regional 28 (19.2) 40 (27.6) 28 (18.9)  
 Outer regional/ Remote/Very remote 17 (11.6) 24 (16.6) 48 (32.4)  
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  Lifetime UV  
  Low Medium High  
Characteristic N (%) N (%) N (%) P-value  
Physical Activity     0.05 
 None 24 (16.6) 20 (14.2) 14 (9.6)  
 Walking  54 (37.2) 42 (29.8) 60 (41.1)  
 Moderate activity 22 (15.2) 30 (21.3) 38 (26.0)  
 Vigorous activity  45 (31.0) 49 (34.8) 34 (23.3)  
Solarium use    <0.001 
 Yes 27 (18.5) 13 (9.0) 5 (3.4)  
 No 119 (81.5) 132 (91.0) 143 (96.6)  
History of skin cancer    0.19 
 Yes 22 (15.2) 32 (22.7) 33 (22.6)  
 No/Unsure 123 (84.8) 109 (77.3) 113 (77.4)  
Mammography    <0.001 
 A least every 2 years 84 (58.3) 92 (63.5) 121 (81.8)  
 Irregularly  24 (16.7) 31 (21.4) 12 (8.1)  
 Never 36 (25.0) 22 (15.2) 15 (10.1)  
Self-exam     0.72 
 Monthly 36 (25.0) 41 (29.1) 41 (28.1)  
 Every 3 months 43 (29.9) 32 (22.7) 41 (28.1)  
 Every 6-12 months 27 (18.8) 30 (21.3) 23 (15.8)  
 Irregularly 18 (12.5) 22 (15.6) 26 (17.8)  
 Never  20 (13.9) 16 (11.4) 15 (10.3)  
Clinical breast exam    0.09 
 Every 6-12 months 46 (31.9) 31 (22.0) 39 (26.7)  
 Every 2 years 44 (30.6) 44 (31.2) 31 (21.2)  
 Irregularly 31 (21.5) 46 (30.5) 42 (28.8)  
 Never 23 (16.0) 23 (16.3) 34 (23.3)  
 
 
5.7 SUMMARY  
Chapter 5 presented the descriptive statistics for the study population, main exposure, and 
the outcome of interest. The following summarize the main findings: 
 Mean age of diagnosis was 59.8 years 
 65.2% were diagnosed with localised breast cancer and 34.8% diagnosed with 
advanced breast cancer 
 Average sun exposure 
o Birth to age 5 years was  22.2 EU 
o Breast development years (ages 7 to 18 years) was 123.7 EU 
o Age 5 years to present was 504.4 EU 
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o Lifetime was 526.7 EU 
 Mammography, history of skin cancer, hormone contraceptives, and HRT were 
significantly associated with menopausal status  
 Tumour size, histological grade, mammography, solarium use, age, and marital 
status were significantly associated with stage at diagnosis 
 There was no significant difference between lifetime UV or UV during breast 
development years by stage at diagnosis (answering the first research question) 
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Chapter 6: Results of Model  
6.1 INTRODUCTION 
Chapter 6 presents the findings from the epidemiological model building process used to 
answer the main research question, “Are women with high levels of lifetime sun exposure 
at a lower risk of being diagnosed with advanced stage breast cancer compared to women 
with medium and low levels of sun exposure?” The process, as discussed in Chapter 4, 
involved building a model for the outcome variable (stage at diagnosis) and the main 
exposure variable (lifetime UV). Covariates were added to the preliminary multivariate 
model if they changed the coefficient of lifetime UV by 5% or greater, as this indicates 
potential confounding. Results of the bivariate analyses are presented in beta coefficients, 
as the coefficient of the covariate is needed to determine the percent change in the 
lifetime UV coefficient. Results of the preliminary and final models are reported as odds 
ratios (OR).  
6.2 STEP 1: BIVARIATE ANALYSIS OF EACH COVARIATE AND THE 
OUTCOME, STAGE AT DIAGNOSIS  
The bivariate association between stage at diagnosis (localised vs. advanced) and all 
covariates was examined using simple logistic regression. The referent category was 
localised for all analyses. Results are presented in Tables 6.1- 6.5.  
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Table 6.1 
Bivariate logistic regression analysis for breast cancer stage at diagnosis (localised vs. 
advanced) in relation to tumour characteristics   
 Advanced Breast Cancer  
Variable  Coefficient 95% CI P-value P-value of 
model 
Age    0.004 
 <50 years 0.752 0.24, 1.26 0.004  
 50-69 years ref --- ---  
 70+ years -0.220 -0.74, 0.30 0.41  
Marital status     0.03 
 Married, living as married ref --- ---  
 Single, living as single  -0.527 -1.02, -0.03 0.04  
Highest level of education     0.73 
 School education level   ref --- ---  
 Certificate/diploma  0.125 -0.32, 0.57 0.58  
 Bachelor degree/equivalent 
or higher  
-0.075 -0.60, 0.45 0.78  
Ethnicity     0.01 
 Caucasian/white ref --- ---  
 Other  1.917 0.33, 3.50 0.02  
Aboriginal or Torres Strait 
Islander  
   0.32 
 No ref --- ---  
 Yes -0.994 -3.15, 1.16 0.37  
Employment     0.33 
 Full time paid work  ref --- ---  
 Part time/Casual paid work  0.225 -0.28, 0.73 0.38  
 Unpaid work  0.595 -0.30, 1.49 0.19  
 Retired -0.207 -0.73, 0.32 0.44  
 Other 0.230 -0.78, 1.24 0.66  
Annual income     0.70 
 $0-$20,799 ref --- ---  
 $20,800-$41,599 -0.387 -1.20, 0.42 0.35  
 $41,600-$83,199 -0.158 -0.90, 0.58 0.68  
 $83,200-$155,999 0.089 -0.67, 0.84 0.82  
 >$156,000 0.041 -0.87, 0.95 0.93  
 Don’t know/don’t want to 
tell  
-0.307 -1.19, 0.58 0.50  
Private health insurance    0.76 
 Yes, full health insurance ref --- ---  
 Yes, some insurance -0.226 -0.92, 0.47 0.52  
 No  -0.117 -0.59, 0.36 0.63  
Born outside Australia     0.41 
 No ref --- ---  
 Yes 0.215 -0.29, 0.72 0.41  
Rurality     0.21 
 Major cities ref --- ---  
 Inner regional -0.390 -0.91, 0.13 0.14  
 Outer regional 0.230 -0.31, 0.77 0.40  
 Remote/Very remote  0.377 -0.59, 1.34 0.44  
BMI    0.84 
 <18.5 0.562 -1.07, 2.19 0.50  
 18.5-24.9 ref --- ---  
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 Advanced Breast Cancer  
Variable  Coefficient 95% CI P-value P-value of 
model 
 25.0-29.9 -0.131 -0.61, 0.35 0.59  
 >30 -0.068 -0.56, 0.42 0.79  
Alcohol     0.22 
 Lifelong non-drinker ref --- ---  
 Drink less than once a 
month 
0.165 -0.61, 0.94 0.68  
 Drink at least once a month  0.407 -0.26, 1.07 0.23  
 Used to drink but have 
stopped 
0.972 -0.04, 1.98 0.06  
Physical Activity     0.06 
 None ref --- ---  
 Walking  -0.344 -0.96, 0.27 0.27  
 Moderate activity -0.921 -1.63, -0.21 0.01  
 Vigorous activity  -0.370 -1.00, 0.26 0.25  
Smoking     0.47 
 Current smoker 0.326 -0.44, 1.09 0.41  
 Used to smoke but have 
quit 
-0.157 -0.58, 0.27 0.47  
 Lifelong non-smoker  ref --- ---  
Hair colour at age 21 yrs    0.99 
 Red/Fair/Blonde ref --- ---  
 Light/Mouse brown/Grey 0.005 -0.50, 0.51 0.98  
 Dark brown/Black -0.013 -0.53, 0.51 0.96  
Eye colour    0.28 
 Blue/Grey ref --- ---  
 Green/Hazel 0.159 -0.28, 0.60 0.48  
 Brown/Black -0.276 -0.82, 0.27 0.32  
Skin colour    0.49 
 Very Fair ref --- ---  
 Fair 0.211 -0.45, 0.87 0.53  
 Olive/Brown -0.069 -0.83, 0.69 0.86  
Skin reaction to the sun    0.66 
 Always burns, never tans ref --- ---  
 Usually burns, sometimes 
tans 
0.211 -0.52, 0.94 0.57  
 Sometimes burns, usually 
tans 
0.339 -0.33, 1.01 0.32  
 Never burns, always tans 0.749 -0.27, 1.76 0.15  
 Don’t Know 0.223 -2.26, 2.70 0.86  
Phenotype index    0.75 
 0-7 ref --- ---  
 >7  0.066 -0.34, 0.47 0.75  
Solarium use     0.01 
 No ref --- ---  
 Yes 0.853 0.23, 1.48 0.01  
Vitamin supplementation    0.41 
 Yes, vit D and/or calcium 0.071 -0.35, 0.49 0.74  
 Yes, other -0.390 -1.06, 0.28 0.25  
 No  ref --- ---  
Grade    <0.001 
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 Advanced Breast Cancer  
Variable  Coefficient 95% CI P-value P-value of 
model 
 Grade 1 ref --- ---  
 Grade 2 0.969 0.29, 1.65 0.01  
 Grade 3 1.284 0.58, 1.99 <0.001  
Oestrogen receptor status     0.80 
 ER+ ref --- ---  
 ER- -.075 -0.66, 0.52 0.80  
Progesterone receptor status     0.61 
 PR+ ref --- ---  
 PR-/Not specified  -0.123 -0.60, 0.35 0.61  
Tumour markers    0.81 
 HER2/neu- ref --- ---  
 HER2/neu+ -0.172 -0.91, 0.56 0.65  
 Equivocal/unk -0.184 -0.74, 0.37 0.52  
Mammography    <0.001 
 At least every 2 years  ref --- ---  
 Irregularly  0.583 0.04, 1.13 0.04  
 Never 1.106 0.58, 1.63 <0.001  
Breast self-exam     0.84 
 Monthly ref --- ---  
 Every 3 months 0.064 -0.47, 0.59 0.81  
 Every 6-12 months -0.118 -0.71, 0.48 0.70  
 Irregularly -0.137 -0.77, 0.50 0.67  
 Never  -0.319 -1.03, 0.39 0.38  
Clinical breast exam    0.10 
 Every 6-12 months ref --- ---  
 Every 2 years -0.391 -0.94, 0.16 0.16  
 Irregularly -0.075 -0.61, 0.46 0.78  
 Never 0.366 -0.22, 0.95 0.21  
Ultrasound    0.16 
 Every 6-12 months ref --- ---  
 Every 2 years 0.842 -0.28, 1.97 0.14  
 Irregularly 0.834 -0.02, 1.69 0.06  
 Never 0.885 0.07, 1.70 0.03  
HRT    0.10 
 Yes ref --- ---  
 No/Unsure  0.360 -0.07, 0.79 0.10  
Hormone contraceptives    0.26 
 Current  ref --- ---  
 Ever 0.608 -0.46, 1.68 0.27  
 Never -0.453 -1.24, 0.33 0.26  
Hysterectomy     0.62 
 Yes ref --- ---  
 No 0.115 -0.34, 0.57 0.62  
Age of menarche -0.026 -0.16, 0.10 0.69 0.69 
Menopause    0.93 
 Yes ref --- ---  
 No -0.014 -0.61, 0.58 0.96  
 Unsure 0.155 -0.66, 0.98 0.71  
History of other cancers    0.06 
 Yes ref --- ---  
 No/Unsure 1.091 -0.16, 2.34 0.09  
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 Advanced Breast Cancer  
Variable  Coefficient 95% CI P-value P-value of 
model 
History of skin cancer    0.26 
 Yes ref --- ---  
 No/Unsure 0.287 -0.22, 0.80 0.27  
Family history of breast cancer    0.26 
 Yes ref --- ---  
 No/Unsure 0.235 -0.17, 0.64 0.26  
History of BBD    0.09 
 Yes ref --- ---  
 No 0.350 -0.62, 0.76 0.10  
Parity     0.76 
 Parous ref --- ---  
 Nulliparous  0.098 -0.54, 0.73 0.76  
Radiotherapy to chest    0.93 
 Yes ref --- ---  
 No 0.077 -1.63, 1.79 0.93  
 
6.3 STEP 2: BIVARIATE ANALYSIS OF EACH COVARIATE AND THE 
EXPOSURE, LIFETIME UV   
Next, bivariate analysis between lifetime UV (low, medium, and high) and all covariates 
was examined using simple logistic regression. High levels of UV were used as the 
referent category for all analyses. Results are presented in Table 6.2.  
Table 6.2 
Bivariate logistic regression analysis for lifetime UV (high vs. low & medium) in relation to all 
covariates 
 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
Age       <0.001 
 <50 years 2.202 1.30, 3.10 <0.001 1.587 0.65, 2.52 0.001  
 50-69 years ref --- --- ref --- ---  
 70+ years -0.955 -1.61, -0.30 0.004 -0.190 -0.72, 0.35 0.49  
Marital status        0.94 
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 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
 Married, living as 
married 
ref --- --- ref --- ---  
 Single, living as 
single  
0.018 -0.52, 0.56 0.95 0.093 -0.45, 0.63 0.74  
Highest level of 
education  
      0.01 
 School education 
level   
ref --- --- ref --- ---  
 Certificate/diploma  -0.587 -1.14, -0.04 0.04 -0.199 -0.71, 0.31 0.45  
 Bachelor 
degree/equivalent or 
higher  
0.116 -0.47, 0.71 0.70 -0.604 -1.26, 0.05 0.07  
Ethnicity        0.03 
 Caucasian/white ref --- --- ref --- ---  
 Other  -0.215 -1.55, 1.12 0.75 -13.658 -827.03, 
799.71 
0.97  
Aboriginal/Torres 
Strait Islander  
      0.58 
 No ref --- --- ref --- ---  
 Yes 0.448 -1.36, 2.25 0.63 -0.686 -3.10, 1.73 0.58  
Employment        0.001 
 Full time paid work  ref --- --- ref --- ---  
 Part time/Casual paid 
work  
-0.378 -0.98, 0.22 0.22 -0.647 -1.27, -0.01 0.04  
 Unpaid work  0.390 -0.74, 1.52 0.50 -0.264 -1.53, 1.00 0.68  
 Retired -1.309 -1.95, -0.67 <0.001 -0.683 -1.27, -0.09 0.02  
 Other -0.773 -1.92, 0.37 0.19 -1.139 -2.42, 0.14 0.08  
Annual income        0.02 
 $0-$20,799 ref --- --- ref --- ---  
 $20,800-$41,599 0.727 -0.36, 1.82 0.19 -0.468 -1.34, 0.40 0.29  
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 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
 $41,600-$83,199 0.850 -0.18, 1.88 0.11 -0.590 -1.40, 0.22 0.15  
 $83,200-$155,999 1.322 0.25, 0.239 0.02 0.089 -0.76, 0.93 0.84  
 >$156,000 1.743 0.44, 3.04 0.01 0.590 -0.53, 1.71 0.30  
 Don’t know/don’t 
want to tell  
0.390 -0.78, 1.56 0.51 -0.688 -1.64, 0.26 0.16  
Private health 
insurance 
      0.17 
 Yes, full health 
insurance 
ref --- --- ref --- ---  
 Yes, some insurance -0.230 -1.05, 0.59 0.58 0.026 -0.73, 0.78 0.95  
 No  0.633 0.08, 1.19 0.03 0.229 -0.36, 0.81 0.45  
Born outside Australia        <0.001 
 No ref --- --- ref --- ---  
 Yes 1.172 0.54, 1.80 <0.001 0.303 -0.40, 1.00 0.40  
Rurality        <0.001 
 Major cities ref --- --- ref --- ---  
 Inner regional -0.338 -0.94, 0.27 0.27 0.239 -0.34, 0.82 0.42  
 Outer regional -1.294 -1.96, -0.63 <0.001 -0.948 -1.60, -0.30 0.00  
 Remote/Very remote  -1.843 -3.40, -0.28 0.02 -0.369 -1.41, 0.67 0.49  
BMI       0.25 
 <18.5 0.811 -0.148, 3.10 0.49 0.539 -1.89, 2.97 0.66  
 18.5-24.9 ref --- --- ref --- ---  
 25.0-29.9 -0.474 -1.02, 0.07 0.09 -0.487 -1.05, 0.08 0.09  
 >30 -0.606 -1.20, -0.02 0.04 -0.201 -0.77, 0.37 0.49  
Alcohol        0.08 
 Lifelong non-drinker ref --- --- ref --- ---  
 Drink less than once -0.100 -0.99, 0.79 0.83 -0.125 -0.94, 0.69 0.76  
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 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
a month 
 Drink at least once a 
month  
0.671 -0.09, 1.43 0.08 0.233 -0.47, 0.94 0.52  
 Used to drink but 
have stopped 
0.230 -0.89, 1.35 0.69 -0.906 -2.22, 0.40 0.18  
Physical Activity        0.04 
 None ref --- --- ref --- ---  
 Walking  -0.644 -1.40, 0.11 0.09 -0.713 -1.50, 0.08 0.08  
 Moderate activity -1.086 -1.93, -0.24 0.01 -0.593 -1.43, 0.24 0.16  
 Vigorous activity  -0.259 -1.05, 0.54 0.52 0.009 -0.80, 0.82 0.98  
Smoking        0.36 
 Current smoker 0.293 -0.19, 0.78 0.24 0.057 -0.43, 0.55 0.82  
 Used to smoke but 
have quit 
0.873 -0.08, 1.83 0.07 0.308 -0.72, 1.34 0.56  
 Lifelong non-smoker  ref --- --- ref --- ---  
Hair colour at age 21 
yrs 
      0.96 
 Red/Fair/Blonde ref --- --- ref --- ---  
 Light/Mouse 
brown/Grey 
-0.111 -0.70, 0.48 0.71 0.00 -0.60, 0.60 1.00  
 Dark brown/Black -0.227 -0.83, 0.38 0.46 -0.056 -0.66, 0.55 0.86  
Eye colour       0.83 
 Blue/Grey ref --- --- ref --- ---  
 Green/Hazel 0.018 -0.49, 0.53 0.95 0.071 -0.45, 0.59 0.79  
 Brown/Black -0.187 -0.81, 0.44 0.56 0.178 -0.43, 0.78 0.56  
Skin colour       0.51 
 Very Fair ref --- --- ref --- ---  
 Fair -0.586 -1.38, 0.21 0.15 -0.515 -1.32, 0.29 0.21  
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 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
 Olive/Brown -0.747 -1.65, 0.15 0.10 -0.466 -1.37, 0.43 0.31  
Skin reaction to the 
sun 
      0.005 
 Always burns, never 
tans 
ref --- --- ref --- ---  
 Usually burns, 
sometimes tans 
0.613 -0.24, 1.46 0.16 -0.166 -0.97, 0.64 0.69  
 Sometimes burns, 
usually tans 
0.118 -0.68, 0.91 0.77 -0.187 -0.91, 0.54 0.61  
 Never burns, always 
tans 
-0.773 -1.96, 0.42 0.20 -2.302 -3.91, -0.69 0.01  
 Don’t Know 11.989 -696.80, 
720.77 
0.97 12.251 -696.53, 
721.03 
0.97  
Phenotype index       0.04 
 0-7 ref --- --- ref --- ---  
 >7 -0.614 -1.09, -0.13 0.01 -0.343 -0.81, 0.13 0.15  
Solarium use        <0.001 
 No ref --- --- ref --- ---  
 Yes 1.870 0.89, 2.85 <0.001 1.036 0.02, 2.09 0.06  
Vitamin 
supplementation 
      0.22 
 Yes, vit D and/or 
calcium 
-0.555 -1.37, 0.26 0.18 0.369 -0.33, 1.07 0.30  
 Yes, other -0.063 -0.55, 0.43 0.80 0.143 -0.36, 0.64 0.56  
 No  ref --- --- ref --- ---  
Grade       0.56 
 Grade 1 ref --- --- ref --- ---  
 Grade 2 -0.541 -1.22, 0.14 0.12 -0.407 -1.09, 0.28 0.24  
 Grade 3 -0.405 -1.12, 0.31 0.27 -0.434 -1.16, 0.29 0.24  
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 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
Oestrogen receptor 
status  
      0.08 
 ER+ ref --- --- ref --- ---  
 ER- -0.652 -1.33, 0.03 0.06 -0.660 -1.34, 0.02 0.06  
Progesterone receptor 
status  
      0.84 
 PR+ ref --- --- ref --- ---  
 PR-/Not specified  -0.163 -0.72, 0.39 0.56 -0.050 -0.59, 0.49 0.86  
Tumour markers       0.94 
 HER2/neu- ref --- --- ref --- ---  
 HER2/neu+ 0.142 -0.72, 1.00 0.75 -0.211 -1.07, 0.65 0.63  
 Equivocal/unk 0.171 -0.50, 0.84 0.62 -0.00 -0.64, 0.64 1.00  
Mammography       <0.001 
 At least every 2 years ref --- --- ref --- ---  
 Irregularly  1.058 0.31, 1.80 0.01 1.223 0.50, 1.94 0.001  
 Never 1.240 0.58, 1.90 <0.001 0.657 -0.05, 1.37 0.07  
Breast self-exam        0.72 
 Monthly ref --- --- ref --- ---  
 Every 3 months 0.178 -0.44, 0.80 0.57 -0.248 -0.88, 0.39 0.44  
 Every 6-12 months 0.290 -0.42, 1.00 0.43 0.266 -0.43, 0.96 0.45  
 Irregularly -0.238 -0.99, 0.51 0.53 -0.167 -0.88, 0.55 0.65  
 Never  0.418 -0.39, 1.22 0.31 0.065 -0.76, 0.89 0.88  
Clinical breast exam       0.09 
 Every 6-12 months ref --- --- ref --- ---  
 Every 2 years 0.185 -0.44, 0.81 0.56 0.579 -0.08, 1.24 0.08  
 Irregularly -0.469 -1.10, 0.16 0.15 0.253 -0.38, 0.89 0.44  
 Never -0.556 -1.24, 0.12 0.11 -0.161 -0.87, 0.55 0.66  
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 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
Ultrasound       0.58 
 Every 6-12 months ref --- --- ref --- ---  
 Every 2 years -0.394 -1.63, 0.84 0.53 0.00 -1.20, 1.20 1.00  
 Irregularly -0.509 -1.37, 0.35 0.25 -0.281 -1.16, 0.60 0.53  
 Never 0.028 -0.78, 0.83 0.95 0.089 -0.74, 0.92 0.83  
HRT       0.01 
 Yes ref --- --- ref --- ---  
 No/Unsure  0.757 0.25, 1.26 0.003 0.273 -0.21, 0.75 0.27  
Hormone 
contraceptives 
      0.08 
 Current  ref --- --- ref --- ---  
 Ever 2.275 0.19, 4.36 0.03 1.432 -0.77, 3.64 0.20  
 Never 0.158 -0.66, 0.98 0.71 -0.136 -1.01, 3.64 0.76  
Hysterectomy        0.24 
 Yes ref --- --- ref --- ---  
 No 0.453 -0.07, 0.98 0.09 0.189 -0.32, 0.70 0.47  
Age of menarche  -0.007 -0.16, 0.14 0.93 0.147 -0.01, 0.30 0.06 0.08 
Menopause       <0.001 
 Yes ref --- --- ref --- ---  
 No -0.996 -1.68, -0.32 0.004 -1.692 -2.51, -0.88 <0.00
1 
 
 Unsure -0.138 -1.02, 0.74 0.76 -1.287 -2.46, -0.11 0.03  
History of other 
cancers 
      0.92 
 Yes ref --- --- ref --- ---  
 No/Unsure -0.007 -1.16, 1.15 0.99 -0.198 -1.31, 0.92 0.73  
History of skin cancer       0.18 
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 Low UV Medium UV P-value 
of 
model  
Variable  Coeff 95% CI P-value Coeff 95% CI P-
value 
 
 Yes ref --- --- ref --- ---  
 No/Unsure 0.490 -0.11, 1.09 0.11 -0.005 -0.56, 0.55 0.99  
Family history of 
breast cancer 
      0.38 
 Yes ref --- --- ref --- ---  
 No/Unsure 0.320 -0.15, 0.79 0.18 0.239 -0.23, 0.71 0.32  
History of BBD       0.22 
 Yes ref --- --- ref --- ---  
 No 0.272 -0.20, 0.74 0.25 0.410 -0.07, 0.89 0.09  
Parity        0.19 
 Parous ref --- --- ref --- ---  
 Nulliparous  0.348 -0.47,  1.16 0.40 0.707 -0.07, 1.48 0.07  
Radiotherapy to chest       0.58 
 Yes ref --- --- ref --- ---  
 No -1.127 -3.40, 1.15 0.33 -0.735 -3.15, 1.68 0.55  
 
6.4 STEP 3: IDENTIFICATION OF POTENTIAL CONFOUNDERS  
Covariates significantly associated with both the outcome (breast cancer stage) and the 
exposure (lifetime UV) in the bivariate analyses (P<0.20, using the P-value of the model), 
were identified as potential confounders (Table 6.3).  
Table 6.3 
Covariates flagged at α<0.2 in bivariate analysis of breast cancer stage (localised vs. advanced) 
AND lifetime UV exposure (high vs. low & medium) 
 Stage at diagnosis Lifetime UV 
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Covariates P-value  P-value  
Mammography <0.001 <0.001 
Physical activity 0.06 0.04 
Ethnicity 0.01 0.03  
Solarium use 0.01 <0.001 
Age at diagnosis  0.004 <0.001 
Clinical breast exam 0.10 0.09 
HRT 0.10 0.01 
 
6.5 STEP 4: EXAMINE THE EFFECT OF POTENTIAL CONFOUNDERS 
ON THE ASSOCIATION BETWEEN LIFETIME UV AND BREAST 
CANCER STAGE  
Multivariate logistic regression was used to determine the effect of potential confounding, 
in which results are presented as beta-coefficients from the logit model. Each covariate 
was introduced into the model containing only lifetime UV and breast cancer stage, and 
changes in the lifetime UV coefficient were assessed by calculating the percent change. 
Percent change was calculated by dividing the change in the value by the original value, 
multiplied by 100. The calculation is as follows:  
Percent change = [(∆V)/(V1)]*100 = [(V2-V1)/(V1)]*100 
Inclusion of mammography, physical activity, ethnicity, solarium use, age at diagnosis, 
and clinical breast exam changed the lifetime UV coefficient by 5% or greater (in both 
categories), confirming these are confounding the association between lifetime UV and 
breast cancer stage. (Table 6.4).  
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Table 6.4 
Effect of potential confounders on the association between breast cancer stage at diagnosis 
(localised vs. advanced) and lifetime UV (high vs. low & medium) 
Model  Coefficient (UV)  % change in UV coefficient  
 Low Medium  Low Medium  
Stage, UV 0.17 -0.12   
Stage, UV, mammography -0.04 -0.28 -121.15 125.35 
Stage, UV, physical activity 0.11 -0.15 -34.76 -67.49 
Stage, UV, ethnicity 0.25 0.00 47.90 -103.04 
Stage, UV, solarium use 0.04 -0.16 -78.50 42.39 
Stage, UV, age at diagnosis -0.11 -0.26 -164.95 113.16 
Stage, UV, clinical breast 
exam 
0.27 -0.04 57.89 -67.49 
Stage, UV, HRT 0.14 -0.13 -19.58 3.07 
 
 Although ethnicity was identified as a confounder, only 9 (2.1%) study participants were 
an ethnicity other than white/Caucasian. Thus ethnicity was not included in the model, as 
there were too few participants in the “Other” ethnicity category to accurately make 
assumptions for this group’s relationship between lifetime UV and breast cancer stage. 
All other identified confounders were included in the preliminary multivariate model 
(Table 6.5). 
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Table 6.5 
Preliminary multivariate model 
 Advanced Breast Cancer  
 Adjusted OR
1 
95% CI P-value  
Model (n=429)   <0.001 
Sun Exposure     
 High UV ref ---- ---- 
 Low UV 0.79 0.46, 1.38 0.41 
 Medium UV 0.75 0.44, 1.28 0.30 
Mammography    
 At least every 2 years ref ---- ---- 
 Irregularly 1.61 0.89, 2.93 0.12 
 Never 2.55 1.79, 5.11 0.01 
Solarium Use    
 Never ref ---- ---- 
 Yes 1.97 1.00, 3.90 0.05 
Physical Activity    
 None ref ---- ---- 
 Light 0.69 0.36, 1.31 0.25 
 Moderate 0.44 0.20, 0.92 0.03 
 Vigorous 0.59 0.30, 1.16 0.12 
Age at diagnosis    
 <50 years 1.43 0.78, 2.63 0.25 
 50-69 years ref ---- ---- 
 70+ years 0.84 0.47, 1.51 0.41 
Clinical breast exam    
 Every 6-12 months ref ---- ---- 
 Every 2 years 0.62 0.35, 1.10 0.10 
 Irregularly 0.79 0.44, 1.42 0.44 
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 Advanced Breast Cancer  
 Adjusted OR
1 
95% CI P-value  
 Never  1.22 0.64, 2.32 0.55 
1 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, and clinical breast exams 
6.6 STEP 5: RE-EXAMINING VARIABLES INITIALLY EXCLUDED  
The confounding effect of variables identified in the literature as important predictors of 
either breast cancer stage or lifetime UV were assessed by adding them into the 
preliminary multivariate model. If the inclusion of the variable changed both lifetime UV 
coefficients by 5% or greater, it was included in the model. The variables tested included 
an additional screening variable (breast self-exams), access to care (rurality), and use of 
HRT. However, only rurality was identified as a confounder (Table 6.6).  
Table 6.6 
Examination of additional potential confounders on the association between breast cancer stage 
at diagnosis (localised vs. advanced) and lifetime UV (high vs. low & medium) 
Model  Coefficient (UV)  % change in UV coefficient  
 Low Medium  Low Medium  
*Preliminary model -0.23 -0.28   
*Preliminary model, HRT -0.22 -0.28 -2.56 -0.09 
*Preliminary model, self-breast exam  -0.21 -0.27 -9.56 -3.67 
*Preliminary model, rurality -0.16 0.20 -29.37 -30.60 
* Preliminary model = Stage at diagnosis, lifetime UV, mammography, physical activity, solarium use, age at diagnosis, and clinical 
breast exam  
 
6.7 STEP 6: EFFECT MODIFICATION AND VARIABLE 
INTERACTIONS  
Based on the analyses in the previous steps, the confounders included in the final model 
were mammography, physical activity, solarium use, age at diagnosis, clinical breast 
exams, and rurality. To test for effect modification, a multiplicative term was added to the 
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final model, one at a time, to assess if the magnitude of the effect varied according to age. 
Significance was determined using Wald tests. No significant interaction was noted 
(P=0.58). Interactions between variables in the model were tested in the same manner. 
Interactions between age and all covariates and screening variables (mammography and 
clinical breast exams) and rurality were tested. No significant interactions were observed.  
6.8 FINAL MODEL FOR THE ASSOCIATION BETWEEN LIFETIME 
UV AND BREAST CANCER STAGE AT DIAGNOSIS  
The results of the final model for the association between lifetime UV (high vs. low and 
medium) and breast cancer stage (localised vs. advanced) are presented in Table 6.7. In 
the crude analysis of lifetime UV and breast cancer stage, risk of advanced breast cancer 
was not associated with low UV (OR=1.18; 95% CI: 0.74, 1.90; P=0.49) or medium UV 
(OR=0.88; 95% CI: 0.54, 1.44; P=0.62). This association remained for both low UV 
(OR=0.85; 95% CI: 0.48, 1.50; P=0.49) and medium UV (OR=0.82; 95% CI: 0.48, 1.41; 
P=0.48) when adjusting for potential confounders.  
Mammography was significantly associated with breast cancer stage in both the crude and 
adjusted analyses. In the crude analysis, women who had mammograms 
irregularly/infrequently or who had never had a mammogram, were 1.79 (OR=1.79; 95% 
CI: 1.04, 3.09; P=0.04) and 3.02 times (OR=3.02; 95% CI: 1.79, 5.11; P<0.001) more 
likely to be diagnosed with advanced breast cancer, respectively, compared to women 
who had mammograms at least every 2 years.  This trend remained in the adjusted 
analysis where women who had irregular/infrequent mammograms or no mammograms 
had  1.60 (OR=1.60; 95% CI: 0.88, 2.93; P=0.12) and 2.55 (OR=2.55; 95% CI: 1.33, 
4.92; P=0.01) increased odds of being diagnosed with advanced breast cancer, 
respectively, compared to those who had a mammogram at least every two years. The 
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association for irregular/infrequent mammograms was not significant in the adjusted 
analysis, however.  
Solarium use was marginally significant in the adjusted analysis with almost 2-times the 
risk (OR=1.98; 95% CI: 1.00, 3.94; P=0.05) of advanced breast for those women who had 
used a solarium compared to those who had not. Moderate physical activity was 
significantly associated with  increased odds, equating to a 55% reduction (OR=0.45; 
95% CI: 0.21, 0.96; P=0.04), in advanced breast cancer compared to no physical activity. 
Although not significant, trends were observed in the adjusted analysis for age at 
diagnosis, whereas as age increased, the risk of being diagnosed with advanced breast 
cancer increased. Women younger than 50 years and women 70 years and older had a 
42% increased risk (OR=1.42; 95% CI: 0.77, 2.64; P=0.26) and a 13% decreased risk 
(OR=0.87; 95% CI: 0.48, 1.57; P=0.65) of being diagnosed with advanced breast cancer 
compared to women aged 50-69 years.  
Table 6.7 
Final model of breast cancer stage at diagnosis (localised vs. advanced) and lifetime UV (high vs. 
low & medium) 
 Advanced Breast Cancer  
 Crude 
OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=429)      <0.001 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.88 0.54, 1.44 0.62 0.82 0.48, 1.41 0.48 
 Low UV 1.18 0.74, 1.90 0.49 0.85 0.48, 1.50 0.58 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
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 Advanced Breast Cancer  
 Crude 
OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
 Irregularly 1.79 1.04, 3.09 0.04 1.60 0.88, 2.93 0.12 
 Never 3.02 1.79, 5.11 <0.001 2.55 1.33, 4.92 0.01 
Solarium Use       
 Never ref ---- ---- ref ---- ---- 
 Yes 2.35 1.26, 4.37 0.01 1.98 1.00, 3.94 0.05 
Physical Activity       
 None ref ---- ---- ref ---- ---- 
 Light 0.71 0.38, 1.31 0.27 0.69 0.36, 1.34 0.27 
 Moderate 0.40 0.20, 0.81 0.01 0.45 0.21, 0.96 0.04 
 Vigorous 0.69 0.37, 1.30 0.25 0.59 0.29, 1.18 0.14 
Age at diagnosis       
 <50 years 2.12 0.27, 3.53 0.004 1.42 0.77, 2.64 0.26 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 0.80 0.48, 1.35 0.41 0.87 0.48, 1.57 0.65 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.68 0.39, 1.17 0.16 0.63 0.35, 1.13 0.12 
 Irregularly 0.93 0.54, 1.59 0.78 0.83 0.46, 1.50 0.55 
 Never  1.44 0.81, 2.58 0.22 1.25 0.64, 2.42 0.51 
Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.68 0.40, 1.14 0.14 0.67 0.38, 1.18 0.16 
 Outer Regional 1.26 0.73, 2.16 0.40 1.26 0.69, 2.30 0.45 
 Remote/Very remote 1.46 0.56, 3.82 0.44 1.25 0.44, 3.57 0.68 
1
 Bivariate analysis between breast cancer stage and each covariate   
2 Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, and rurality   
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6.9 THE RELATIONSHIP BETWEEN BREAST CANCER STAGE AND 
UV DURING BREAST DEVELOPMENT YEARS  
To answer the research question, “Does lifetime sun exposure or sun exposure during the 
years of breast development matter more in influencing breast cancer stage at 
diagnosis?”, the association between UV during breast development years and stage at 
diagnosis was examined using logistic regression, controlling for the confounders 
identified in the previous model. Low (OR=0.96; 95% CI: 0.56, 1.64; P=0.89) and 
medium (OR=1.16; 95% CI: 0.70, 1.92; P=0.57) levels of UV during breast development 
years was not significantly associated with stage at diagnosis (Table 6.8).  
Table 6.8 
Association of breast cancer stage at diagnosis (localised vs. advanced) and UV during breast 
development years (high vs. low & medium) 
 Advanced Breast Cancer  
 Crude 
OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=429)      <0.001 
Sun Exposure    0.87    
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 1.04 0.65, 1.66 0.88 1.16 0.70, 1.92 0.57 
 Low UV 0.91 0.56, 1.48 0.70 0.96 0.56, 1.64 0.89 
1
 Bivariate analysis between breast cancer stage and UV during breast development years    
2 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, and rurality   
 
Similarly, both lifetime sun exposure and sun exposure during breast development years 
were not significantly associated with breast cancer stage at diagnosis.  
6.10 ADDITIONAL ANALYSES  
Additional models were used to further explore the relationship between UV and breast 
cancer stage at diagnosis, including a model controlling for tumour characteristics and a 
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model using grade as a prognostic indicator of breast cancer, rather than stage at 
diagnosis. 
 
6.10.1 Controlling for tumour characteristics  
While stage takes into account tumour size, nodal involvement, and metastasis of the 
cancer, additional tumour characteristics such as hormone receptor status and tumour 
markers are associated with advanced breast cancer.
156
 Therefore, we undertook 
additional analyses whereby these variables were added individually to the final model to 
examine the relationship between lifetime UV and breast cancer stage, as well as to 
examine the relationship between breast cancer stage and UV during breast development 
years. ER status, PR status, and HER2/neu status were not significant when added to 
either model. Additionally, their inclusion did not affect lifetime UV or UV during breast 
development years, as the exposure variables remained insignificant in the model. See 
Appendix I and Appendix J for details of the models.   
6.10.2 Using other prognostic indicators  
In addition to using breast cancer stage, a new model was built using tumour grade as a 
measure of prognosis. Confounders identified in this model included those in the previous 
model, with the addition of education and the exclusion of physical activity and solarium 
use. Again, no significant association was observed between grade and lifetime UV.  
Tumour characteristic variables (ER status, PR status, and HER2/neu status) were then 
added to the model individually. ER
-
 (OR=11.38; 95% CI: 1.53, 84.58; P=0.02) and 
Equivocal/Unknown HER2/neu (OR=0.15; 95% CI: 0.03, 0.64; P=0.01) were 
significantly associated with breast cancer grade in their respective models and were 
therefore both included in an additional model where they retained their significance (ER
-
 156 Chapter 6: Results of Model 
: OR=9.48, P=0.03; Equivocal/Unknown HER2/neu: OR=0.17, P=0.02). For additional 
details of this model, see Appendix K.  
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Chapter 7: Discussion 
7.1 INTRODUCTION 
Breast cancer is the most commonly diagnosed cancer among Australian women (with the 
exception of non-melanoma skin cancers) and contributes to 28% of all new cancers in 
Australian women.
74
 Prior studies have investigated the relationship between sun 
exposure and breast cancer risk and mortality, but results have been inconsistent.
24
 While 
some studies have found sun exposure to be protective against risk of breast cancer and 
breast cancer mortality, others have failed to find any such relationship. To date, no 
studies have examined whether there is a relationship between lifetime sun exposure and 
breast cancer stage at diagnosis. This thesis addresses this research gap.  
The aim of the PhD research project was to investigate the relationship between lifetime 
sun exposure and breast cancer stage at diagnosis. The objectives of the study were to: 1) 
Define the role that location of residence has on breast cancer stage at diagnosis; 2) 
Measure lifetime sun exposure in women newly diagnosed with breast cancer; 3) Develop 
a model to define the role that lifetime sun exposure has on breast cancer stage at 
diagnosis, controlling for known breast cancer risk factors, and 4) Determine at what 
stage of life sun exposure matters most in breast cancer stage at diagnosis.I answered two 
primary research questions: 1) Do women diagnosed with localised breast cancers have a 
higher lifetime sun exposure than women diagnosed with advanced breast cancers? and 2) 
Are women with high levels of lifetime sun exposure at lower risk of being diagnosed 
with advanced stage breast cancer compared to women with medium and low levels of 
sun exposure? The secondary research question examined whether lifetime sun exposure 
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or sun exposure during the years of breast development matter more in influencing breast 
cancer stage.  
This chapter will discuss the findings of the initial proof of concept study, the PhD study, 
the results of the PhD study compared to those of previous studies, and possible 
explanations for the findings. Additionally, this chapter addresses the strengths and 
weaknesses of the study and discusses directions for future research.  
7.2 BREAST CANCER STAGE AND LOCATION OF RESIDENCE IN 
THE US POPULATION  
The aim of this study was to investigate the association between location of residence and 
breast cancer stage at diagnosis in the U.S., corresponding to the first objective.  Data 
were obtained from the U.S. Surveillance, Epidemiology and End Results (SEER) 
program, a publically available population- based database containing 18 cancer 
registries, representing approximately 28% of the U.S. population.
135
  
The study population included women aged 20 years and over (at diagnosis) with 
invasive breast cancer from January 1, 2000 to December 31, 2010 identified in the SEER 
18 registry, and excluded women with records of missing or unknown values. Breast 
cancer stage at diagnosis was categorised as “localised” and “advanced,” where localised 
stage refers to cancers that have not spread past the site of origin (breast) and advanced 
stage is defined as cancer spread beyond the local site (includes regional and distant 
breast cancer metastases). Location of residence at time of diagnosis was defined by 
latitude, which was dichotomized into “North,” residential locations >37°N, and “South,” 
residential locations <37°N. Logistic regression was used to examine the association 
between location of residence and stage at diagnosis, while adjusting for potential 
confounders which included age at diagnosis, oestrogen receptor (ER) status, 
  
Chapter 7: Discussion 159 
progesterone receptor (PR) status, marital status, rurality, race, mammography, education, 
family income, poverty level, unemployment, being foreign born, and smoking. These 
variables were selected, as past research has suggested they may be associated with breast 
cancer stage.
142,157-159
  
In this study, no significant association between location of residence and risk of 
advanced breast cancer (OR=1.00; 95% CI: 0.99, 1.02; P=0.74) was observed in the final 
model (adjusted for age at diagnosis, ER status, PR status, marital status, rurality, race, 
mammography, education, family income, poverty level, unemployment, being foreign 
born, and smoking). Similarly, no significant association between location of residence 
and risk of advanced breast cancer was found when restricting the analysis to white 
women only (OR=1.01; 95% CI: 0.99, 1.03; P=0.18).  However, when restricting the 
analysis to black women, black women living in the North (<37°N) were 7% (OR=0.93; 
95% CI: 0.88, 0.98; P=0.01) less likely to be diagnosed with advanced breast cancer 
compared to black women living in the South (>37°N).  
A possible explanation for why a significant association was observed for black women 
but not for white women is that differences in sociodemographic and breast cancer-related 
characteristics exist between black and white populations.  
A study investigating the clinical associations of breast cancer subtypes among racial 
groups found that premenopausal African American women had a higher prevalence of 
the more aggressive basal-like breast cancer (39% vs. 16%) and a lower prevalence of the 
less aggressive luminal A subtype (36% vs. 54%), indicating a poorer prognosis for 
African American women.
160
 Consistent with these findings, Morris et al found that 
African American patients were more likely to be diagnosed with tumours of a later stage 
and higher grade.
161
 Additionally, in comparison to white women, black women tend to 
have more children, have children at younger ages, and have an earlier age at menarche, 
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be overweight or obese, all of which can potentially increase the risk of breast 
cancer.
141,162-164
 
Differences in sociodemographic characteristics between black women living in the North 
and black women living in the South may explain why northern black women had a 
reduced risk of advanced breast cancer when compared to southern black women. When 
compared to black women living in the North, black women in the South resided in areas 
that had significantly lower education levels, lower family income, more families living 
below the poverty line, and higher proportions of unemployment. Furthermore, black 
women living in the South were less likely to live in metropolitan areas or be married and 
were more likely to be diagnosed at a younger age (<30 years and 30-49 years) than black 
women living in the North. A study conducted in the US found that being African 
American (OR=3.0; 95% CI: 1.9, 4.7), having a low income (OR=3.7; 95% CI: 2.1, 6.5), 
never being married (OR=2.9; 95% CI: 1.4, 5.9), delaying seeing a physician because of a 
lack of money (OR=1.6; 95% CI: 1.1, 2.5), or lacking transportation (OR=2.0; 95% CI: 
1.2, 3.6) were significant predictors for advanced breast cancer stage.
165
 Although these 
variables were controlled for in the analyses, residual confounding may have occurred, as 
the sociodemographic variables were a county-level measure, rather than individual-level.  
Although the overall findings from this study did not support the hypothesis of the PhD 
study, that women with a higher lifetime sun exposure would be less likely to be 
diagnosed with advanced breast cancers compared to women with a lower lifetime sun 
exposure, there was a need to further examine the relationship between lifetime sun 
exposure and breast cancer stage in Australia, as key differences exist between the two 
populations and several limitations of the SEER study need to be considered. The U.S. 
breast cancer population may differ from  Australia’s, for example differences in 
sociodemographic characteristics, tumour characteristics and variables known to be 
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associated with breast cancer risk could contribute to the  findings. Australia has a higher 
UV index year round than the U.S., which could result in different findings, as UV index 
will affect individual sun exposure, sun-seeking behaviours, and utilisation of sun 
protection (sunscreen and protective clothing). In the SEER study, latitude was used as a 
proxy measure for sun exposure, and I was unable to measure lifetime sun exposure, as 
only the latitudes of the participants at the time of diagnosis were available. Several 
factors that may affect levels of sun exposure were not accounted for, such as recreational 
and occupational exposure, and sun-seeking behaviours. The outcomes of this work 
suggest that a further examination of a potential relationship between breast cancer stage 
and sun exposure should be explored. Therefore, I utilised a large Australian breast 
cancer cohort study where I could measure sun exposure and breast cancer stage. This 
study is described in the following sections.  
7.3 LIFETIME SUN EXPOSURE AND BREAST CANCER STAGE: A 
BREAST CANCER OUTCOMES STUDY NESTED 
OBSERVATIONAL STUDY 
This was a retrospective cohort study, which involved measuring individual lifetime sun 
exposure among women recently diagnosed with breast cancer, meeting the second 
objective of this study. Study participants consisted of a subset of women participating in 
the Breast Cancer Outcomes Study (BCOS), conducted by Cancer Council Queensland. 
Sociodemographic and breast cancer-related data were obtained from telephone 
interviews and the Queensland Cancer Registry, and UV-related data were collected via a 
sun exposure questionnaire. Sun exposure was calculated for two time points, that is 
lifetime sun exposure and sun exposure during the years of breast development, and were 
categorised into tertiles (high, medium, and low). An epidemiological model building 
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method was used to examine the association between sun exposure and breast cancer 
stage, while controlling for confounders, meeting the third objective of this study. 
This study found no significant association between lifetime sun exposure and breast 
cancer stage at diagnosis. Some variables included in the model (solarium use, 
mammography, physical activity, and rurality) had a significant association with lifetime 
sun exposure. Women with low lifetime sun exposure were more likely to report solarium 
use, never having a mammogram, no physical activity, and living in major cities (as 
defined by ARIA) compared to women with medium and high lifetime sun exposure 
levels, thus controlling for these variables could account for the difference in trends.  
To answer the research question, “Does lifetime sun exposure or sun exposure during the 
years of breast development matter more than lifetime sun exposure in breast cancer stage 
at diagnosis?”, additional analyses were performed to determine if sun exposure during 
breast development years (7-18 years old) was associated with breast cancer stage 
(objective 4). Sun exposure levels during breast development years were also not 
associated with breast cancer stage at diagnosis in both the crude and adjusted analyses 
(Low UV: OR=0.96, P=0.89; Medium UV: OR=1.16, P=0.57). Because no significant 
associations were observed for either time period of sun exposure, it was concluded that 
no relationship exists between breast cancer stage and sun exposure for both lifetime and 
years of breast development. Further, no significant associations between lifetime sun 
exposure and breast cancer stage were observed when including ER status (Low UV: 
OR=0.83, P=0.52; Medium UV: OR=0.77, P=0.36), PR status (Low UV: OR=0.85, 
P=0.58; Medium UV: OR=0.79, P=0.40), and HER2/neu status (Low UV: OR=0.82, 
P=0.49; Medium UV: OR=0.81, P=0.46) in the model or when using tumour grade (Low 
UV: OR=0.57, P=0.11; Medium UV: OR=0.64, P=0.20).  
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The model was additionally reanalysed using a lifetime sun exposure variable calculated 
from individual latitude coordinates rather than UV bands to determine if results differed. 
No significant association was observed between lifetime sun exposure (calculated using 
latitude) and breast cancer stage at diagnosis. These results therefore reject our hypothesis 
that women with low lifetime sun exposure will have a higher risk of advanced breast 
cancer compared to women with medium and high lifetime sun exposure.  
7.4 RESULTS IN CONTEXT OF PREVIOUS RESEARCH  
7.4.1 Results in context of the SEER study  
The first objective of the study, define the role that location of residence has on breast 
cancer stage at diagnosis, was investigated in both the SEER study and the PhD study.  In 
the SEER study, location of residence was solely defined by latitude, whereas the PhD 
study used latitude in conjunction with other variables to define the sun exposure 
variable. The findings from the SEER study are consistent with those from the PhD study 
in that no significant association was observed between location of residence/lifetime sun 
exposure and breast cancer stage at diagnosis. In the SEER study, no significant 
association between latitude and risk of advanced breast cancer was observed for all races 
(OR=1.00; 95% CI: 0.99, 1.02; P=0.74) and white women (OR=1.01; 95% CI: 0.99, 1.03; 
P=0.18) (adjusting for age at diagnosis, ER status, PR status, marital status, rurality, race, 
mammography, education, family income, poverty level, unemployment, being foreign 
born, and smoking). Although black women living in the North (<37°N) were found to be 
7% (OR=0.93; 95% CI: 0.88, 0.98; P=0.01) less likely to be diagnosed with advanced 
breast cancer compared to black women living in the South (>37°N), these results aren’t 
able to be compared to those of the PhD study, as almost all of the PhD study population 
(97.9%) were Caucasian/White.  
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While findings of the PhD study were similar to the outcomes of the SEER study, key 
differences must be considered when comparing the two. The SEER study used women 
living in the U.S., while the PhD study was conducted with women living in Queensland, 
Australia. Population characteristics may differ between the U.S. and Australia, such as 
cultural and lifestyle differences, which may have an effect on the results. In the SEER 
study, latitude of residence at the time of diagnosis was used as a measure of UV, 
whereas in the PhD study, lifetime UV was calculated using latitude, duration, 
occupational UV exposure and recreational UV exposure for each residence. The 
confounders adjusted for in the model differed between the two studies. Additionally, 
some confounders that were adjusted for in both studies were measured and/or 
categorised differently (e.g., rurality and mammography). Lastly, the SEER study had a 
much larger population size (n=490,463) than the PhD study (n=429), which could have 
affected the results, as an insufficient sample size limits the ability to detect a true effect 
while a sample size that is too large may produce statistically significant results when, in 
reality, the association is not significant.  
7.4.2 Results in the context of other published studies  
While to our knowledge this is the first study of its kind to investigate the relationship 
between lifetime sun exposure and breast cancer stage, as a measure of prognosis, similar 
research has been conducted using different measures of sun exposure and/or prognosis. 
The results of our study were inconsistent with those from a U.S. study that observed a 
trend in the association between advanced breast cancer and sun exposure, where the risk 
of advanced breast cancer increased with increasing sun exposure index in light 
pigmented women. In the adjusted analysis (adjusted for age, race/ethnicity, education, 
family history of breast cancer, personal history of BBD, number of full-term 
pregnancies, breastfeeding, height, alcohol consumption, composite variable of body 
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mass index, menopausal status, history of hormone therapy use and month of skin 
pigmentation measurements), the study found that compared to women with a low sun 
exposure index, women with a high sun exposure index had a 47% reduction in risk of 
advanced breast cancer (OR=0.53; 95% CI: 0.31, 0.91, P=0.02).
18
 However, lifetime sun 
exposure was measured differently from in our study, as the sun exposure index was 
defined using skin pigmentation measurements. A study using history of skin cancer as a 
measure of sun exposure observed a decreased risk  of advanced stage (stages III and IV)  
breast cancer in women with a history of basal cell carcinoma (BCC) (SIR=0.53; 95% CI: 
0.30, 0.88).
166
 These findings are again inconsistent with our study.
166
 However, the same 
study found no significant association between risk of advanced breast cancer and 
squamous cell carcinoma (SCC) (SIR=0.97; 95% CI: 0.31, 2.27) consistent with our 
results, where history of skin cancer was not significantly associated with risk of 
advanced breast cancer. Pressler et al found that women with a history of keratinocyte 
cancer (SCC and BCC), had an increased risk of advanced breast cancer, specifically 
breast cancers with positive lymph nodes (HR=1.31; 95% CI: 1.04, 1.65; P=0.02) and 
regional stage (HR=1.32; 95% CI: 1.06, 1.66; P=0.02), after adjusting for age, ethnicity 
and time-dependent mammography during the study.
167
 However, history of skin cancer 
is not a direct measure of lifetime sun exposure and does not take into account other 
factors contributing to cancer, such as genetic predisposition. A Norwegian study found 
no association between residential sun exposure and breast cancer prognosis.
168
  In this 
study, sun exposure categories were a combination of latitude and erythemogenic UV 
radiation, and were only representative of current residence. Additionally, prognosis was 
measured as risk of death from breast cancer.  
A plausible mechanism by which sun exposure may affect breast cancer stage at 
diagnosis is through UV-induced vitamin D production. UV exposure contributes to 
 166 Chapter 7: Discussion 
higher vitamin D levels in the population and research suggests that high levels of vitamin 
D reduce the risk and mortality of breast cancer by inhibiting cellular proliferation and 
inducing differentiation and apoptosis of DNA-damaged breast cancer cells.
34,119,130
 
Palmieri et al found women with early-stage breast cancer had significantly higher 
vitamin D levels than those with advanced breast cancer.
139
 Contradictory to these results, 
another study found that vitamin D deficiency was not associated with an increased risk 
of advanced breast cancer (Stage II and III).
169
 As serum vitamin D (25(OH)D) levels are 
only representative of the past 15 days of sun exposure,
92
 it may not be indicative of 
lifetime levels, making it difficult to compare to lifetime sun exposure.  
7.5 POSSIBLE EXPLANATIONS FOR FINDINGS  
There are several possibilities that may explain why no significant association between 
lifetime sun exposure and breast cancer stage at diagnosis was observed in the models. 
The exposure variable, stage at diagnosis, was used as a prognostic indicator. 
Mammography is the most effective method for early detection of breast cancer (which 
could result in a less advanced stage at diagnosis), thus mammography was controlled for 
in the analyses. Therefore, an advanced breast cancer stage in the model may indicate a 
more aggressive breast cancer or simply a breast cancer detected late.  Interval breast 
cancers are those that develop within the time interval between mammograms, and 
research shows that 15-30% of interval breast cancers appeared in a previous 
mammogram but were interpreted as negative.
170
 Therefore, some women in the study 
(who reported participating in regular breast screens) may have been diagnosed with 
advanced breast cancer due to a prior false-negative mammogram.  
The observation that no significant relationship existed between lifetime sun exposure 
and advanced breast cancer in this study, may be due to how UV was categorised. After 
UV was calculated for individual participants, the variable was categorised into tertiles. 
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However, in comparison to other countries/regions, Australia has a higher UV index year 
round. Therefore, even in the lowest tertile, the actual amount of sun exposure women 
received may be quite higher than that for women living in areas with lower ambient UV. 
Additionally, there are mechanisms that may explain why high levels of sun exposure 
may not correspond with a lower risk of advanced breast cancer. As previously stated, an 
increase in sun exposure causes an increase in 25-hydroxyvitamin D3 (25(OH)D), which 
can then be hydroxylated in breast tissue to produce the biologically active form of 
vitamin D, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3).
33,34
 Conversion to 1,25(OH)2D3 is 
not tightly regulated in breast tissue, suggesting that the UV-mediated increase in 25D 
may contribute to an increase of 1,25(OH)2D3.
34
 The main vitamin D catabolizing enzyme 
is 24-hydroxylase (CYP24), which is often upregulated in breast tumours compared to 
normal breast tissue.
171
 This overexpression of CYP24 reduces levels of 1,25(OH)2D3, 
which may counteract the anti-carcinogenic activity of vitamin D.
171
 Additionally, levels 
of CYP24 expression are higher in invasive breast tumours compared to in situ breast 
tumours, indicating that the anti-tumour properties of vitamin D may not be as effective 
in advanced breast cancers.
97
 Therefore, high vitamin D levels, possibly mediated by high 
sun exposure, may not correlate with reduced progression in breast tumours 
overexpressing CYP24, especially those in advanced stages.  
Anti-proliferative properties of vitamin D may be reduced due to high levels of vitamin 
D. Concentrations of 1,25(OH)2D3 are regulated by a negative feedback system.
171
 Thus, 
high levels of vitamin D increase CYP24 activity, which in turn decreases 1,25(OH)2D3, 
limiting vitamin D availability.
171
 This theory is consistent with studies that show that 
both low and high levels of vitamin D increase the risk of cancer by different intracellular 
mechanisms.
172
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UV-induced immunosuppression may also explain the lack of association between high 
sun exposure and decreased risk of advanced breast cancer. Studies have found that UV 
exposure can decrease immune response to skin cancers and infectious agents.
173
 One 
mechanism through which UV affects the immune system is through the generation of T 
regulatory cells (Treg).
174
 While Treg cells help to protect against autoimmune disease, in 
breast cancer, high numbers of Treg cells, which increase in conjunction with disease 
stage, are associated with poorer overall survival and increased relapse.
175
 This suggests 
that the presence of Treg cells may promote tumour progression.
175
 Additionally, exposure 
to UV radiation triggers the production of several immune regulators, including Cox-2.
176
 
As mentioned in Chapter 2, over expression of Cox-2 is associated with a larger tumour 
size, higher grade, increased proliferation of cancer cells, and an overall worse 
prognosis.
15,34
  While no studies have found a direct association between UV-induced 
immune suppression and breast cancer, there is evidence to suggest immunosuppression 
(by Treg cells) may be associated with more aggressive breast cancers and a higher 
grade,
177
 possibly resulting in a more advanced stage at diagnosis.  
Lastly, a possible explanation for our findings could simply be due to there being no 
association between lifetime sun exposure and breast cancer stage at diagnosis.  
7.6 OTHER KEY FINDINGS  
7.6.1 Findings from the model 
While the exposure variable of interest (sun exposure) was not associated with breast 
cancer stage, mammography, solarium use and physical activity were significantly 
associated with risk of advanced breast cancer. Women who had reported never having a 
mammogram prior to diagnosis were 2.5-times more likely to be diagnosed with 
advanced breast cancer compared to women who had mammograms at least every two 
years (OR=2.55; 95% CI: 1.33, 4.92; P=0.01). These results are consistent with previous 
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research showing mammography is the most effective method for early detection of 
breast cancer.
67
  
Women who had ever used a solarium were two-times as likely to be diagnosed with 
advanced breast cancer compared to women who never used a solarium (OR=1.98; 95% 
CI: 1.00, 3.94; P=0.05).   Yang et al. found that women who used a solarium at least once 
between the ages of 10 and 39 years had a reduced risk of breast cancer (HR=0.63; 95% 
CI: 0.41, 0.96).
178
  Similar results for solarium use and breast cancer risk were found in a 
Canadian study, suggesting UV exposure during breast development years may be more 
important for breast cancer risk than exposures later in life.
7,178
 However, these studies 
investigated breast cancer risk rather than breast cancer stage, which could account for the 
differing results. In our study, women categorised as having used a solarium were those 
who reported ever using a solarium, regardless of length, frequency or age of use. 
Therefore, some women in this category may have used a solarium only once, which may 
not correlate with a high UV exposure. However, those who use a solarium may be more 
prone to “high risk” behaviours, which could potentially affect their breast cancer stage at 
diagnosis. However, when I examined solarium use and other variables associated with 
breast cancer stage (e.g, mammography, CBEs, breast self-exams, physical activity, BMI, 
and smoking), no association was observed. A potential reason for why solarium use 
appeared to be associated with an increased risk of advanced breast cancer may be due to 
UV-induced immunosuppression. As mentioned earlier, UV affects the immune system 
through the generation of Treg cells, which may promote tumour progression; and by 
producing immune regulators, such as Cox-2, which are associated with a larger tumour 
size, higher grade, increased proliferation of cancer cells, and an overall worse 
prognosis.
15,34,174
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Women who reported participating in moderate physical activity had a reduced risk of 
advanced breast cancer compared to those with sedentary lifestyles (OR=0.45; 95% CI: 
0.21, 0.96; P=0.04). Physical activity has been shown to decrease the risk of breast cancer 
in several studies. A systematic review found that among postmenopausal women, leisure 
activity (non-occupational physical activity) accounted for at least a 20% reduction 
(range, 20-80%) in breast cancer risk.
179
 This association continued among pre- and 
postmenopausal women combined, with leisure activity reducing breast cancer risk by 
20%.
179
 However, the association was much weaker when premenopausal women were 
considered alone.
179
 A dose-response relationship between physical activity and breast 
cancer risk was observed, with a 6% decrease in breast cancer risk for every one 
additional hour of physical activity per week.
179
 There are several proposed mechanisms 
to explain the influence of physical activity on breast cancer. Hormones play a role in the 
development of breast cancer. Physical activity may help to stop tumour development by 
decreasing hormone production, specifically in post-menopausal women.
180,181
 Physical 
activity may lower insulin levels and insulin-like growth factor I (IGF-I), which in turn 
improves the immune response.
180
 Furthermore, physical activity helps maintain a normal 
body weight and to normalise calorie intake, and studies have shown that calorie 
restrictions prevent breast tumours.
180-182
 
However, the studies mentioned above examined breast cancer risk, rather than stage. 
Additionally, most studies investigating physical activity and breast cancer risk 
categorised physical activity in terms of frequency (e.g., hours per week), while our study 
categorised physical activity by intensity. In our study, fewer women were in the 
‘moderate’ category (20.8%) compared to the ‘walking’ (36.1%) and ‘vigorous’ (29.6%) 
categories, thus the significant association between moderate physical activity and 
advanced breast cancer could be due to issues with sample size. Other possible 
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explanations may include misclassification of physical activity intensity. Women were 
asked in a typical week, how often they participated in light activity (walking), moderate 
activity, and vigorous activity and then categorised into their respective intensity levels 
regardless of time per week spent doing the physical activity. If women reported physical 
activity participation of more than one intensity level (i.e walking and moderate activity), 
the highest reported intensity level was used. Therefore, some women may have been 
categorised into a higher intensity level, when in reality they had spent more time 
participating in a lower intensity physical activity.   
Age at diagnosis was not significantly associated with risk of advanced breast cancer in 
the model. While the bivariate analysis found women less than 50 years of age had over 
double the risk of advanced breast cancer at diagnosis (OR=2.12; 95% CI: 1.27, 3.53; 
P=0.004) compared to women 50-69 years of age, this association was not significant in 
the model. This is surprising, as increasing age is an important risk factor for breast 
cancer and can affect breast cancer stage and prognosis.
183-185
 Younger women are more 
likely to have more aggressive breast cancers (larger tumour size, higher grade, increased 
lymph node involvement, less ER expression, and higher rates of HER2 expression),
186
 
thus potentially resulting in a more advanced stage at diagnosis. Additionally, in Australia 
the national breast cancer screening program target women 50 to 69 years (although this 
has recently been extended to women up to 74 years).
37
 Therefore, early detection of 
breast cancer through mammography is less likely in women younger than 50 years, 
possibly contributing to the higher likelihood of this group being diagnosed with 
advanced stage breast cancer.  
Rurality was also found to have no significant relationship with breast cancer stage in the 
adjusted model. This is consistent with a study showing that despite poorer access to 
breast screening facilities, Australian women (aged 50-64) living in rural areas are just as 
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likely to report ever having a mammogram (97% vs 96%) or having a mammogram 
within the last 2 years (87% vs 83%) as women living in urban areas.
187
 However, other 
studies have found there is a difference in screening between women residing in rural 
areas and women residing in urban areas. A systematic review investigating the effect of 
rurality on breast cancer screening found that across the US, the rural population was less 
likely to have  mammograms compared to urban populations.
188
 Additionally, a report 
from the Australian Institute of Health and Welfare (AIHW) stated that in 2011 and 2012, 
the lowest breast screening rates were in very remote areas (46%).
189
 A study preformed 
in Queensland found that women living in outer regional (OR=1.18; 95% CI: 1.07, 1.30) 
and remote/very remote (OR=1.19; 95% CI: 1.00, 1.41) (defined by ARIA) areas had 
significantly higher rates of advanced breast cancer when compared to women living in 
major cities.
190
 These differences may exist due to disparities in the quality, availability 
and accessibility of health care services that often exist in rural communities,
191
 which 
may affect breast cancer screening.  Additionally, residents of rural communities tend to 
have lower education levels and higher poverty levels than urban residents,
191
 potentially 
affecting access to breast screening and consequently contributing to an advanced stage at 
diagnosis.  
7.7 STRENGTHS  
This study had several strengths. Data from the CATI were collected by trained CCQ 
interviewers. Interviews over the telephone allowed interviewers to probe where 
necessary, and data were keyed directly into a database. I was  able to obtain participant 
data from several sources (CATI, sun exposure questionnaire and QCR), which provided 
information for a large number of variables. This allowed me to measure the effect of 
many potential confounders when examining any potential relationship between lifetime 
sun exposure and breast cancer stage. Additionally, the QCR provided medical records 
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containing accurate pathology reports on stage and other tumour characteristics used in 
the model (for example, ER, PR, HER2 status). This allowed me to adjust for tumour 
characteristics that are associated with stage, whereas in some previous studies 
investigating stage, these characteristics haven’t been included.18  
7.7.1 Participant characteristics in comparison to BCOS cohort and Queensland 
data 
A strength of the study is that most of the characteristics of the study population, both 
sociodemographic and breast cancer-related, are similar to the entire BCOS cohort, as 
well as the Queensland female population of breast cancer cases. Therefore, while the 
study sample was relatively small, the results may be generalised to the Queensland 
population.  
Sociodemographic characteristics  
Study participants were compared to the general population of females living in 
Queensland using data from the Australian Bureau of Statistics (ABS). The mean age of 
the study participants (59.8 years) and the participants of the BCOS (57.6 years) was 
similar. However, study participants were older than the Queensland population,
192
 which 
is most likely due to the fact that the majority of breast cancers are diagnosed in women 
over the age of 50 years. Marital status was similar for study participants, BCOS 
participants and the Queensland population, with the majority of women being married or 
living as married.
192
 Indigenous women in Queensland account for 2.7%, which is similar 
to the study population (1.4%) and the BCOS population (1.6%).
192
 Over a quarter 
(27.14%) of women in Queensland held full-time paid employment and 23.8% held part-
time paid employment,
192
 which is comparable to the BCOS population with 31.0% 
reporting full-time employment and 27.8% reporting part-time employment. This is 
slightly lower than the study population, but the Queensland data included all females 
 174 Chapter 7: Discussion 
aged 15 years or older, which could account for these differences. Annual family income 
for the Queensland female population corresponded well with the family income of study 
participants. The study population had a lower proportion of women born outside 
Australia (17.8%) compared to the Queensland population (22.0%), however, the 
majority of women in both populations were born in Australia.
192
 BMI of the study 
participants were similar to  those of Queensland women overall and to the BCOS cohort, 
where 41.8% of Queensland women and 38.5% of BCOS women were underweight or of 
normal weight (<24.9 kg/m
2
); 29.4% of Queensland women and 31.9% of BCOS women 
were overweight (25.0-29.9 kg/m
2
); and 28.9% of Queensland women and 29.7% of 
BCOS women were obese (>30.0 kg/m
2
).
193
 Queensland women had similar proportions 
of walking (35.2%) and moderate physical activity (19.0%) to the study participants 
(36.1% and 20.8%, respectively).
193
 However, Queensland women had higher proportions 
of no physical activity (39.4% vs. 13.5%) and lower proportions of vigorous physical 
activity (6.3% vs. 29.6%).
193
 Current smoking was more prevalent in the Queensland 
population (18.4%) compared to the study population (6.8%).
193
 Overall, in terms of 
sociodemographic characteristics, the study participants are representative of the entire 
BCOS cohort and the general female population of Queensland.  
Breast cancer characteristics  
Almost two-thirds of women in our study were diagnosed with localised breast cancer 
(65.2%) and 34.8% were diagnosed with advanced breast cancer. While statistics for 
summary staging were unavailable for Queensland, New South Wales had similar 
proportions of localised breast cancer (60.0%).
194
 When using TNM staging, 47.5% of 
study participants were diagnosed with stage I breast cancer and 52.5% with stages II, III, 
and IV. This corresponds with stage at diagnosis statistics for women in Queensland, 
where 47% were diagnosed with stage I breast cancer and 45% with stages II, III, and 
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IV.
27
 Stage proportions were similar for women participating in the BCOS, with 49.5% 
diagnosed with stage I, 39.0% diagnosed with stage II, and 115% diagnosed with stages 
III and IV breast cancer. The majority (74%) of breast cancers in Queensland are 
diagnosed in women aged 50 years or older,
27
 and similarly, 82.0% of study participants 
were 50 years or older. Women in Queensland less than 40 years old and 40-49 years old 
were more likely to be diagnosed with advanced breast cancer (61% and 53%, 
respectively).
27
 This resembles the study population, with 50.4% of women less than 50 
years of age diagnosed with advanced breast cancer. Over half (56%) of Queensland 
women aged 50-69 years participated in the mammography program (BreastScreen 
Queensland) in 2006-2007,
194
 and 60.8% of the BCOS cohort reported having a 
mammogram at least every 2 years. This is lower than the proportion of study participants 
of the same age who reported having regular mammograms (74.0%), which may be due 
to participants having mammograms conducted by private facilities.  
7.8 LIMITATIONS 
The results of this study should be interpreted with limitations. Due to the timing of 
recruitment, the sample size was lower than expected in the study, thus reducing the 
power in the study and thus the ability to detect any true effect between the variables of 
interest. A small sample size increases the amount of uncertainty in the results and can 
cause overestimation (or underestimation) of the effect. Much of the data were self-
reported which can potentially result in bias. Participants were required to recall dates, 
residencies, occupations, activities, behaviours, family history and breast screening 
history. Self-reported data were collected via questionnaires and interviews, possibly 
introducing bias, as participants may have answered questions in a direction that is 
“socially acceptable.”195 However, it is likely that any biases would be similar between 
study groups. For some CATI questions, participants were asked about the accuracy of 
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their response, which ranged from ‘exact’ to ‘best guess/don’t know.’ The responses 
provided were used regardless of their certainty level.  Almost all (98%) of the study 
participants were white and all women were living in Queensland at the time of diagnosis, 
which may not be representative of the Australian population as a whole. Additionally, 
results may not be comparable globally due to the lack of diversity within the study 
population.  
Limitations exist in the measure of lifetime sun exposure. To limit recall bias, I excluded 
questions relating to sun protection (e.g. clothing, sun screen use) and sun-seeking 
behaviours. However, this could potentially alter lifetime sun exposure measurements in 
some participants, such as those who lived in high UV latitude areas but always used sun 
protection. While misclassification may have occurred, it is unknown whether this would 
have a similar effect for women with localised or advanced breast cancer. Furthermore, 
UV bands used in the calculation were based on average UV levels by latitude. However, 
no actual measurements of UV were used, and latitude may be misrepresentative of UV 
levels in some areas. Additionally, the sun exposure measure did not take into account 
factors that affect UV, such as altitude of residence. Lifetime sun exposure may not be 
analogous worldwide, as the majority of women in the study had never lived outside 
Australia, and the average annual UV index for most of Australia is ‘High’, ‘Very High’ 
or ‘Extreme.’196 While the sun exposure questionnaire was not formally validated similar 
questionnaires examining lifetime sun exposure have been used with reasonable accuracy.     
Although all women in the study had breast cancers reported to the QCR, various 
pathology labs were used for examining and reporting on tumours. Pathology labs may 
use different tests for the same outcome measure, such as Immunohistochemistry (IHC) 
and Ligand-binding Assays (LBA) for ER testing, which could result in inconsistent 
measures among the participants.
197
 Additionally, outcomes of tests, such as lymph node 
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involvement, may differ based on the section of the tumour examined, and there is no 
standardised protocol for sectioning tumours.
198
 This potentially could have affected the 
outcome variable, stage at diagnosis.  
7.9 INTERPRETATION OF FINDINGS   
The results from this study do not support the hypothesis that a higher lifetime sun 
exposure is associated with a decreased risk of advanced breast cancer. While this study 
is the first of its kind, results of previous research investigating the relationship between 
sun exposure and breast cancer risk have been inconsistent. Of those studies that have 
found a significant association, limitations need to be taken into consideration when 
interpreting study results. Because there is no gold standard for measuring personal sun 
exposure, various methods are used across studies such as latitude, UV radiation 
measures, region of residence, outdoor activities, occupational exposure, sun-seeking 
holidays, solarium use, skin colour, history of sunburns, use of sun protection, and history 
of skin cancers (specifically keratinocyte cancers). Inconsistencies in sun exposure 
measurements make it difficult to compare results among studies and will potentially bias 
results. Several studies investigating sun exposure and breast cancer risk did not measure 
lifetime sun exposure, but rather sun exposure within certain age groups, at time of 
diagnosis, or time of study, and this may not be representative of sun exposure throughout 
one’s lifetime. Additionally, there are many be variables directly and indirectly related to 
sun exposure (for example, vitamin D production, calcium production, and differences in 
lifestyles and health statuses of those with high sun exposure versus low exposure), which 
could contribute to its effect on breast cancer and explain why findings are inconsistent.  
Some studies have attributed the association between sun exposure and risk of breast 
cancer to vitamin D production.
4,199
 However, some studies have found no significant 
association between vitamin D and breast cancer stage.
169
 Within these studies, vitamin D 
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was measured at or after diagnosis. Because serum 25(OH)D levels only correspond to 
the previous two weeks and constantly change over time, vitamin D measures do not 
represent lifetime levels and cannot be substituted for lifetime sun exposure. Furthermore, 
studies that report women with advanced breast cancer have lower serum 25(OH)D levels 
than women with localised breast cancer, cannot infer causality. Additionally, there is no 
evidence indicating at which stage of life vitamin D matters most in terms of protecting 
against breast cancer. While in vitro studies show that vitamin D can inhibit proliferation 
and induce apoptosis and differentiation of breast cancer cells, these findings are only 
clinically significant if they can be reproduced in vivo, and several studies have not done 
so.
24
 
7.10 FUTURE DIRECTIONS   
This study was the first to investigate the association between lifetime sun exposure and 
breast cancer stage.  While this study did not find any relationships between lifetime sun 
exposure and breast cancer stage at diagnosis, inconsistencies in results of previous 
research relating to the association between sun exposure and/or vitamin D and breast 
cancer risk rationalise the need for further investigation.  Because UV levels are high year 
round in Australia, it would be beneficial to replicate this study in an area where UV 
varies among seasons in order to compare results. Standardising lifetime sun exposure 
measures would be beneficial to any future studies. These measures would include 
various sun-related factors (e.g. UV radiation, latitude, skin colour, aging of skin, sun-
seeking behaviours, use of sun protection, occupational exposure, recreational exposure 
and solarium use, as well as others), which represent the most important in determining 
an individual’s exposure level. Additionally, while no formal validation of the 
questionnaire was conducted, such a study could be done by comparing skin cast 
measurements in a subset of women. This could be done by comparing the questionnaire 
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results to skin casts measurements of a subset of women. Future studies would also 
benefit from measuring both individual sun exposure and vitamin D levels in order to 
examine whether one or both factors are contributing to the effect on breast cancer stage. 
The challenge is in deciding at what time vitamin D levels should be measured. 
Additionally more research should be conducted to better understand the possible 
mechanisms by which sun exposure may affect breast cancer stage. In regards to the 
relationship between vitamin D and breast cancer stage, more research is needed to 
determine whether breast cancer is affected by vitamin D from supplementation and/or 
sun-induced vitamin D. Furthermore, reasons behind the inconsistencies in results 
between in vitro and in vivo studies examining vitamin D and breast cancer, should be 
investigated further.  
While stage at diagnosis is an indicator of prognosis, the effect of lifetime sun exposure 
on other breast cancer prognostic indicators may be worth exploring. As discussed in 
Chapter 2, breast cancers can be categorised into molecular subtypes using tumour 
receptor status, HER2/neu status, proliferation markers (ki67), TP53 mutations, and 
histologic grade. The molecular subtype of breast cancer can be indicative of prognosis. 
Future research could examine the relationship between lifetime sun exposure and 
molecular subtype of breast cancer, controlling for known confounders.   
7.11 CONCLUSION  
This study aimed to determine the relationship between lifetime sun exposure and breast 
cancer stage. No significant relationship between lifetime sun exposure and breast cancer 
stage was observed; however the study had several limitations, potentially biasing results. 
While the study found no significant relationship between lifetime sun exposure and 
breast cancer stage, it did show some important findings. Mammography was 
significantly associated with breast cancer stage. Women who reported never having a 
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mammogram were 2.5-tmes more likely to be diagnosed with advanced breast cancer 
than women who reported having a mammogram at least every 2 years. This study thus 
added to the body of evidence supporting the public health benefit of screening for breast 
cancer among women in the relevant age range.  Additionally, there was an observed 
relationship between physical activity and breast cancer stage. Although only significant 
for moderate physical activity, there was an inverse relationship between participating in 
physical activity and increased risk of advanced breast cancer. Again, while these results 
should be interpreted with caution due to the sample size and possible misclassification of 
physical activity, they do warrant further investigation.  
The study succeeded in addressing all objectives and answering all research questions. 
The objectives of this study were: 
1. Define the role that location of residence has on breast cancer stage at 
diagnosis;  
2. Measure lifetime sun exposure in women newly diagnosed with breast cancer;  
3. Develop a model to define the role that lifetime sun exposure has on breast 
cancer stage at diagnosis, controlling for known breast cancer risk factors; 
4. Determine at what stage of life sun exposure matters most in breast cancer 
stage at diagnosis  
Both the SEER study and the PhD study defined the role that location of residence has on 
breast cancer stage at diagnosis (Objective 1). The SEER study used latitude as a 
measurement of location of residence, while the PhD study used latitude in addition to 
other variables. Both studies found no significant relationship between location of 
residence and breast cancer stage at diagnosis. Lifetime sun exposure levels were 
calculated for all women in the study by combining residential history (latitude), 
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occupational exposure, and recreational exposure (Objective 2). An epidemiological 
model was developed to investigate the relationship between lifetime sun exposure and 
breast cancer stage at diagnosis, and controlled for mammography, age at diagnosis, 
solarium use, clinical breast exams, physical activity, and rurality (objective 3). Objective 
four was addressed by calculating sun exposure during breast development years (ages 7-
18 years) and using it in the model. Results from the lifetime sun exposure model and the 
sun exposure during breast development were then compared to determine at what stage 
of life sun exposure matters most in determining breast cancer stage at diagnosis. 
The research questions were as follows: 
1. Do women diagnosed with localised breast cancers have a higher lifetime sun 
exposure than women diagnosed with advanced breast cancers? 
2. Are women with high levels of lifetime sun exposure at a lower risk of being 
diagnosed with advanced stage breast cancer compared to women with medium 
and low levels of sun exposure?  
3. Does lifetime sun exposure or sun exposure during the years of breast 
development matter more in influencing breast cancer stage at diagnosis?  
To answer Research Question 1, lifetime sun exposure, as a continuous variable, was 
plotted by stage of diagnosis. There were no significant differences between mean 
lifetime UV for localised breast cancer (537.6 EU) and for advanced breast cancer (506.3 
EU). Research Question 2 was answered by building a model and controlling for known 
risk factors. After adjusting for mammography, physical activity, solarium use, age at 
diagnosis, clinical breast exams, and rurality, no significant association between lifetime 
sun exposure and risk of advanced breast cancer was observed. Research Questions 3 was 
answered by using lifetime sun exposure measures during breast development years (ages 
 182 Chapter 7: Discussion 
7-18 years) in the model. Again, sun exposure during breast development years was not 
significantly associated with advanced breast cancer. Thus, neither lifetime sun exposure 
nor sun exposure during breast development years matter more for influencing breast 
cancer stage at diagnosis, as neither were significant in the model.  
This was the first study of its kind, thus further research is needed to determine if lifetime 
sun exposure affects breast cancer stage at diagnosis.  
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Primary Tumour (T) 
Classification Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget) Paget disease of the nipple NOT associated with invasive carcinoma and/or 
carcinoma in situ (DCIS and/or LCIS) in the underlying breast parenchyma. 
Carcinomas in the breast parenchyma associated with Paget disease are 
categorized based on the size and characteristics of the parenchymal disease, 
although the presence of Paget disease should still be noted 
T1 Tumour ≤20 mm in greatest dimension 
T1mi Tumour ≤1 mm in greatest dimension 
T1a Tumour >1 mm but ≤5 mm in greatest dimension 
T1b Tumour >5 mm but ≤10 mm in greatest dimension 
T1c Tumour >10 mm but ≤20 mm in greatest dimension 
T2 Tumour >20 mm but ≤50 mm in greatest dimension 
T3 Tumour >50 mm in greatest dimension 
T4 Tumour of any size with direct extension to the chest wall and/or to the skin 
(ulceration or skin nodules)
a
 
T4a Extension to the chest wall, not including only pectoralis muscle 
adherence/invasion 
T4b Ulceration and/or ipsilateral satellite nodules and/or edema (including peau 
d'orange) of the skin, which do not meet the criteria for inflammatory 
carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
a 
Invasion of the dermis alone does not qualify as T4 
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Regional Lymph Nodes (N) 
Classification Description  
NX Regional lymph nodes cannot be assessed (e.g. previously removed) 
N0 No regional lymph node metastases 
N1 Metastases to movable ipsilateral level I, II axillary lymph node(s). 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that are 
clinically fixed or matted 
OR 
Metastases in clinically detected
*
 ipsilateral internal mammary nodes in 
the absence of clinically evident axillary lymph node metastases 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one 
another (matted) or to other structures. 
N2b Metastases only in clinically detected* ipsilateral internal mammary 
nodes and in the absence of clinically evident level I, II axillary lymph 
node metastases. 
N3 Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) 
with or without level I, II axillary lymph node involvement. 
OR 
Metastases in clinically detected
*
 ipsilateral internal mammary lymph 
node(s) with clinically evident level I, II axillary lymph node metastases. 
OR 
Metastases in ipsilateral supraclavicular lymph node(s) with or without 
axillary or internal mammary lymph node involvement. 
N3a Metastases in ipsilateral infraclavicular lymph node(s). 
N3b Metastases in ipsilateral internal mammary lymph node(s) and axillary 
lymph node(s). 
N3c Metastases in ipsilateral supraclavicular lymph node(s). 
*
Clinically detected is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical 
examination and having characteristics highly suspicious for malignancy or a presumed pathologic 
macrometastasis based on fine needle aspiration biopsy with cytologic examination.  
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Distant Metastases (M) 
Classification Description 
M0 No clinical or radiographic evidence of distant metastases 
cM0(i+) No clinical or radiographic evidence of distant metastases, but deposits 
of molecularly or microscopically detected tumour cells in circulating 
blood, bone marrow, or other nonregional nodal tissue that are ≤0.2 mm 
in a patient without symptoms or signs of metastases 
M1 Distant detectable metastases as determined by classic clinical and 
radiographic means and/or histologically proven >0.2 mm 
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Anatomic Stage/Prognostic Groups 
Stage  T  N  M  
0 Tis N0 M0 
IA T1
a
 N0 M0 
IB T0 N1mi M0 
 T1
a
 N1mi M0 
IIA T0 N1
b
 M0 
 T1
a
 N1
b
 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1
a
 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
a
 T1 includes T1mi 
b 
T0 and T1 tumours with nodal micrometastases only are excluded from Stage IIA and are classified Stage 
IB. 
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Appendix B 
Computer Assisted Telephone Interview (Time 1) – shortened to only include 
questions used in the PhD study 
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Computer Assisted Telephone Interview 
 
 
 
 
A multilevel investigation of inequalities in clinical and 
psychosocial outcomes for women with Breast Cancer 
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PERSONAL HISTORY 
 
I am now going to ask you about your personal medical history such as your use of contraceptives and 
pregnancies if you have had any. These questions may seem a little personal but they are about things we 
would like to look at to see if they relate to a person’s risk of getting breast cancer, or if they might have a 
protective effect. 
 
His1 How old are you now?  
 Age in years     
His3 What is your current weight?  
 Weight in kg    or  stones     
   
His4 What was your weight before diagnosis?  
 Weight in kg    or on stones     
   
His5 What is your height?   
 Height in cms    or   feet and   inches  
   
His6 At what age did you first get your periods?  
 Age years  
   
His7 Have you ever been pregnant?  
 Yes 1 
 No (Go to His10) 2 
   
His8 How many children have you given birth to?  
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His9 How old were you when you had your:  
His9a1 1st child                 Age of the participant   yrs  
His10 Have you ever used a form of hormone contraceptive? This may include the Pill, 
contraceptive implant (Implanon), or injection (e.g. Depo-provera). 
 
 Yes 1 
 No (Go to His14) 2 
 Don’t know (Go to His14) 3 
   
His11 Can you remember how old you were when you first went on a hormone 
contraceptive? 
 
   yrs  
   
His12 Can you remember how old you were when you last came off a hormone 
contraceptive? 
 
   yrs  
   
His13 How many years in total have you used hormone contraceptives?  
   yrs  
   
His14 Do you use any form of contraceptive now?         
 Yes 1 
 No (Go to His16) 2 
   
His15 What type of contraceptive are you using now?    
 Hormone contraceptive (includes  Implanon or injection, NOT the Pill) 1 
 The Pill (includes Mini Pill) 2 
 I use condoms  4 
 I use emergency contraception (eg morning after pill) 5 
  
Appendices 207 
 I use the withdrawal method 7 
 I use a copper intrauterine device (IUD) 8 
 I use a progestogen intrauterine device (IUD) (eg Mirena) 9 
 Partner has had a vasectomy  11 
His15Txt Other (specify)     12 
   
His16 Have you had a Hysterectomy (surgery to remove your uterus)?  
 Yes           1 
 No  (Go to His18)     2 
 Don’t know (Go to His18)         3 
   
His17 How old were you when you had your hysterectomy?  
   yrs  
   
His19 Have you gone through menopause?  
 Yes 1 
 No (Go to His23) 2 
 Don’t know (Go to His23) 3 
   
His20 Have your periods now stopped?  
 Yes 1 
 No (Go to His23) 2 
 Irregular 3 
   
His21 How old were you when they stopped?  
  yrs  
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His23 Have you ever used Hormone Replacement Therapy, for reasons other than for 
breast cancer treatment? 
 
 Yes 1 
 No (Go to Com1) 2 
 Don’t know/Unsure (Go to Com1) 3 
   
His24 How old were you when you first starting using HRT?  
  yrs  
   
His26 How many years in total have you used HRT?  
  yrs  
His28 How old were you when you last used HRT?  
   yrs  
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DEMOGRAPHICS 
 
To begin with, I’d first like to ask you a few questions about your background 
 
 Where were you born?   
Dem1     city  
Dem1a     Country (if not in Australia) If blank( born is Australia) skip to Dem3  
   
Dem3 Are you of Aboriginal or Torres Strait Islander origin?  
 Yes, Aboriginal (Go to Dem5) 1 
 Yes, Torres Strait Islander origin (Go to Dem5) 2 
 No 3 
   
Dem4 How would you describe your ethnic origin?  
(Prompt if necessary to determine whether they consider themselves to be white or 
other). If more information is needed, add:  “Ethnicity is how you see yourself; it is a 
mixture of culture, religion, skin colour, language, the origins of yourself and your 
family. It is not the same as nationality.” 
 
 Caucasian or white (Australian, European, white American, Canadian, white South 
African) 
1 
 South-East Asian (Originated from Brunei, Cambodia, Indonesia, Laos, Malaysia, 
Myanmar/Burma, Philippines, Singapore, Thailand, Vietnam) 
2 
 North-East Asia (Originated from China, Hong Kong, Japan, Korea, Macau, Taiwan) 3 
 South Asia (Originated from Afghanistan, Bangladesh, India, Nepal, Pakistan, Sri Lanka) 4 
 Middle Eastern (Originated from Israel, Iran, Iraq, Lebanon, Turkey, Egypt or Arab) 5 
 Pacific Islander (New Zealand Maori or originated from Pacific Islands, Hawaii, New 
Guinea) 
6 
 Indigenous American (American Indian) 7 
 Black American (Black person originating from USA, Canada, Puerto Rico, Caribbean) 8 
 South American of Spanish or local “Indian” descent (Originating from Mexico, Central 9 
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or South America) 
 Black African (Originating from North Africa, Sub-Saharan Africa, Zimbabwe or Black 
South African) 
10 
Dem4Txt Other (specify)      11 
 Don’t know 12 
   
Dem5 Which of the following best describes your current marital status? And by married I 
mean legally married 
 
 Married (in a registered marriage) 1 
 Separated, but not legally divorced 2 
 Divorced 3 
 Widowed 4 
 Not married, but living with someone in a relationship 5 
 Never married, and not living with someone in a relationship 6 
 Do not want to tell 7 
   
Dem6 Do you have any private health insurance?  
 Yes, full health insurance  1 
 Yes, basic hospital cover only 2 
 Yes, extras cover only 3 
 DVA cover 4 
 No 5 
Dem6Txt Other (specify)    6 
   
Dem7 What is the highest year of school you have completed?   
 Did not go to school 1 
 Year 8 or below 2 
 Year 9 or equivalent 3 
 Year 10 or equivalent 4 
 Year 11 or equivalent 5 
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 Year 12 or equivalent 6 
   
Dem8 What is the level of the highest qualification you have completed?  
 School education level 1 
 Certificate level 2 
 Advanced Diploma or Diploma level 3 
 Bachelor Degree level 4 
 Graduate Diploma or Graduate Certificate level 5 
 Postgraduate Degree level 6 
Dem8Txt Other (specify)     7 
   
Dem9 Which one of the following best describes your current employment situation? One 
response only 
 
 Full time paid work in a job, business or profession 1 
 Part time paid work in a job, business or profession 2 
 Casual paid work in a job, business or profession 3 
 Work without pay in a family or other business 4 
 Home duties, not looking for work (Go to Dem13) 5 
 Unemployed, looking for work (Go to Dem13) 6 
 Retired (Go to Dem13) 7 
 Permanently unable to work (Go to Dem13) 8 
 Student (Go to Dem13) 9 
Dem9Txt Other (specify)   10 
   
Dem13 Which one of the following best describes your employment situation prior to your 
diagnosis? One response only 
 
 Full time paid work in a job, business or profession (Go to Dem15) 1 
 Part time paid work in a job, business or profession (Go to Dem15) 2 
 Casual paid work in a job, business or profession (Go to Dem15) 3 
 Work without pay in a family or other business (Go to Dem15) 4 
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 Home duties not looking for work (Go to Dem14) 5 
 Unemployed looking for work (Go to Dem14) 6 
 Retired (Go to Dem14) 7 
 Permanently unable to work (Go to Dem14) 8 
 Student (Go to Dem14) 9 
Dem13Txt Other (specify)   10 
   
Dem14 Have you worked in the past?  
 Yes 1 
 No  (Go to Dem19) 2 
   
Dem15 In that job, were you...?  
 Employed by someone else (Go to Dem16)  
 Self-employed in own business with employees  
 Self-employed in own business with no employees (Go to Dem16)  
   
Dem19 Prior to your diagnosis, what was your annual household income before tax? (weekly 
income is in brackets) 
 
 Negative income  1 
 Nil income 2 
 $1-$7,799 ($1-$149) 3 
 $7,800-$12,999 ($150-$249) 4 
 $13,000-$20,799 ($250-$399) 5 
 $20,800-$31,199 ($400-$599) 6 
 $31,200-$41,599 ($600-$799) 7 
 $41,600-$51,999 ($800-$999) 8 
 $52,000-$67,599 ($1,000-$1,299) 9 
 $67,600-$83,199 ($1,300-$1,599) 10 
 $83,200-$103,999 ($1,600-$1,999) 11 
 $104,000-$129,999 ($2,000- $2,499) 12 
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 $130,000-$155,999 ($2,500-$2,999) 13 
 $156,000-$181,999 ($3,000-$3,4999) 14 
 $182,000-$207,999 ($3,500-$3,999) 15 
 $208,000 or more ($4,000 or more ) 16 
 Don’t know 17 
 Don’t want to tell 18 
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 GENERAL HEALTH HABITS AND OTHER RISK BEHAVIOURS 
 
 PHYSICAL ACTIVITY 
 
 I would now like to ask you about your physical activity prior to your diagnosis of breast 
cancer. 
Phy1 In a typical week prior to your diagnosis, how many times did you walk continuously, for at 
least 10 minutes, for recreation, exercise, or to get to or from places?  
   times 
  
Phy2 In a typical week prior to your diagnosis, how much time did you spend walking in this way? 
(enter whether time is in minutes or hours per week) 
  minutes or   hours per week 
  
 The next questions (Phy3-6) EXCLUDE household chores, gardening or yard work 
Phy3 In a typical week prior to your diagnosis, how many times did you do any vigorous physical 
activity that made you breathe harder or puff and pant? This does not include household 
chores, gardening or yard work. (e.g. jogging, cycling, aerobics, competitive tennis). 
   times 
  
Phy4 In a typical week prior to your diagnosis, how much time did you spend doing this vigorous 
physical activity? (enter whether time is in minutes or hours per week) 
  minutes or  hours per week 
  
Phy5 In a typical week prior to your diagnosis, how many times did you do any more moderate 
physical activities that you have not already mentioned? This does not include household 
chores, gardening or yard work. (E.g. gentle swimming, social tennis, golf, etc.) 
   times 
  
Phy6 In a typical week prior to your diagnosis, how much time did you spend each week doing 
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these activities? (enter whether time is in minutes or hours per week) 
  minutes or   hours per week 
  
 SMOKING 
 
 
 Now I will ask you few questions related to tobacco smoking  
Smo1 Have you ever smoked at least 100 cigarettes in your entire life?   
 Yes 1 
 No (Go to Alc1) 2 
 Don’t know/Unsure (Go to Alc1) 3 
   
Smo2 Could you tell me how old you were when you first started to smoke at least once 
per week?  
 
  yrs old  
   
Smo3 Do you now smoke cigarettes every day, some days or not at all?  
 Every day 1 
 Some days 2 
 Not at all (Go to Smo5) 3 
  
 
 
Smo4 On average, how many cigarettes do you smoke per day now?  
 No.     (Go to Alc1)  
   
Smo5 About how long has it been since you quit smoking cigarettes? (Round up where 
necessary). 
 
  days or    months or  years  
   
 
 ALCOHOL  
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 I will be asking you about your alcohol drinking habits now  
   
Alc1 Prior to your diagnosis of breast cancer, which of the following BEST describes 
your alcohol consumption? (Read out responses) 
 
 I am a life-long NON-drinker (Go to Alc6) 1 
 I drank alcohol less than once a month (Go to Alc4) 2 
 I drank alcohol at least once a month (Go to Alc3) 3 
 I used to drink alcohol but have stopped 4 
   
Alc2 How old were you when you stopped drinking alcohol?   
  yrs old (Go to Alc6)  
   
Alc3 How old were you when you first started to drink alcohol at least once a month?   
  yrs old   
   
Alc4 In the 12 months prior to your diagnosis, on how many days per week did you 
usually drink alcohol? (Read out responses) 
 
 Less than one day a week 1 
 On 1 or 2 days a week 2 
 On 3 or 4 days a week 3 
 On 5 or 6 days a week 4 
 Every day 5 
 Don’t know (Do not read) 6 
 Refused (Do not read) 7 
   
Alc5 In the 12 months prior to your diagnosis, on a day when you did drink alcohol, can 
you tell me how many drinks you would normally have? (Interviewer: Calculate 
according to guide 
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CO-MORBIDITIES AND FAMILY HISTORY  
Com16 Has a doctor ever told you that you have had benign breast disease such as a non-
cancerous cyst or breast lump? 
 
 Yes 1 
 No (Go to Com18) 2 
   
Com17 How old where you when you were first diagnosed with benign breast disease?  
  years   
   
Com18 Have you ever been diagnosed with cancer other than breast cancer?  
 Yes 1 
 No (Go to Com20) 2 
 Don’t know (Go to Com20) 3 
   
 What type of cancer were you diagnosed with? In what year or how old were 
you? 
 
Com19a Melanoma                                                                                                           
Year    or Age at diagnosis                     
 
Com19b Other skin cancer (not sunspots)                                                                      
Year    or Age at diagnosis                     
 
Com19c Colon/rectum/bowel cancer (colorectal)                                                        
Year   or Age at diagnosis                     
 
Com19d Breast cancer                                                                                                         
Year    or Age at diagnosis                     
 
Com19e Lung cancer (include trachea, pleura and bronchus)                                     
Year    or Age at diagnosis                     
 
Com19f Cervical cancer                                                                                                       
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Year    or Age at diagnosis                     
Com19g Uterine or endometrial cancer                                                                           
Year    or Age at diagnosis                     
 
Com19h Ovarian cancer                                                                                                      
Year    or Age at diagnosis                     
 
Com19i Bladder/kidney cancer                                                                                       
Year    or Age at diagnosis                     
 
Com19j Stomach cancer                                                                                                   
Year    or Age at diagnosis                     
 
Com19k Leukaemia                                                                                                             
Year    or Age at diagnosis                     
 
Com19l Lymphoma (include Non-Hodgkin Lymphoma)                                              
Year    or Age at diagnosis                     
 
Com19m Cancer of unknown primary site                                                                       
Year    or Age at diagnosis                     
 
Com19n Other (specify)                                                                                                         
Year    or Age at diagnosis                     
 
   
Com20 Do any of your first degree relatives (mother, sister, daughter, father, brother) 
have now or in the past had breast cancer? 
 
 Yes 1 
 No (Go to Com21) 2 
 Don’t know (Go to Com21) 3 
   
Com20a What is your relationship with that relative?  
Com20aa Mother  
Com20ab Sister  
Com20ac Daughter  
Com20ad Father  
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Com20ae Brother  
Com20af Son  
   
Com22 Have any of your second degree relatives (maternal or paternal aunt or 
grandmother) been diagnosed with breast cancer? 
 
 Yes   1 
 No (Go to Com23) 2 
 Don’t know (Go to Com23) 3 
   
Com22a What is your relationship with that relative?  
Com22aa Grandmother  
Com22ab Aunt  
Com22ac Grandfather  
Com22ad Uncle  
Com22ae/ 
Com22aeTxt 
Other (specify)      
   
Com22b What was her/his age when he/she got diagnosed?  
  yrs 
 
 (loop back to Com22a until all relatives are recorded)  
Com24 Have any of your first degree relatives been tested to see if they carry the BRCA1 or 
BRCA2 gene? 
 
 Yes 1 
 No (Go to Sun1) 2 
 Don’t know (Go to Sun1) 3 
   
Com24a What is your relationship with that relative? (multiple answers allowed)  
Com24aa Mother  
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Com24ab Sister  
Com24ac Daughter  
Com24ad Father  
Com24ae Brother  
Com24af Son  
   
Com24b Did they find out that they carry the BRCA1 or BRCA2 gene?  
 Yes   1 
 No 2 
 Don’t know 3 
Com24bTxt Other (specify if more than one relative tests)   4 
 (loop back to Com24a until all relatives are recorded))  
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MEDICAL EXAMINATIONS AND TESTS PERFORMED BEFORE DIAGNOSIS 
 
 
 I would now like to ask you some questions about screening examinations and tests 
that you may have had in the past, such as mammograms and breast examinations. In 
the next questions I am asking only about the time before you first noticed any 
symptoms/your doctor or health professional noticed something was wrong, that is, 
before (date – symptom detected, dr detected, screening detected)  
 
   
Med1 Have you ever examined your breasts to check for signs of breast cancer?  
 Yes 1 
 No (Go to Med4) 2 
   
Med2 How old were you when you first examined your breasts?  
    yrs  
   
Med3 Since then, how often on average have you examined your breasts?  
 Monthly 1 
 Every 3 months 2 
 Every 6 months 3 
 Once a year 4 
 Once every 2 years 5 
Med3Txt Other (specify)      6 
 Don’t know 7 
   
Med4 Has a doctor ever examined your breasts prior to (date – symptom detected, dr 
detected, screening detected)? 
 
 Yes 1 
 No (Go to Med11) 2 
 Don’t remember    (Go to Med11) 3 
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Med5 How old were you when a doctor first examined your breasts?  
   yrs  
                              
Med6 Since then, how often on average has a doctor (date – symptom detected, dr 
detected, screening detected) examined your breasts? 
 
 Every 6 months 1 
 Once a year 2 
 Once every 2 years 3 
 Other (specify)                 4 
 Don’t know 5 
   
Med7 Before (date – symptom detected, Dr detected, screening detected), remember that 
is before you/doctor/health professional noticed anything was wrong, can you tell 
me the date when a doctor last examined your breasts [do not include exam that 
discovered your breast cancer]? 
                     /                   / 
     Day            Month        Year           or   years ago 
  
Med14 How old were you when you had your first mammogram?  
Age    or year    
 
   
Med15 Since then, how often on average have you had a mammogram?  
 Every 6 months 1 
 Once a year 2 
 Once every 2 years 3 
Med15Txt Other (specify)    4 
 Don’t know 5 
   
Med16 Before (date – symptom detected, Dr detected, screening detected) can you tell me 
the date when you last had a mammogram? [do not include exam that discovered 
your breast cancer]? 
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                     /                   / 
     Day            Month        Year             or   years ago 
Med23 Have you ever had a breast MRI that is, a scan after injecting a radioactive drug, to 
detect for early signs of breast cancer? 
 
 Yes 1 
 No (Go to Med32)     2 
 Don’t know (Go to Med32)     3 
   
Med24 How old were you when you had your first MRI to detect early signs of breast cancer?
  
Age   or year     
 
   
Med25 Since then, how often on average have you had a breast MRI?  
 Every 6 months 1 
 Once a year 2 
 Once every 2 years 3 
Med25Txt Other (specify)    4 
 Don’t know 5 
   
Med32 Have you ever had an ultrasound to detect early signs of breast cancer?   
 Yes 1 
 No  (Go to Med41)     2 
 Don’t know  (Go to Med41) 3 
   
Med33 How old were you when you had your first ultrasound?  
Age    or year    
 
   
Med34 Since then, how often on average have you had an ultrasound to detect early signs of  
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breast cancer? 
 Every 6 months 1 
 Once a year 2 
 Once every 2 years 3 
Med34Txt Other (specify)     4 
 Don’t know 5 
   
Med43 Have you had any genetic testing to see if you carry the BRCA1 or BRCA2 gene?  
 Yes   1 
 No (Go to Med45) 2 
   
Med44 Do you carry the gene?  
 Yes 1 
 No 2 
   
Med45 Have you ever had any radiotherapy to the chest area before? You may have had 
radiotherapy as treatment for Hodgkin’s Disease or another form of cancer, mastitis, 
enlarged thymus or thyroid condition, or some skin diseases. 
 
 Yes 1 
 No (Go to Tre1) 2 
   
Med46 How old where you? 
  yrs 
 
 
  
225 
 
Appendix C 
Lifetime Sun Exposure Questionnaire
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Breast Cancer Outcomes Study 
Vitamin D supplementation, sun and your skin type, 
and where you have lived 
 
 
1. In the 12 months prior to breast cancer diagnosis, did you take any vitamin supplements?  
  Yes       No   
If NO, please go to section 2. 
If YES, please complete the table below. The first two lines provide examples of commonly 
known vitamin D and multivitamin supplements.  
 Name of Supplement Brand of 
Supplement 
Dosage (e.g. 
2 pills/day) 
Was this 
prescribed/ 
advised by 
your doctor? 
(yes or no) 
For how many 
months did 
you take this 
supplement? 
EX: Caltrate 600mg with 
500IU vitamin D 
Caltrate 1 pill/day Yes 4 
EX: Mega Potency 
Women’s 
Multivitamin  
Nature’s Own 1 pill/day No  2 
1      
2      
3      
4   
 
   
 
Office Use Only ID   
SECTION 1: Vitamin supplementation 
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1.     What colour best describes your natural hair colour at age 21? Please tick one box 
  Red (including Auburn)  Fair or Blonde (including White)  
  Light or mouse brown  Grey     Dark Brown   Black    
  Don’t Know   
                      
2. Which colour best describes the colour of your eyes? Please tick one box 
  Blue or Grey      Green or Hazel      Brown or Black      Don’t Know 
 
3. Which colour type best describes your skin before tanning or on areas never exposed to 
the sun, such as the inside of your upper arm?  
Please tick one box 
  Very fair  Fair      Olive or Brown      Asian      Black      
  Don’t Know  Other (please specify) _________________ 
 
4.      In general, how does your skin react to the sun? Please tick one box 
  Always burns, never tans    Usually burns, sometimes tans  
  Sometimes burns, usually tans    Never burns, always tans  
  Don’t know 
 
 
SECTION 2: Some questions about your hair, eye, skin colour and sun 
protection 
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1.    Have you ever used a solarium or sun-tanning unit? please tick one box   
   Yes       No 
 If NO, please go to section 4. If YES, please continue 
 
2.    Have you used a solarium or a sun-tanning unit in the last 12 months?   
   Yes       No 
If NO, please continue to question 4  
If YES, How many times have you used a solarium or sun-tanning unit in the last 12 
months? Please tick one box   
     2 or more times a week        Weekly      
    Fortnightly                                    Once or twice, not regularly  
  In concentrated bursts until I get tanned  
(e.g., 2-3 times a week but only for 1 or 2 weeks)  
 
 3. On occasions when you used the solarium or sun-tanning unit in the last 12 months, how 
long on average did you use the solarium or sun-tanning unit each time? Please tick one box 
      Less than 15 minutes      About 15 minutes      
  Between 15 and 30 minutes   About 30 minutes  
 Longer than 30 minutes  
 
 4. Total number of lifetime solarium sessions   ___________ 
 
SECTION 3: Solarium use 
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We would like to know where you lived from birth to age 5 years. For each location, please write 
the name of the city/town/suburb and state you lived in and if known, the postcode. If you lived 
outside of Australia, please write the name of the city AND country. For every time you have 
moved, please begin a new line, and indicate between what ages you lived at that location. 
Remember this question is only to age 5 years. 
Location 
 
Postcode  
(if known) 
From Age  To Age  
For example: 
Cairns, QLD  
 
4870 
 
Birth 
 
5 
1.    
2.    
3.    
4.    
5.    
6.    
7.    
8.    
 
 
 
SECTION 4: Where did you live from birth to age 5 years? 
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We would now like to know where you lived from age 5 onwards, whether your occupation or activity was mainly indoors, outdoors or a combination 
of both, and whether you played an outdoor sport during that time. Please list in order each job or activity (e.g., student, farmer, office worker, etc...). 
Include periods of retirement, study, home duties, unemployment, etc. For times when you were in school, list occupation as “student”. Every time you 
have changed occupations, please begin a new line. If you have kept the same occupation (e.g., nurse, teacher, etc…) but have worked/lived in different 
locations, please begin a new line for each location. Please indicate between what ages you held each job/activity. When listing your current 
job/activity and location, please write your current age in the “age to” column.  
Outdoor occupations mean working (paid or unpaid) outdoors for > 30 minutes per day between the hours of 9am to 5pm.  
Outdoor Sports/Activities include: going to the beach or swimming pool, sailing, windsurfing, water skiing, fishing from a boat, tennis, field sports, golf, 
lawn bowls, gardening, walking or jogging, etc… and participating for > 30 minutes per day 
Job/Activity Location 
List town & state, or country and city 
if outside Australia 
Post code 
(if known) 
Age from Age to 
 
Was main job or activity 
mainly indoors, outdoors 
or both? 
Did you play an 
outdoor sport? 
(Yes or No) 
For example 
Student 
 
Carindale, Brisbane 
 
4152 
 
5 
 
9 
 
Both 
 
Yes 
       
       
       
SECTION 5: Where did you live during your schooling and work life? 
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Job/Activity Location 
List town & state, or country and city 
if outside Australia 
Post code  
(if known) 
Age from Age  
to 
Was main job or activity 
mainly indoors, outdoors 
or both? 
Did you play an 
outdoor sport? 
(Yes or No) 
       
       
       
       
       
       
       
       
       
       
Thank you for completing this questionnaire. 
SECTION 5: Where did you live during your schooling and work life? (continued)  
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Details of variable categorisation 
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Variable Description Variable Name Categorisation Description 
Breast cancer stage  lrdcat 1=localized 
2=regional/distant 
 
Age at diagnosis  agecat3 1=<50 yrs 
2=50-69 yrs 
3=70 yrs  
 
Lifetime UV uvlifecat 0=115-405 
1=407-594.5 
2=596-1182 
Categorised into 
tertitles 
Total UV (UV from 
age 5 to present) 
uvtotalcat 0= 105-384 
1= 385-570 
2 = 574.5-1152  
Categorised into 
tertitles 
UV from birth to age 
5 
uv5ycat 0= 0-18 
1= 20-24 
2= 25-30 
Categorised into 
tertitles 
Body Mass Index BMIcat 1=<18.5 (underweight) 
2=18.5-24.9 (normal) 
3=25-29.9 (overweight) 
4 >30 (obese) 
 
Season of diagnosis seasondx 1= winter (June, July, Aug) 
2= spring (Sept, Oct, Nov) 
3= summer (Dec, Jan, Feb) 
4= fall (Mar, Apr, May) 
 
Current marital 
status  
marstat 1= married/living as 
married 
2= single/living as single  
 
Highest completed 
education 
qualification  
edu2 1= school level  
2= Certificate/advanced 
diploma 
3=bachelor degree or 
higher 
 
Income prior to 
diagnosis 
income_prior2 1= no income - $20,799 
2= $20,800-41,599 
3=$41,600-83,199 
4=$83,200-155,999 
5=> 156,000 
6= don’t know/don’t want 
to tell 
Based on 
Australian Tax 
brackets 
Current private 
health insurance 
status  
insur2 1= full private health 
coverage 
2= some (basic hospital, 
extras only, DVA) 
3= none  
 
Aboriginal status  aborig2 1= not aboriginal or Torres 
Strait  
2= Aboriginal, Torres Strait, 
or both  
 
Ethnicity  ethnic2 1= white/Caucasian  
2= other  
 
Employment status job_prior2 1= full-time paid 
2= part-time/casual paid  
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prior to diagnosis  3= retired 
4= other 
Physical activity  phys 1= no exercise  
2= walking  
3= moderate exercise 
4= vigorous exercise  
if they said yes to 
vigorous activity, 
they were placed in 
that category 
regardless if they 
walked/did 
moderate exercise 
as well  
Menopausal status menop2 1= yes 
2= no/don’t know 
 
Contraceptives use contra 1= currently taking 
(hormone only*) 
2= have taken but stopped 
3= never  
*Included in this 
category are those 
who said they were 
still using a form of 
contraceptives but 
did not include 
those who are using 
non-hormonal 
types (e.g., 
condoms, 
withdrawal 
method, partner 
vasectomy)  
Mitotic index  mitosis  1= 0-9 /10 hpf 
2= 10-19 /10 hpf 
3= >20 /10 hpf  
based on categories 
in literature  
Tumour size tsizecat 0= 0-19 mm (T1) 
1= 20-49 mm (T2) 
2= >50 mm (T3) 
based on categories 
in literature  
Family history of 
breast cancer 
familybc3 1= either 1
st
 or 2
nd
 relative 
had bc  
2= no bc in family  
3= unsure  
 
Hair colour hair_col2 1= red/fair/blonde 
2= light brown/mouse 
brown/grey 
3= dark brown/black 
 
Current smoking 
status  
smoke 1= ever smoked 
2= still currently smoking  
3= never smoked  
 
Australian born Ozborn 1= born in Australia 
2= not born in Australia 
 
Rurality  Aria_catv2 1= major cities 
2= inner regional  
3= outer regional 
4=remote/very remote 
 
Alcohol consumption alcohol 1= lifelong non-drinker  
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2= drink less than 
once/month 
3= drink at least once a 
month 
4= used to drink but have 
stopped 
UV during breast 
development years 
uv18cat 1= 22-109 
2= 110-149 
3= 150-220 
Categorised into 
tertitles 
Skin reaction to the 
sun 
skin_rxn 1= Always burns, never 
tans  
2 =Usually burns, 
sometimes tans  
3= Sometimes burns, 
usually tans 
4= Never burns, always 
tans 5= Don’t Know 
 
Solarium use Sol_ever 1= Never used 
2= Have used  
 
Hair colour Hair_col2 1= Red/Fair/Blonde 
2= Light/Mouse 
brown/Grey 
3= Dark brown/Black 
 
Vitamin 
supplementation  
Vitamin  1= Viatmin D and/or 
calcium 
2= other vitamins 
3= none 
 
Eye colour Eye_col 1= Blue/Grey 
2= Green/Hazel 
3= Dark brown/Black 
 
Skin colour Skin_col 1= Very fair 
2= Fair 
3= Olive/Brown 
 
Hormone 
Replacement therapy  
HRT2 1= Yes 
2= No/unsure 
 
Grade Histologicalgrade 1= Grade 1 
2= Grade 2 
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3= Grade 3 
Oestrogen receptor 
status 
Erresult 1= ER+  
2= ER- 
 
Progesterone 
receptor status 
Prresult 1= PR+  
2= PR-/not specified  
 
HER2/neu status  Her2 1= HER2/neu- 
2= HER2/neu+ 
3= Equivocal/unk 
 
History of 
hysterectomy 
Hyst 1= yes 
2= no 
 
History of benign 
breast disease 
BBD 1= yes 
2= no 
 
History of other 
cancer 
Dx_other3 1= yes 
2= no 
 
History of skin 
cancer 
Skincan 1= yes 
2= no 
 
Parity Pregever 1= parous 
2= nulliparous 
 
History of 
radiotherapy to chest  
Radiotherapy 1= yes 
2= no 
 
Self-breast exams Selfex 1= Monthly 
2= Every 3 months  
3= Every 6-12 months 
4= Irregularly 
5= Never 
 
Clinical breast exams drex 1= Every 6-12 months 
2= Every 2 years 
3= Irregularly 
4= Never 
 
Mammography Mammamt3 1= At least every 2 years 
2= Irregularly 
3= Never 
 
History of ultrasound  Ultsnd2 1= Every 6-12 months 
2= Every 2 years 
3= Irregularly 
4= Never 
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      GRIFFITH UNIVERSITY HUMAN RESEARCH ETHICS COMMITTEE 
 
                                                              05-
Nov-2009 
 
 
Dear Ms Parekh 
 
I write further to the additional information provided in relation 
to the provisional approval granted to your application for ethical 
clearance for your project "A multi-level investigation of 
inequalities in clinical and psychosocial outcomes for women after 
breast cancer" (GU Ref No: PSY/C4/09/HREC).   
 
The additional information was considered by Deputy chair. 
 
This is to confirm that this response has addressed the comments and 
concerns of the HREC. 
 
It would be preferable if the privacy statement and the details of 
the independent contact for concerns about the ethical conduct of 
the research could be split into two separate paragraphs. 
 
Consequently, you are authorised to immediately commence this 
research on this basis. 
 
The standard conditions of approval attached to our previous 
correspondence about this protocol continue to apply. 
 
Regards 
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Dr Gary Allen 
Manager, Research Ethics 
Office for Research 
Bray Centre, Nathan Campus 
Griffith University 
ph: 3735 5585 
fax: 3735 7994 
email: g.allen@griffith.edu.au 
web:  
 
Cc:  
 
At this time all researchers are reminded that the Griffith 
University Code for the Responsible Conduct of Research provides 
guidance to researchers in areas such as conflict of interest, 
authorship, storage of data, & the training of research students. 
You can find further information, resources and a link to the 
University's Code by visiting 
http://www62.gu.edu.au/policylibrary.nsf/xupdatemonth/e7852d226231d2
b44a25750c0062f457?opendocument PRIVILEGED,  PRIVATE AND 
CONFIDENTIAL 
  
 
 
  
250 
Appendix F 
Patient consent form 
 The Causes of Melan●ma Study MQ v1.0 18 Jan 2007 ©QIMR 2007 
 
 
Understanding outcomes after Breast Cancer Study 
 
Patient Consent Form  
 
 
I ……………………………………........................................................…………consent to take part in the above study. 
                    (Print name) 
 
1. I have read and understood the Patient Information Sheet. This sheet describes the purpose of the project and 
what I’m asked to do if I take part.  The research project has been fully explained to me and I have had all my 
questions answered. I know that I may ask for more information about the project as it goes on.  
2. I understand that taking part in this project is voluntary, and that I may stop taking part in the project at any 
time. My choice to take part in the study no way affects my future medical treatment, my relationship with CCQ 
or Griffith University.  
3. I understand that although the purpose of the project is to improve medical care, I may not directly benefit from 
taking part in this study. 
4. I have had the opportunity to discuss taking part in this study with a family member or friend. 
5. I consent to telephone interviews and questionnaires at the start of the study and at the end of the study where I 
will be asked to provide information about health status and my treatment. 
6. I understand that telephone calls related to this research will be audio-taped for training and supervision of 
project staff, and that all records will be erased at the completion of the study. 
7. I give permission for the Queensland Cancer Registry to release my records held in the Queensland Cancer 
Registry to the researchers undertaking the study.  
8. I give permission for the research team to access my records from Cancer Registries in Australia and relevant 
pathology laboratories and from any public or private health care facility that I have attended for health care and 
tests concerning my breast cancer. 
9. I understand that the conduct of this research involves the access to my identified personal information. 
However, the information collected will be completely confidential and will not be disclosed to third parties 
without my consent, except to meet government, legal or other regulatory authority requirements. A de-
identified copy of this data may be used for other research purposes.  
10. I understand that my information will be treated in the strictest confidence and used for medical research 
purposes only. I understand that I will not be personally identified in any reports from this project. 
Office Use Only ID   
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11. I assign and waive all claims to patents, commercial exploitation, property or any material or products which may 
form part of or arise from this study.  
12. I understand that this research will comply with the National Health and Medical Research Council’s National 
Statement on Ethical Conduct in Research Involving Humans. 
13. I understand that this study has been approved by the Griffith University Human Research Ethics Committee and 
the Royal Brisbane & Women's Hospital Human Research Ethics Committee and if I have any questions about the 
ethical conduct of this study, I can contact the Research Ethics Officer at Griffith University on 07 3735 5585 or 
visit www.gu.edu.au/ua/aa/vc/pp for more information. 
 
Blood sample: We would also like to obtain a small sample of your blood for this project. If you agree, you will be 
given the choice of attending the Genomics Research Centre Clinic or a pathology collector in your area to provide a 
blood sample. 
I am happy to give a blood sample for this project   
I do not wish to give a blood sample for this project   
  
Retesting: Once this project is over, we may want to use what remains of your blood for future breast cancer 
research and retesting. Any such research would be bound by the same strictures regarding your personal data and 
privacy. 
I am happy for my blood to be used for future breast cancer research studies or retesting  
I do not wish for my blood to be used for future breast cancer research studies or retesting  
 
Contact for future studies: Once this project is over, we may want to contact you about taking part, or your family 
taking part, in future breast cancer research. 
I am happy to be contacted about taking part in future breast cancer research studies  
I do not wish to be contacted about taking part in future breast cancer research studies  
 
 
Patient’s Address: .................................................................................................................................... 
                            
                                 .................................................................................................................................... 
 
Phone Numbers:    Home ...........................................................   
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   Mobile .......................................................... 
 
Work... .......................................................... 
 
 
Patient Signature: ..........................................................................  
Date: ...............................................    
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Ethics application and approval (Griffith University submission) 
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                              Reference Number  PSY/01/11/HREC 
 
GRIFFITH UNIVERSITY 
HUMAN RESEARCH ETHICS COMMITTEE 
 
EXPEDITED ETHICAL REVIEW CHECKLIST 
 
PART A – PROJECT DETAILS 
Project I Subject  Title  A multi-level investigation of inequalities in clinical and 
psychological outcomes for women after breast cancer  
Element   School of Psychology 
 
Duration of data collection I human research 
Date From: 01-07-2010 Date To: 31-12-2014 
PART B – CONTACT PERSON 
Title   Dr 
Family Name  Youl 
Give Names  Philippa 
Relevant Qualifications MPH, PhD 
Contact Address Cancer Council Queensland  PO Box 201 Spring Hill, QLD 4004 
Telephone  07 3624 5301 
Email   PipYoul@cancerqld.org.au 
 
Title   Mrs 
Family Name  Connell  
Give Names  Carmen 
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Relevant Qualifications Research officer  
Contact Address Cancer Council Queensland  PO Box 201 Spring Hill, QLD 4004 
Telephone  07 3634 5186 
Email   carmenconnell@cancerqld.org.au  
PART C – IDENTIFICATION OF ETHICAL ISSUES 
 
C1.  Third party 
identification 
 
 
NO 
 
 
C13.  Psychological or 
emotional stress 
 
YES 
YES 
C2.  Participants who 
cannot consent  
NO C14.  Civil,criminal or other 
action 
NO 
C3.  Minors NO C15.  Sensitive personal NO 
  information  
C4.  Unequal relationship 
cs.  Indigenous persons 
or issues 
NO 
NO 
C16.  Economic loss 
C17.  Impact on personal 
relations 
NO 
NO 
C6.  Collectivity members 
r iss s 
NO C18.  Coercive inducements NO 
C7.  Ingested,Injected or 
invasive 
C8.  Tissue extraction 
NO 
 
YES 
C19.  Covert observation 
 
C20. Deception 
NO 
 
N0 
C9.  Physical injury NO C21.  Privacy  legislation I YES 
  regulation  
C10.Disease or infection NO C22.  Genetic testing NO 
C11.Pain or significant 
discomfort  
 
NO C23.  CTN I CTX scheme NO 
 
 C12.Ionising radiation I X- Ray      NO       C24.  Overseas                               NO 
 
C25. If you answered "No" to all QC1-C24, the project appears to qualify for 
Expedited Ethical Review Level1.Proceed to Part E. 
If you answered "Yes" to one or more QC1-C24,but were not advised that full 
ethical clearance was required by the corresponding questions in Part D, then 
your project appears to qualify for Expedited Ethical Review Level 2.Proceed to 
Part E. 
 
PART D – ELIGIBILITY FOR EXPEDITED ETHICAL REVIEW LEVEL 2 
 
D1.  
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D1a. Prior warning given     Y/N  
D1b. Specific consent      Y/N  
D1c. Confirm accuracy     Y/N 
D2.  
D2a. Supplementary consent     Y/N  
D3.  
D3a. Minor and/or parental consent    Y/N 
D3b. Contrary to best interests    Y/N  
D4.  
 D4a. Managed special processes    Y/N 
 D4b. Captive relationship      Y/N  
D5.  
 D5a. Community consultation     Y/N  
 D5b. Indigenous person on research team   Y/N  
 D5c. Report and flow of benefits    Y/N 
D6.  
 D6a. Community consultation     Y/N 
 D6b. Collectivity member on research team   Y/N 
 D6c. Report and Flow of benefits    Y/N 
D9.  
D9a. Prior warning      Y/N  
D9b. Appropriate screening            Y/N/NA  
D9c. Conducted by experienced person   Y/N  
D9d. Compliance with WHS procedures   Y/N/NA  
D9e. Compliance with other standards   Y/N/NA  
D9f. Licensed/Accredited           Y/N/NA  
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D10.  
D10a. Prior Warning      Y/N 
D10b. Appropriate Screening           Y/N/NA 
D10c. Life threatening or significant     Y/N 
D11.  
D11a. Prior warning      Y/N  
D11b. Appropriate screening            Y/N/NA  
D11c. Life threatening or significant     Y/N  
 
D12.  
 D12a. Prior warning       Y/N 
 D12b. Appropriate screening             Y/N/NA 
 D12c. Conducted by experience person   Y/N 
 D12d. Compliance with WHS procedures          Y/N/NA  
 D12e. Compliance with other standards   Y/N/NA 
 D12f. Licensed/accredited              Y/N/NA 
D13.  
 D13a. Prior warning      Y/N  YES 
 D13b. Appropriate screening             Y/N/NAYES 
 D113c. Significant       Y/N NO 
D14.  
 D14a. Prior warning      Y/N 
 D14b. Duty of care/duty of disclosure   Y/N 
D15.  
 D15a. Prior warning      Y/N YES 
D16.  
 D16a. Prior warning      Y/N 
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 D16b. Duty of care/duty of disclosure   Y/N 
D17.  
 D17a. Prior warning      Y/N 
 D17b. Duty of care/duty of disclosure   Y/N 
D19.  
 D19a. Activity innocuous     Y/N 
 D20b. Identifiable by research team?    Y/N 
D20. 
 D20a. No alternatives      Y/N 
 D20b. Risks not compounded    Y/N 
 D20c. Debriefing      Y/N 
 D20d. Withdraw date      Y/N 
D21.  
 D21a. Appropriate consent     Y/N YES 
D22.  
 D22a. Prior warning      Y/N  
 D22b. Counseling      Y/N  
D25.  
 Are the risks easily negated, minimized or managed Y/N YES 
Details 
 
Participants will be asked to provide a blood sample. By providing blood, they will be exposed to 
risks of pain of a standard blood test. Risks may include minimal pain, discomfort or bruising. All 
blood samples will be obtained by trained practitioners either through Sullivan & Nicolaides 
pathology or qualified research staff at Griffith University. The collection of blood does not 
include any risks of infection or pain greater than that arising within the normal diagnosis or 
treatment of breast cancer. Some participants may experience psychological distress when 
speaking about their cancer diagnosis and treatment outcomes. The psychological distress will 
be no greater than the experience when discussing these issues with their doctor. Therefore, the 
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psychological distress associated with the project will be no greater than day-to-day living for 
breast cancer patients participating in this study. Research staff at CCQ are trained to assess if 
any participant is experiencing levels of distress over and above what might be expected. Where 
this has been identified, participants will be referred to appropriated sources of support and 
counseling. All staff working on research projects at CCQ are trained in referral procedures. 
Participants will not be informed of their genetic results. Data will be kept separate from 
personal identifiers. Personal genetic data will remain confidential, preventing the release of 
individual data leading to various forms of genetic discrimination. Results of the research will 
need subsequent confirmation by future research in order for their true significance to be 
assessed. Providing participants with their genetic information resulting from this study will not 
give them any significant understanding of any additional risks to them of their families 
compared to currently known factors in breast cancer in the family and may instead lead to 
distorted response’s that might lead to harm. Aggregate study results will be given only.  
 
 
D26.  
 D26a. Cleared by another HREC, listed procedure  Y/N 
 
 
 
 
 
 
PART E – PROJECT DETAILS 
 
E1. Brief project description 
 
Details   
Breast cancer is the most common invasive cancer affecting Australian women. A third of all 
women diagnosed with breast cancer will experience high levels of psychological distress, and 
this distress will be greatest for younger and poorer women. Inequalities in survival for women 
with breast cancer continue to exist in Australia, particularly for women living in rural and 
remote areas and for those from areas of disadvantage. 
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While we know some of the reasons for these differences we have little understanding of the 
associations that exist between individual and area-level factors, and clinical and psychosocial 
outcomes and survival from breast cancer. There is also a limited understanding of how modes 
of presentation, time course, diagnostic pathways, treatment, and utilisation of psychosocial 
care services vary for younger (< 50 years) women, women within the target age of population-
based mammographic screening (50 to 69 years) and older women (70+ years).  
Additionally, around 10% of women who get breast cancer have some inherited factor that 
greatly increased their risk. The remaining 90% of women who get breast cancer do not have 
any particular inheritable variation in their DNA that would explain the disease development and 
these are called sporadic breast cancers. There is a growing body of evidence that a woman’s 
genetic makeup can also influence response to therapy, recurrence of cancer or other factors 
that may strongly impact her life once the cancer develops. 
This project will use an innovative multilevel approach to investigate inequalities in diagnostic 
and treatment processes, utilisation of psychosocial care services, genetic influences and 
survival for women recently diagnosed with breast cancer in Queensland. Queensland is the 
ideal state to investigate these issues in detail since it has the most decentralised population in 
Australia and large distances between major cancer treatment centres. 
The overall aims of the project are 
1. To systematically describe modes of presentation, time course, diagnosis, treatment, 
utilisation of psychosocial care services, unmet psychological supportive care needs, rates of 
recurrence and survival for women newly diagnosed with breast cancer. 
2. To examine differences in these factors according to individual characteristics (including age (< 
50 years, 50-69 years and 70+ years), spread of disease, comorbidity, rurality, socioeconomic 
status) and area-level characteristics (geographical remoteness, area socioeconomic 
disadvantage). 
3. To model the independent contribution that the area-level and individual-level factors make 
to the variation in recurrence and survival from breast cancer. 
4. To determine if genetic makeup, or genetic responses are associated with any of the 
conditions suffered during and post the development of breast cancer 
5. To determine how genetic factors may affect responses to treatment  and other factors 
relating to the biology of their individual cancer. 
6. To examine general cancer risk in a traditional association study utilising an already recruited 
control populations. 
We hypothesise that at 6 months and 18 months post diagnosis 
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1. Compared to women who live in major cities, the diagnostic pathway will be significantly 
longer for women from rural and remote areas independently of individual level factors. 
2. Women from rural and remote areas will choose more extensive surgery compared to those 
from major cities independent of disease stage and other individual-level factors. 
3. Women from rural and remote areas and areas of disadvantage will have greater unmet 
needs and poorer psychological adjustment and quality of life, independent of disease stage and 
other individual-level factors. 
4. Younger women (< 50 years) will report lower levels of utilisation of psychosocial care services 
and greater unmet psychological supportive care needs compared to women aged 50-69 years. 
5. Women from rural and remote areas and areas of disadvantage will have higher rates of 
recurrence and poorer survival independent of disease stage and other individual-level factors. 
6. The strength and type of association between individual-level factors and breast cancer 
outcomes will depend on the extent of geographic remoteness and area socioeconomic 
disadvantage. 
The proposed study involves the collection and modelling of individual- and area-level data. 
Individual-level data 
Individual level data will be obtained through a longitudinal study of women newly diagnosed 
with breast cancer. Quantitative and qualitative data will be collected by Computer Assisted 
Telephone Interview (CATI) and self-administered questionnaires (SAQ) at two time points: 4 to 
6 months post diagnosis (Time 1) and 18 months post diagnosis (Time 2). 
Blood will be collected from participants. Both DNA and RNA will be used to determine if genetic 
makeup, or genetic responses are associated with any of the conditions suffered during and post 
the development of breast cancer, as well as examining general cancer risk in a traditional 
association study utilising an already recruited control population. An additional SAQ will be 
administered to obtain specific family histories to help exclude influence from other genetic 
disorders. 
Area-level data 
Statistical local areas (SLA), often based on the incorporated bodies of local governments who 
are responsible for service provision and infrastructure at the local and regional level, will be the 
primary focus for the area-level analysis. 
Census data: area-level information about education levels, household income, types of 
occupation, median mortgage and rental payments and other socioeconomic indicators, 
comparable to the same information collected at the individual level, by age group and sex for 
each SLA will be obtained from the census data files released by the Australian Bureau of 
Statistics (ABS) for 2006 and 2011. 
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Life expectancy: average life expectancy will be calculated from the unit record mortality file for 
Queensland from the ABS that contains year-specific details of all-cause mortality by SLA. 
This research will produce three important outcomes: 
1) Enable us to determine whether areas themselves have an impact on the clinical and psycho-
social outcomes from breast cancer independently of the characteristics of the women who live 
in the areas; 
2) Provide health care providers with targeted information to improve the future management 
of women with breast cancer; and 
3) Inform the development of recommendations for strategies to improve psychosocial care for 
women with breast cancer on a system and community level. 
 
 
E2. Qualifications, experience and skill 
 
Details 
Philippa Youl: Philippa Youl has a background  in clinical oncology and cancer 
epidemiology. She has over 18 years’ experience in epidemiological studies, particularly  
involving large population- based studies. 
 
Peter Baade: Dr Baade has developed a strong interest in population-based descriptive 
cancer epidemiology  during last 15 years, and particularly  quantifying inequalities in cancer 
incidence and survival across Queensland utilizing spatial (GIS) technology and Bayesian 
methods. 
 
Joanne Aitken: A/Professor  Aitken is a cancer epidemiologist with a long-standing research 
interest and experience in large scale, population-based studies of the causes, early 
detection and management of cancer. 
 
Suzanne Chambers:  Professor  Suzanne Chambers  is a health psychologist and has been 
working as a practitioner-researcher in psycho-oncology for 20 years and has extensive 
experience in the psychosocial aspects of cancer. 
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Jeff Dunn: Professor Dunn has extensive experience in the development of supportive care 
programs for people  with cancer and in particular women with breast cancer, both in 
Australia and internationally. 
 
Christopher Pyke: Dr Chris Pyke is a breast cancer  surgeon. He is currently Chairman of the 
Board in General Surgery of the RACS, the Deputy Chair of the Breast Section of the RACS. 
Assoc Prof Gavin Turrell is currently working at the Queensland University of Technology 
and has extensive experience in research relating to socio demographics, and geographical 
differences. 
 
Prof. Griffiths is a research scientist with many years of experience conducting  genetic and 
genomic research.  She is the director of the Genomics Research Centre and currently 
supervises many genetic research projects.  
 
Lindsay Brandon is a PhD student at QUT working in the AusSun Research Lab. She has a Masters 
degree in public health with a concentration in epidemiology.  
 
 
E3. Participants 
 
Details  
All women aged 20 to 79 years resident in Queensland with a histologically confirmed 
diagnosis of invasive breast cancer (ICD0-3 C50) between July 1 2010 and December 31 
2012 and notified to the Queensland Cancer Registry (QCR) will be eligible to participate. 
This is a population-based register with virtually universal coverage of individuals 
diagnosed with cancer in Queensland. Those excluded from the study will include women 
unable to speak or understand English and women with cognitive impairment. Based on 
2005 and 2006 Queensland incidence figures for breast cancer, and allowing for increasing 
trends in counts, it is anticipated that approximately 5,080 women will be eligible. For the 
recruitment we will approach the treating doctor requesting their permission for the 
patient to be approached. Only the patients for whom we receive the treating doctor’s 
permission will be forwarded a study information sheet, consent form and a reply-paid 
envelope along with a letter from their doctor informing them of the study. This study, 
excluding the collection and analysis of blood, has received previous ethical approval and is 
currently being conducted (PSY/C4/09/HREC). Consent from existing recruited patients will 
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be sought for the genetic component of the study, following the consent procedures 
outlined below. 
 
E.4 Data collection 
Details 
At Time of recruitment (4-6 months post diagnosis), study participants will receive a 
structured telephone interview using CATl system. The Cancer Council Queensland (CCQ) has 
a dedicated CATI system within their research department.This telephone interview will 
collect the information about the demographics, pathways to diagnosis and treatment 
pathways. Participants will be asked to complete and return a self- administered 
questionnaire comprising previously validated measures assessing attitudes to help seeking,  
unmet supportive care needs, psychological adjustment (anxiety/depression), and quality of 
life. At 18 months post diagnosis participants will receive a similar structured telephone 
interview and SAQ as at 4-6 months post diagnosis. In the CATI at Time 2 (18 months post 
diagnosis), patients will answer questions related to their lifetime sun exposure. These questions 
will collect information on occupational exposure, residential exposure, sunscreen use, solarium 
use, residential history, vacation history, clothing worn in the sun, and perceived skin type.  With 
the patient's consent, the treating clinician(s) will be sent a brief questionnaire approximately  
12 months after diagnosis requesting information on the diagnostic process including  
diagnostic tests undertaken, presenting symptoms, type and date of surgical procedures,  
postoperative complications; radiation therapy including start and completion  date; 
cytotoxic and hormonal manipulation, start and completion dates and agents administered, 
indicators  of illness and disease progression.  
 
Student Project 
 
In a self-administered questionnaire, patients will answer questions related to their lifetime sun 
exposure. The sun exposure questionnaire has been developed based on past research. The 
questionnaire will collect a detailed residential history from birth to current location of 
residence. Additional questions will collect information on occupational exposure, recreational 
exposure, sunscreen use, protective clothing worn, phenotypic characteristics, solarium use, 
past and current supplementation use (specifically those that contain vitamin D and/or calcium), 
and fertility medications. Additionally, we will be testing 25(OH)D levels from blood samples 
previously collected for the BCOS. This will be done using DiaSorin LIAISON 25-OH Vitamin D 
TOTAL assay. Blood samples will also be used to test for additional prognostic indicators of 
breast cancer, specifically levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9).  
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E5. Informed Consent 
 
Details 
Patients’ names and details of their treating doctors will be obtained from the QCR. We will 
contact the treating doctors requesting their permission to approach the patient. Once 
doctors’ consent has been obtained, a letter to the patient from their doctor, information 
sheet, consent form and reply-paid envelope will be sent to participants.  Permission will be 
requested for researchers to access their records within the QCR and to allow matching of 
their name to other data sources such as interstate cancer registries and the National 
Death Index. Where participant consent has already been obtained for the epidemiological 
part of the study and not the genetic component, an additional consent form and 
information sheet will be sent, requesting consent for the additional genetic component. 
Participants choosing not to be involved in the genetic component will not affect their 
current involvement in the epidemiological study 
 
 
 
 
E6. Communication of results/reporting 
 
Details  
A final report will be generated for the Cancer Council Queensland. 
Results will be disseminated by way of presentations to scientific meetings and publications 
in peer-reviewed scientific journals.  All results will be published in the form of statistical aggregates 
from which it will not be possible to identify any participants. At the end of the project each 
participant will receive a letter that includes the project outcomes in lay terms as well as the 
importance of their participation and thanking them for the same. 
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GRIFFITH UNIVERSITY HUMAN RESEARCH ETHICS COMMITTEE                                                              
20-Aug-2013 
 
 
Dear Ms Carmen 
 
I write further to your application for a variation to your approved 
protocol "A multi-level investigation of inequalities in clinical 
and psychosocial outcomes for women after breast cancer" (GU Ref No: 
PSY/01/11/HREC).  This request has been considered by the Office for 
Research. 
 
The OR resolved to approve the requested variation: 
 
Request to amend the Time 2 questionnaires to add in a few 
additional questions relating to residential history & sun exposure. 
Of interest is whether there is an association between vitamin D and 
stage of breast cancer at diagnosis.  Copies of amended recruitment 
letter and questionnaires provided. 
 
This decision is subject to ratification at the next meeting of the 
HREC.  However, you are authorised to immediately commence the 
revised project on this basis.  I will only contact you again about 
this matter if the HREC raises any additional questions or comments 
about this variation. 
 
Regards 
 
 
 
Dr Gary Allen 
Senior Policy Officer 
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Office for Research 
Bray Centre, Nathan Campus 
Griffith University 
ph: +61 (0)7 3735 5585 
fax: +61 (0)7 3735 7994 
email: g.allen@griffith.edu.au 
web:  
 
Cc: Researchers are reminded that the Griffith University Code for 
the Responsible Conduct of Research provides guidance to researchers 
in areas such as conflict of interest, authorship, storage of data, 
& the training of research students. 
You can find further information, resources and a link to the 
University's Code by visiting 
http://policies.griffith.edu.au/pdf/Code%20for%20the%20Responsible%2
0Conduct%20of%20Research.pdf 
PRIVILEGED,  PRIVATE AND CONFIDENTIAL 
This email and any files transmitted with it are intended solely for 
the use of the addressee(s) and may contain information which is 
confidential or privileged. If you receive this email and you are 
not the addressee(s) [or responsible for delivery of the email to 
the addressee(s)], please disregard the contents of the email, 
delete the email and notify the author immediately
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Appendix H 
Ethics application and approval (QUT submission)
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ADMINISTRATIVE REVIEW COVERSHEET FOR RESEARCH INVOLVING 
HUMAN PARTICIPANTS 
 
December 2012 
ENSURE YOU FOLLOW THE SUBMISSION INSTRUCTIONS AT THE END OF THIS DOCUMENT 
PROJECT TITLE The influence of sun exposure on breast cancer stage at diagnosis  
DETAILS OF OTHER HREC 
(Human Research Ethics Committee) 
Institution that is leading 
the project 
Cancer Council Queensland and QUT 
 HREC that has provided 
approval 
Griffith University  
 
Summary of QUT’s role in 
the project 
PhD candidate is undertaking a substudy within a large 
longitudinal study being conducted by Cancer Council 
Queensland 
PROJECT DATES HREC approved start date 12/2/2010 (dd/mm/yyyy) 
HREC approved end date 31/12/2015 (dd/mm/yyyy) 
QUT LEAD INVESTIGATOR 
Undergrad / Honours students cannot 
be considered CIs. They should 
instead be listed as other research 
team members 
Lindsay Brandon   
Staff / Student number N8361762 Contact number 3138 0400 
(If known) AOU code  Email lindsay.brandon@qut.edu.au  
   
QUT SUPERVISOR OR 
ALTERNATE CONTACT  
(only applicable if the applicant is a 
student) 
 
Prof. Michael Kimlin    
Staff / Student number  Contact number 3138 5802 
(If known) AOU code  Email m.kimlin@qut.edu.au  
   
OTHER MEMBERS OF 
THE RESEARCH TEAM 
If there are additional team members, 
please attach a separate document 
Dr. Pip Youl   
Staff / Student number  Email Pipyoul@cancerqld.org.au  
OR        External details 
Senior Research Fellow,  Cancer Council Queensland; associate 
supervisor of lead investigator 
 
Prof. Eliza Whiteside   
Staff / Student number  Email e.whiteside@qut.edu.au  
OR        External details 
Lecture in Faculty of Health at QUT; associate supervisor of lead 
investigator  
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Carmen Connell    
Staff / Student number  Email 
carmenconnell@cancerqld.org.a
u 
OR        External details Research officer at Cancer Council Queensland 
 
   
Staff / Student number  Email  
OR        External details  
LEVEL OF RISK  X Negligible Risk  Low Risk  More than Low Risk 
       
  Tick this box if the research involves a designated chapter of the National Statement 
IS THIS STUDENT  
OR STAFF RESEARCH? 
 X Student research – provide the student research details below: 
 X PhD/Prof Doc (Confirmed)  Masters    Honours  
 Undergrad (not 
Honours)  
   PhD/Prof Doc (NOT Confirmed) 
  
Staff research 
 
 
 
IS THE PROJECT FUNDED? 
 
 NO X YES – who is the administering office?  Office of Research  
 
      
NOTE: Failure to provide this information may cause account opening 
delays. 
 
Office of Commercial 
Services  
 
If YES: grant/RM number or other 
details: 
Cancer Australia ID: 100639 
IS THIS PROJECT 
COMMERCIAL IN 
CONFIDENCE? 
  YES X NO  
      
SECTION A:  PRIVACY OF PERSONAL OR HEALTH INFORMATION – S95 AND S95A GUIDELINES 
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The S95 Guidelines and the S95A Guidelines were both developed to provide a framework for making decisions about handling 
'identifiable' data (personal or health information) that is required for research purposes, where consent from the individual cannot 
be obtained. 
Does this project require access to information held by a Commonwealth agency or private sector organisation? 
 
X YES  
N
O 
If NO – go to Section B. 
If YES – complete the questions below sequentially unless otherwise advised. 
 
 
    
SECTION A1: Privacy of Health Information Held by Commonwealth Agencies – S95 Guidelines 
NOTE: These questions relate to compliance with the s95 Guidelines, which provide a framework for medical research to proceed 
using personal information held by Commonwealth agencies without obtaining consent. s95 provides a process to resolve any conflict 
that may arise between the public interest in privacy and the public interest in medical research, where this would otherwise involve 
a breach of privacy under the Privacy Act 1988. 
A1.1 Is this a medical research proposal (including epidemiological research)? X YES  NO – go to A2 
     
A1.2 Does it require the use or disclosure of information from a Commonwealth agency?  YES X NO – go to A2 
     
A1.3 Does it require use or disclosure of personal information from a Commonwealth agency?  YES X NO – go to A2 
NOTE: Personal information is identifiable information (information or an opinion (including information or an opinion forming part 
of a database), whether true or not, and whether recorded in material form or not, about an individual whose identity is apparent, or 
can reasonably be ascertained, from the information or opinion. 
A1.4 Does it involve not obtaining consent from the individuals to whom the information relates?  YES X NO 
SECTION A2: Privacy of Health Information Held by Private Sector Organisations – S95A Guidelines 
NOTE: These questions relate to compliance with the s95A Guidelines. The s95A Guidelines establish a process for undertaking 
research, statistical or health service management activities using health information held by a private sector organisation. It is a 
condition of using the s95A Guidelines that it must be necessary to use identifying information and that it is impracticable to seek 
consent from the individual to whom the information relates.  
A2.1 Does the proposal involve research relevant to public health or safety? 
  NO  X YES – provide 
details: 
 
A2.2 Does the proposal involve the compilation or analysis of statistics relevant to public health or safety? 
  NO  X YES – provide 
details: 
 
A2.3 Does the proposal involve the management, funding or monitoring of a health service? 
 X NO   YES – provide 
details: 
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** If you answered NO to questions A2.1 – A2.3 go to Section B ** 
A2.4 Does it involve collection, use or disclosure of information from a private sector organisation? X YES  NO – go to A3 
     
A2.5 Will it be necessary to collect, use or disclose health information (i.e. identifiable data)?  X YES  NO – go to A3 
NOTE: Health information is personal information (i.e. identifiable information): about an individual’s health or disability at any time 
(that is past, present or future); about an individual’s expressed wishes regarding future health services; about health services 
provided or to be provided to the individual; collected whilst providing a health service or collected in connection with the donation 
or intended donation of body parts and substances. Health information includes any information collected by a health service 
provided during the course of providing treatment and care to an individual.  
A2.6 Will it be impracticable to gain consent from the individuals to whom the health information 
relates? 
 
YES 
X 
NO  
** If you answered YES to any of questions A1.3 – A1.4 and A2.5 – A2.6 please provide the following information ** 
SECTION A3: Specific details 
A3.1 From which commonwealth agencies / private sector organisations will the records be obtained? 
Cancer Council Queensland’s Cancer Registry and Breast Cancer Outcomes Study data  
A3.2 Describe the data items to be sought from each individual Commonwealth agency and private sector organisation 
Cancer Council Queensland (CCQ) is conducting at study entitled  the Breast Cancer Outcomes Study (BCOS), and I will be using a 
cohort of women that have been recruited for this study. Therefore, I will have access to the data collected for this study through the 
computer-assisted telephone interview (CATI), the Queensland Cancer Registry (QCR), and the clinical/hospital data. Information 
collected in the CATI include: Sociodemographics, diagnosis of breast cancer medical examinations/tests prior to diagnosis, treatment 
for breast cancer, satisfaction with health care system, peer support, personal history, co-morbidities/family history, general health 
habits and other risky behaviour (smoking, physical activity, alcohol), and complementary therapies. Clinical and demographic info 
will be extracted from the QCR database including: date of birth, date of diagnosis, tumour site, morphology, histological grade, 
stage, degree of lymph node involvement, and ER/PR status. Additionally, clinical and hospital data from the patient’s physicians and 
medical records will be collected by CCQ. This information includes: diagnostic tests, presenting symptoms, type and date of surgical 
procedures, therapies, indicators of illness status, information from BreastScreen Queensland Register and Queensland Oncology 
Repository. Although I will have access to the data mentioned above for a cohort of women, it will be extracted from the database for 
me, and the patients will remain unidentifiable to me. 
A3.3 How many records will be involved?  
~500 
A3.4 Will this access constitute a breach of a National Privacy Principle (e.g. access to participant data without their prior approval)? 
No 
A3.5  If you answered ‘Yes’ to A3.4 provide a response to S95/S95A of the Act, explaining why personal information is needed and 
justifying how the public interest in the research outweighs, to a substantial degree, the public interest in the protection of 
privacy. 
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SECTION B:  RESEARCH SAFETY 
Research projects should be discussed with your H&S representative (www.hrd.qut.edu.au/healthsafety/incidents/whsr.jsp) to identify 
potential health and safety risks. Has the research safety of the project been considered? 
B1 X 
The research safety of the project has been considered and, as required, approved by an Institute/Faculty/School approved 
process. 
   
B2  The research safety of the project is yet to be considered by an Institute/Faculty/School approved process.  
   
B3  I believe that this project requires an expert /external research safety review. 
SECTION C:  CONFLICTS OF INTEREST 
Please indicate if there are any perceived or actual conflicts of interest for the applicant / research team / supervisor / Head of 
School in regard to this project.  For definitions refer to Code of Conduct for Research www.mopp.qut.edu.au/D/D_02_06.jsp. 
C1  YES X NO ...with any funding body. 
      
C2  YES X NO ...with the supervision of the research student. 
      
C3  YES X NO ...with any commercial activity.     
     
Will this research be undertaken on behalf of (or at the request of) a sponsor or other commercial 
entity? If yes, please outline the nature of this support / request (this information must also be 
included in the informed consent package provided to potential participants in the research).  
C4  YES X NO Other conflict: Do the researchers expect to obtain any direct or indirect financial or other benefits 
from conducting this project? 
     
If you answer “YES” to any of the above, please provide details and indicate how they will be managed. 
 
SECTION D.  CHECK LIST 
You MUST check off each item (as appropriate) that will be submitted with your application. 
You MUST provide all data collection documents when submitting your application.  
Incomplete applications will not be reviewed and will be returned to the researcher. 
Coversheet 
 
 X YES   Provide an electronic signed coversheet – signed by yourself, your supervisor (if applicable) and the Head of 
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School or equivalent.  A paper copy is not required. 
 
 
Other documentation to be provided  
      
 X YES   The approval letter/email from the other HREC 
      
 X YES   The complete application that was submitted to the other HREC for review 
      
 X YES   Any review HREC comments and your responses 
      
SECTION E:  DECLARATIONS 
QUT Lead Investigator 
In submitting this application I declare that: 
 All ethical implications of the proposed research, and all relevant local, state and national guidelines, regulations and legislation 
have been considered and the measures taken are appropriate and in accordance with University policy and the National 
Statement on Ethical Conduct in Human Research. 
 The research / scientific merit of this project has been considered and validated. 
 The research safety of the project has been considered and the measures taken are appropriate. 
 There are no perceived or actual conflicts of interest (or these have been declared above). 
 The qualifications and experience of all investigators are appropriate to the study to be undertaken. 
 All support staff involved in the project (e.g. administrative staff who undertake data entry) will be required to understand and 
observe the assurances provided to participants (e.g. to safeguard their anonymity. 
 Approval from the University Human Research Ethics Committee (UHREC) will be requested for any divergence from the 
protocol stated in this proposal. 
 UHREC will be advised immediately of any adverse effects arising from this study (eg unexpected adverse outcomes, 
unexpected community/subject risk factors or complaints, etc). 
 A progress report will be provided at least annually. 
Name: Lindsay Brandon 
School
: Public Health and Social Work 
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Signature:  Date:  
 
 
 
QUT SUPERVISOR OR ALTERNATE CONTACT (only applicable if the applicant is a student) 
I have considered this application and believe: 
 All ethical implications of the proposed research, and all relevant local, state and national guidelines, regulations and legislation 
have been considered and the measures taken are appropriate and in accordance with University policy and the National 
Statement on Ethical Conduct in Human Research. 
 The research / scientific merit of this project has been considered and validated. 
 The research safety of the project has been considered and the measures taken are appropriate. 
 There are no perceived or actual conflicts of interest (or these have been declared above). 
 The qualifications and experience of all investigators are appropriate to the study to be undertaken. 
 UHREC will be advised immediately of any adverse effects arising from this study (eg unexpected adverse outcomes, 
unexpected community/subject risk factors or complaints, etc) 
Name: Michael Kimlin 
School
: Public Health and Social Work  
    
Signature:  Date:  
 
 
 
HEAD OF SCHOOL / CENTRE DIRECTOR / HEAD OF DISCIPLINE 
** If Head of School/Centre Director/Head of Discipline is a member of the research team, then the Dean or Dean of Research 
should sign ** 
I have considered this application and believe: 
 All ethical implications of the proposed research, and all relevant local, state and national guidelines, regulations and legislation 
have been considered and the measures taken are appropriate and in accordance with University policy and the National 
Statement on Ethical Conduct in Human Research. 
 The research / scientific merit of this project has been considered and validated. 
 The research safety of the project has been considered and the measures taken are appropriate. 
 There are no perceived or actual conflicts of interest (or these have been declared above). 
 The qualifications and experience of all investigators are appropriate to the study to be undertaken. 
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Name:  
School
:  
    
Signature:  Date:  
    
ALL APPLICATIONS ARE REVIEWED ELECTRONICALLY 
Please email the application with ALL attachments to the relevant area below: 
QUT Business School  Email to Dr Marilyn Healy 
 businessethics@qut.edu.au 
Faculty of Education Email to A/Prof Annette Woods
 educationethics@qut.edu.au 
            Faculty of Education Health & Safety Form link:               
www.ed.qut.edu.au/research/facultyresearch/ 
Faculty of Law  Email to Dr Fiona McDonald 
 lawethics@qut.edu.au   
All other Faculties Email to the Research Ethics Unit 
 ethicscontact@qut.edu.au 
ALL documents should be clearly numbered, named and listed – see below 
Once you have gained a pre-review and the APPROPRIATE SIGNATURES, please scan the coversheet and send the complete 
application via email. 
*** Please DO NOT submit a paper copy – send your signed coversheet via email only *** 
 
Also, ensure you: 
1. Check that the document ordering is logical, as this defines the order of review. 
2. Name your files appropriately using the TILS (Division of Technology, Information and Learning Support) 
document naming convention.  To access an extended guide to document naming, go to: 
 www.tils.qut.edu.au/initiatives/informationmanagement/resources.jsp 
Note: Your application should not contain 2 documents with the same number and the numbers should run consecutively. 
It is not necessary to include your (first/last) name in the file name. 
All documents should begin with “01_a_...” then “01_b_...” etc and should run consecutively, with the date at the 
end changed as appropriate. For example (20yy=year      mm=month      dd=day): 
01_a_ETH_HumanCoversheet_v1_20yymmdd.doc 
01_b_ETH_HumanLowRiskApp_v1_20yymmdd.doc 
  
278 
01_c_ETH_Info-consent-interview_v1_20yymmdd.doc 
For future reference: When re-submitting any documents at a later date, ensure you amend the file name 
appropriately (ie  v2_20yymmdd). 
IF YOU ARE UNSURE ABOUT THIS REQUIREMENT PLEASE CONTACT THE RESEARCH ETHICS 
UNIT ON 3138 5123. 
 The Causes of Melan●ma Study MQ v1.0 18 Jan 2007 ©QIMR 2007 
Dear Prof Michael Kimlin 
Project Title:  The influence of sun exposure on breast cancer stage at 
diagnosis 
Ethics category:                  Human - Administrative Review  
QUT approval number:    1300000682 (As per Griffith University, Approval 
number: PSY/C4/09/HREC) 
 
QUT clearance until:         31/12/2014 
We are pleased to advise that your administrative review application has 
been reviewed by the Chair, University Human Research Ethics Committee 
(UHREC), and confirmed as meeting the requirements of the National 
Statement on Ethical Conduct in Human Research (2007). 
I can therefore confirm that your application has received QUT 
administrative review approval based on the approval gained from the 
responsible Human Research Ethics Committee (HREC). We note this HREC has 
awarded the project ethical clearance until 31/12/2014. 
CONDITIONS OF APPROVAL 
Please ensure you and all other team members read through and understand 
all UHREC conditions of approval prior to commencing any data collection:  
   - Standard: Please see attached or 
www.research.qut.edu.au/ethics/humans/stdconditions.jsp 
   - Specific:     
Projects approved through an external organisation may be subject to that 
organisation's review arrangements. Researchers must immediately notify the 
QUT Research Ethics Unit if their project is selected for investigation / 
review by an external organisation. 
VARIATIONS 
All variations must first be approved by the responsible HREC before 
submission to QUT for ratification.  Once approval has been obtained please 
submit this to QUT using our online variation form:  
  www.research.qut.edu.au/ethics/humans/var/ 
  
 
MONITORING 
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Please ensure you also provide QUT with a copy of each adverse event report 
and progress report submitted to the responsible HREC. 
Administrative review decisions are subject to ratification at the next 
available UHREC meeting. You will only be contacted again in relation to 
this matter if UHREC raises additional questions or concerns. 
Please don't hesitate to contact us if you have any queries. 
We wish you all the best with your research. 
  
Kind regards 
Janette Lamb on behalf of the Chair UHREC Research Ethics Unit  |  Office 
of Research  |  Level 4 88 Musk Avenue Kelvin Grove  | Queensland 
University of Technology | p:+61 7 3138 5123 |e: ethicscontact@qut.edu.au| 
w: www.research.qut.edu.au/ethics/ 
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Appendix I 
Results of model including tumour characteristics (lifetime sun exposure)
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Table I.1 Final model of breast cancer stage at diagnosis (localized vs. advanced) and lifetime UV (high vs. 
low & medium) including ER status  
 Advanced Breast Cancer  
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=424)      <0.001 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.88 0.54, 1.44 0.62 0.83 0.47, 1.47 0.52 
 Low UV 1.18 0.74, 1.90 0.49 0.77 0.45, 1.34 0.36 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.79 1.04, 3.09 0.04 1.64 0.89, 3.00 0.11 
 Never 3.02 1.79, 5.11 <0.001 2.61 1.35, 5.05 0.00 
Solarium Use       
 Never ref ---- ---- ref ---- ---- 
 Yes 2.35 1.26, 4.37 0.01 1.91 0.95, 3.83 0.07 
Physical Activity       
 None ref ---- ---- ref ---- ---- 
 Light 0.71 0.38, 1.31 0.27 0.77 0.40, 1.51 0.45 
 Moderate 0.40 0.20, 0.81 0.01 0.51 0.24, 1.10 0.09 
 Vigorous 0.69 0.37, 1.30 0.25 0.66 0.33, 1.35 0.26 
Age at diagnosis       
 <50 years 2.12 0.27, 3.53 0.004 1.45 0.79, 2.71 0.23 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 0.80 0.48, 1.35 0.41 0.89 0.49, 1.61 0.70 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.68 0.39, 1.17 0.16 0.63 0.35, 1.13 0.12 
 Irregularly 0.93 0.54, 1.59 0.78 0.82 0.45, 1.48 0.50 
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 Never  1.44 0.81, 2.58 0.22 1.26 0.65, 2.47 0.49 
Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.68 0.40, 1.14 0.14 0.69 0.39, 1.21 0.19 
 Outer Regional 1.26 0.73, 2.16 0.40 1.25 0.68, 2.29 0.47 
 Remote/Very remote 1.46 0.56, 3.82 0.44 1.29 0.45, 3.70 0.63 
Oestrogen receptor 
status 
      
 ER+ ref ---- ---- ref ---- ---- 
 ER- 0.93 0.51, 1.67 0.80 0.76 0.40, 1.45 0.41 
1
 Bivariate analysis between breast cancer stage and each covariate   
2 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, 
rurality, and oestrogen receptor status    
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Table I.2 Final model of breast cancer stage at diagnosis (localized vs. advanced) and lifetime UV (high vs. 
low & medium) including PR status  
 Advanced Breast Cancer  
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=424)      0.001 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.88 0.54, 1.44 0.62 0.85 0.48, 1.51 0.58 
 Low UV 1.18 0.74, 1.90 0.49 0.79 0.46, 1.37 0.40 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.79 1.04, 3.09 0.04 1.64 0.90, 3.01 0.11 
 Never 3.02 1.79, 5.11 <0.001 2.55 1.32, 4.92 0.01 
Solarium Use       
 Never ref ---- ---- ref ---- ---- 
 Yes 2.35 1.26, 4.37 0.01 1.88 0.94, 3.75 0.08 
Physical Activity       
 None ref ---- ---- ref ---- ---- 
 Light 0.71 0.38, 1.31 0.27 0.76 0.39, 1.49 0.43 
 Moderate 0.40 0.20, 0.81 0.01 0.50 0.23, 1.07 0.07 
 Vigorous 0.69 0.37, 1.30 0.25 0.65 0.32, 1.31 0.23 
Age at diagnosis       
 <50 years 2.12 0.27, 3.53 0.004 1.43 0.77, 2.65 0.25 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 0.80 0.48, 1.35 0.41 0.89 0.49, 1.61 0.70 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.68 0.39, 1.17 0.16 0.63 0.35, 1.13 0.12 
 Irregularly 0.93 0.54, 1.59 0.78 0.82 0.45, 1.49 0.51 
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 Never  1.44 0.81, 2.58 0.22 1.27 0.65, 2.47 0.49 
Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.68 0.40, 1.14 0.14 0.68 0.39, 1.19 0.17 
 Outer Regional 1.26 0.73, 2.16 0.40 1.24 0.68, 2.27 0.49 
 Remote/Very remote 1.46 0.56, 3.82 0.44 1.27 0.44, 3.65 0.65 
Progesterone receptor 
status 
      
 PR+ ref ---- ---- ref ---- ---- 
 PR- 0.88 0.55, 1.43 0.61 0.89 0.53, 1.48 0.64 
1
 Bivariate analysis between breast cancer stage and each covariate   
2 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, 
rurality, and progesterone receptor status    
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Table I.3 Final model of breast cancer stage at diagnosis (localized vs. advanced) and lifetime UV (high vs. 
low & medium) including tumour markers    
 Advanced Breast Cancer  
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=417)      0.001 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.88 0.54, 1.44 0.62 0.82 0.46, 1.46 0.49 
 Low UV 1.18 0.74, 1.90 0.49 0.81 0.47, 1.40 0.46 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.79 1.04, 3.09 0.04 1.83 0.98, 3.41 0.06 
 Never 3.02 1.79, 5.11 <0.001 2.59 1.32, 5.07 0.01 
Solarium Use       
 Never ref ---- ---- ref ---- ---- 
 Yes 2.35 1.26, 4.37 0.01 2.01 0.99, 4.07 0.05 
Physical Activity       
 None ref ---- ---- ref ---- ---- 
 Light 0.71 0.38, 1.31 0.27 0.80 0.41, 1.58 0.52 
 Moderate 0.40 0.20, 0.81 0.01 0.51 0.23, 1.11 0.09 
 Vigorous 0.69 0.37, 1.30 0.25 0.68 0.33, 1.39 0.29 
Age at diagnosis       
 <50 years 2.12 0.27, 3.53 0.004 1.44 0.77, 2.69 0.25 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 0.80 0.48, 1.35 0.41 0.94 0.52, 1.72 0.84 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.68 0.39, 1.17 0.16 0.57 0.31, 1.03 0.06 
 Irregularly 0.93 0.54, 1.59 0.78 0.75 0.41, 1.38 0.36 
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 Never  1.44 0.81, 2.58 0.22 1.18 0.60, 2.34 0.63 
Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.68 0.40, 1.14 0.14 0.67 0.38, 1.19 0.17 
 Outer Regional 1.26 0.73, 2.16 0.40 1.30 0.70, 2.39 0.40 
 Remote/Very remote 1.46 0.56, 3.82 0.44 1.25 0.43, 3.57 0.68 
Tumour markers        
 HER2/neu- ref ---- ---- ref ---- ---- 
 HER2/neu+ 0.84 0.40, 1.76 0.65 1.06 0.47, 2.41 0.89 
 Equivocal/unk 0.83 0.48, 1.45 0.52 1.00 0.54, 1.85 1.00 
1
 Bivariate analysis between breast cancer stage and each covariate   
2 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, 
rurality, and tumour markers     
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Appendix J 
Results of model including tumour characteristics (sun exposure during breast 
development years) 
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Table J.1. Final model of breast cancer stage at diagnosis (localized vs. advanced) and UV during breast 
development years (high vs. low & medium) including ER status  
 Advanced Breast Cancer  
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=424)      0.001 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 1.04 0.65, 1.66 0.88 1.11 0.67, 1.84 0.69 
 Low UV 0.91 0.56, 1.48 0.70 0.93  0.54, 1.61 0.81 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.79 1.04, 3.09 0.04 1.59 0.88, 2.90 0.13 
 Never 3.02 1.79, 5.11 <0.001 2.57 1.34, 4.96 0.01 
Solarium Use       
 Never ref ---- ---- ref ---- ---- 
 Yes 2.35 1.26, 4.37 0.01 1.88 0.94, 3.75 0.07 
Physical Activity       
 None ref ---- ---- ref ---- ---- 
 Light 0.71 0.38, 1.31 0.27 0.79 0.41, 1.54 0.49 
 Moderate 0.40 0.20, 0.81 0.01 0.52 0.24, 1.11 0.09 
 Vigorous 0.69 0.37, 1.30 0.25 0.68 0.33, 1.35 0.26 
Age at diagnosis       
 <50 years 2.12 0.27, 3.53 0.004 1.40 0.76, 2.57 0.28 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 0.80 0.48, 1.35 0.41 0.91 0.50, 1.64 0.75 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
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 Every 2 years 0.68 0.39, 1.17 0.16 0.62 0.34, 1.11 0.11 
 Irregularly 0.93 0.54, 1.59 0.78 0.81 0.44, 1.47 0.49 
 Never  1.44 0.81, 2.58 0.22 1.27 0.65, 2.48 0.49 
Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.68 0.40, 1.14 0.14 0.68 0.39, 1.20 0.19 
 Outer Regional 1.26 0.73, 2.16 0.40 1.31 0.72, 2.39 0.37 
 Remote/Very remote 1.46 0.56, 3.82 0.44 1.33 0.47, 3.79 0.59 
Oestrogen receptor 
status 
      
 ER+ ref ---- ---- ref ---- ---- 
 ER- 0.93 0.51, 1.67 0.80 0.79 0.42, 1.50 0.47 
1
 Bivariate analysis between breast cancer stage and each covariate   
2 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, 
rurality, and oestrogen receptor status    
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Table J.2. Final model of breast cancer stage at diagnosis (localized vs. advanced) and UV during breast 
development years (high vs. low & medium) including PR status  
 Advanced Breast Cancer  
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=424)      0.001 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 1.04 0.65, 1.66 0.88 1.12 0.68, 1.87 0.65 
 Low UV 0.91 0.56, 1.48 0.70 0.96  0.56, 1.65 0.88 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.79 1.04, 3.09 0.04 1.60 0.88, 2.92 0.12 
 Never 3.02 1.79, 5.11 <0.001 2.52 1.31, 4.85 0.01 
Solarium Use       
 Never ref ---- ---- ref ---- ---- 
 Yes 2.35 1.26, 4.37 0.01 1.85 0.93, 3.68 0.08 
Physical Activity       
 None ref ---- ---- ref ---- ---- 
 Light 0.71 0.38, 1.31 0.27 0.78 0.40, 1.52 0.47 
 Moderate 0.40 0.20, 0.81 0.01 0.50 0.24, 1.08 0.08 
 Vigorous 0.69 0.37, 1.30 0.25 0.65 0.32, 1.32 0.23 
Age at diagnosis       
 <50 years 2.12 0.27, 3.53 0.004 1.38 0.76, 2.54 0.29 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 0.80 0.48, 1.35 0.41 0.90 0.50, 1.63 0.73 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
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 Every 2 years 0.68 0.39, 1.17 0.16 0.62 0.35, 1.12 0.11 
 Irregularly 0.93 0.54, 1.59 0.78 0.81 0.45, 1.48 0.50 
 Never  1.44 0.81, 2.58 0.22 1.27 0.65, 2.49 0.48 
Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.68 0.40, 1.14 0.14 0.67 0.38, 1.19 0.17 
 Outer Regional 1.26 0.73, 2.16 0.40 1.30 0.72, 2.37 0.39 
 Remote/Very remote 1.46 0.56, 3.82 0.44 1.32 0.46, 3.75 0.61 
Progestrogen receptor 
status 
      
 PR+ ref ---- ---- ref ---- ---- 
 PR- 0.88 0.55, 1.43 0.61 0.90 0.54, 1.50 0.68 
1
 Bivariate analysis between breast cancer stage and each covariate   
2 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, 
rurality, and progestrogen receptor status    
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Table J.3. Final model of breast cancer stage at diagnosis (localized vs. advanced) and UV during breast 
development years (high vs. low & medium) including tumour markers    
 Advanced Breast Cancer  
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=417)      0.001 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 1.04 0.65, 1.66 0.88 1.10 0.66, 1.83 0.73 
 Low UV 0.91 0.56, 1.48 0.70 0.92 0.53, 1.58 0.76 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.79 1.04, 3.09 0.04 1.79 0.97, 3.33 0.06 
 Never 3.02 1.79, 5.11 <0.001 2.55 1.31, 4.97 0.01 
Solarium Use       
 Never ref ---- ---- ref ---- ---- 
 Yes 2.35 1.26, 4.37 0.01 1.98 0.98, 3.99 0.06 
Physical Activity       
 None ref ---- ---- ref ---- ---- 
 Light 0.71 0.38, 1.31 0.27 0.82 0.42, 1.61 0.56 
 Moderate 0.40 0.20, 0.81 0.01 0.52 0.24, 1.12 0.10 
 Vigorous 0.69 0.37, 1.30 0.25 0.69 0.34, 1.40 0.30 
Age at diagnosis       
 <50 years 2.12 0.27, 3.53 0.004 1.37 0.74, 2.54 0.31 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 0.80 0.48, 1.35 0.41 0.97 0.53, 1.76 0.91 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
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 Every 2 years 0.68 0.39, 1.17 0.16 0.56 0.31, 1.02 0.06 
 Irregularly 0.93 0.54, 1.59 0.78 0.75 0.41, 1.37 0.35 
 Never  1.44 0.81, 2.58 0.22 1.19 0.60, 2.36 0.62 
Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.68 0.40, 1.14 0.14 0.67 0.38, 1.18 0.17 
 Outer Regional 1.26 0.73, 2.16 0.40 1.36 0.74, 2.48 0.32 
 Remote/Very remote 1.46 0.56, 3.82 0.44 1.29 0.45, 3.68 0.63 
Tumour markers        
 HER2/neu- ref ---- ---- ref ---- ---- 
 HER2/neu+ 0.84 0.40, 1.76 0.65 1.07 0.47, 2.44 0.87 
 Equivocal/unk 0.83 0.48, 1.45 0.52 1.00 0.54, 1.85 0.99 
1
 Bivariate analysis between breast cancer stage and each covariate   
2 
Adjusted for mammography, physical activity, solarium use, age at diagnosis, clinical breast exams, 
rurality, and tumour markers     
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Appendix K 
Results of model using grade as the outcome variable 
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Table K.1 Final model of breast cancer grade (grade 1 vs. grades 2 and 3) and lifetime UV (high vs. low & 
medium)  
 Grade 2 and Grade 3 
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=425)      0.36 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.66 0.34, 1.27 0.21 0.60 0.30, 1.20 0.15 
 Low UV 0.61 0.32, 1.17 0.14 0.56 0.27, 1.14 0.11 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.36 0.63, 2.91 0.44 1.35 0.59, 3.07 0.48 
 Never 1.52 0.71, 3.25 0.28 1.58 0.62, 3.98 0.34 
Highest level of 
education 
      
 School education 
level 
ref ---- ---- ref ---- ---- 
 Certificate/diploma 1.29 0.73, 2.27 0.38 1.39 0.77, 2.51 0.27 
 Bachelor 
degree/equivalent or 
higher 
2.13 1.00, 4.53 0.05 2.54 1.15, 5.63 0.02 
Age at diagnosis       
 <50 years 1.07 0.53, 2.14 0.86 0.98 0.43, 2.26 0.97 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 1.01 0.53, 1.91 0.98 1.01 0.50, 2.02 0.98 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.77 0.39, 1.53 0.46 0.80 0.40, 1.62 0.54 
 Irregularly 0.96 0.47, 1.93 0.90 1.03 0.48, 2.18 0.94 
 Never  1.69 0.69, 4.10 0.25 1.68 0.65, 4.39 0.29 
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Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.85 0.45, 1.58 0.60 0.93 0.48, 1.82 0.84 
 Outer Regional 0.79 0.39, 1.57 0.49 0.68 0.32, 1.43 0.31 
 Remote/Very remote 3.10 0.40, 23.96 0.28 3.06 0.38, 24.61 0.29 
1
 Bivariate analysis between breast cancer grade and each covariate   
2 
Adjusted for mammography, education, age at diagnosis, clinical breast exams, and rurality, 
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Table K.2. Final model of breast cancer grade (grade 1 vs. grades 2 and 3) and lifetime UV (high vs. low & 
medium) including oestrogen receptor  
 Grade 2 and Grade 3 
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=421)      0.02 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.66 0.34, 1.27 0.21 0.64 0.31, 1.32 0.23 
 Low UV 0.61 0.32, 1.17 0.14 0.61 0.29, 1.26 0.18 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.36 0.63, 2.91 0.44 1.34 0.58, 3.08 0.49 
 Never 1.52 0.71, 3.25 0.28 1.47 0.58, 3.72 0.41 
Highest level of 
education 
      
 School education 
level 
ref ---- ---- ref ---- ---- 
 Certificate/diploma 1.29 0.73, 2.27 0.38 1.44 0.79, 2.63 0.23 
 Bachelor 
degree/equivalent or 
higher 
2.13 1.00, 4.53 0.05 2.61 1.17, 5.81 0.02 
Age at diagnosis       
 <50 years 1.07 0.53, 2.14 0.86 0.94 0.41, 2.17 0.89 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 1.01 0.53, 1.91 0.98 1.01 0.50, 2.05 0.97 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.77 0.39, 1.53 0.46 0.84 0.41, 1.72 0.64 
 Irregularly 0.96 0.47, 1.93 0.90 1.08 0.50, 2.32 0.84 
 Never  1.69 0.69, 4.10 0.25 1.72 0.65, 4.56 0.28 
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Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.85 0.45, 1.58 0.60 0.89 0.45, 1.76 0.75 
 Outer Regional 0.79 0.39, 1.57 0.49 0.68 0.32, 1.45 0.32 
 Remote/Very remote 3.10 0.40, 23.96 0.28 2.89 0.35, 23.71 0.32 
Oestrogen receptor 
status 
      
 ER+ ref ---- ---- ref ---- ---- 
 ER- 12.63 1.72, 92.80 0.01 11.38 1.82, 9.37 0.02 
1
 Bivariate analysis between breast cancer grade and each covariate   
2 
Adjusted for mammography, education, age at diagnosis, clinical breast exams, rurality, and oestrogen 
receptor  
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Table K.3. Final model of breast cancer grade (grade 1 vs. grades 2 and 3) and lifetime UV (high vs. low & 
medium) including progesterone receptor  
 Grade 2 and Grade 3 
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=421)      0.23 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.66 0.34, 1.27 0.21 0.58 0.29, 1.19 0.14 
 Low UV 0.61 0.32, 1.17 0.14 0.53 0.26, 1.09 0.09 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.36 0.63, 2.91 0.44 1.34 0.58, 3.07 0.50 
 Never 1.52 0.71, 3.25 0.28 1.64 0.65, 4.17 0.29 
Highest level of 
education 
      
 School education 
level 
ref ---- ---- ref ---- ---- 
 Certificate/diploma 1.29 0.73, 2.27 0.38 1.41 0.78, 2.56 0.26 
 Bachelor 
degree/equivalent or 
higher 
2.13 1.00, 4.53 0.05 2.59 1.16, 5.75 0.02 
Age at diagnosis       
 <50 years 1.07 0.53, 2.14 0.86 1.01 0.44, 2.33 0.98 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 1.01 0.53, 1.91 0.98 1.00 0.49, 2.01 0.99 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.77 0.39, 1.53 0.46 0.82 0.41, 1.67 0.59 
 Irregularly 0.96 0.47, 1.93 0.90 0.99 0.46, 2.11 0.98 
 Never  1.69 0.69, 4.10 0.25 1.63 0.62, 4.31 0.32 
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Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.85 0.45, 1.58 0.60 0.95 0.49, 1.86 0.88 
 Outer Regional 0.79 0.39, 1.57 0.49 0.69 0.32, 1.46 0.33 
 Remote/Very remote 3.10 0.40, 23.96 0.28 2.95 0.36, 23.94 0.31 
Progesterone receptor 
status 
      
 PR+ ref ---- ---- ref ---- ---- 
 PR-    1.82 0.88, 3.77 0.11 
1
 Bivariate analysis between breast cancer grade and each covariate   
2 
Adjusted for mammography, education, age at diagnosis, clinical breast exams, rurality, and progesterone 
receptor  
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Table K.4. Final model of breast cancer grade (grade 1 vs. grades 2 and 3) and lifetime UV (high vs. low & 
medium) including tumour markers  
 Grade 2 and Grade 3 
 Crude OR
1 
95% CI P-value Adjusted 
OR
2 
95% CI P-value 
Model (n=414)      0.01 
Sun Exposure        
 High UV ref ---- ---- ref ---- ---- 
 Medium UV 0.66 0.34, 1.27 0.21 0.59 0.28, 1.24 0.16 
 Low UV 0.61 0.32, 1.17 0.14 0.50 0.24, 1.05 0.07 
Mammography       
 At least every 2 
years 
ref ---- ---- ref ---- ---- 
 Irregularly 1.36 0.63, 2.91 0.44 1.53 0.61, 3.83 0.36 
 Never 1.52 0.71, 3.25 0.28 1.33 0.51, 3.45 0.56 
Highest level of 
education 
      
 School education 
level 
ref ---- ---- ref ---- ---- 
 Certificate/diploma 1.29 0.73, 2.27 0.38 1.51 0.82, 2.78 0.19 
 Bachelor 
degree/equivalent or 
higher 
2.13 1.00, 4.53 0.05 2.88 1.25, 6.61 0.01 
Age at diagnosis       
 <50 years 1.07 0.53, 2.14 0.86 1.19 0.49, 2.85 0.70 
 50-69 years ref ---- ---- ref ---- ---- 
 70+ years 1.01 0.53, 1.91 0.98 1.23 0.59, 2.54 0.58 
Clinical breast exam       
 Every 6-12 months ref ---- ---- ref ---- ---- 
 Every 2 years 0.77 0.39, 1.53 0.46 0.73 0.35, 1.52 0.41 
 Irregularly 0.96 0.47, 1.93 0.90 1.02 0.46, 2.23 0.97 
 Never  1.69 0.69, 4.10 0.25 1.46 0.54, 3.93 0.46 
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Rurality        
 Major Cities ref ---- ---- ref ---- ---- 
 Inner Regional 0.85 0.45, 1.58 0.60 0.93 0.47, 1.84 0.84 
 Outer Regional 0.79 0.39, 1.57 0.49 0.76 0.34, 1.67 0.49 
 Remote/Very remote 3.10 0.40, 23.96 0.28 3.16 0.38, 26.18 0.29 
Tumour markers        
 HER2/neu- ref ---- ---- ref ---- ---- 
 HER2/neu+ 0.43 0.10, 1.79 0.24 0.29 0.06, 1.56 0.15 
 Equivocal/unk 0.20 0.06, 0.67 0.01 0.15 0.03, 0.64 0.01 
1
 Bivariate analysis between breast cancer grade and each covariate   
2 
Adjusted for mammography, education, age at diagnosis, clinical breast exams, rurality, and tumour 
markers 
 
 
 
 
 
 
